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CHAPTER I 
General introduction 
Pulmonary hypertension and increased pulmonary blood flow both lead to functional 
and structural changes in the pulmonary vasculature. Pulnlollary vascular disease 
constitutes an ongoing threat to children with congenital heart disease. Without .early 
surgical repair, an estimated 30% of patients with congenital heart disease will develop 
signitlcant pulmonary vascular disease. Pulmonary hypertension and pulmonary 
vascular disease arc important causes of morbidity and mortality in patients with 
congenital heart disease. Pulmonary plexogenic arteriopathy is a eharactetistic form 
of pulmonary vascular disease and is most frequently associated with congenital heart 
defects. The combination of increased pulmoluu')' blood t10w with elevated pulmonary 
artery pressure, causes a rapid progression of the pulmonary vascular remodeling 
process that may progress to irreversibility and, then, precludes curative therapy or 
both the heart- and the vascular disease. Although the time course in which pulmonary 
arteriopathy progresses towards this stage is highly variable in different patients and 
different heart defects, our current knowledge, mainly based on empiricism, has lead 
to management strategies in pediatric cardiology Owt aims at surgical interventions 
early in life. On the other hand, at present, surgical corrections of complex congenital 
heart diseases may be delayed because of a staged approach. In addition, earlier and 
potentially reversible stages of plexogenic arteriopathy can jeopardize the outcome 
of surgical procedures because of acute pulmonary hypertensive crises perioperativcly. 
This aspect is of special importance in dIe management of patients with a univentricular 
heart, who will undergo Norwood- or Fontan procedures. These procedures are being 
performed in a rapidly increasing frequency in the current era and create a circulation, 
in which no ventricular force faces the pulmonary vasculaturc. In such a condition, 
already early stages of pulmonary vascular disease may be detrimental to surgical 
outcome and prognosis. 
An accurate assessment of the progression and functional consequences of pulmonary 
vascular disease is crucial in the management and prognosis of children with congenital 
heart defects. The management of univentricular hearts makes new demands on the 
evaluation of the pulmonary vasculature. The possibilities of the cut1'ently available 
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techniques to assess the progression of the vascular disease and its functional 
consequences for the integrated pulmonary circulation and, thus, the work load ofthe 
heart, are restricted by conceptual and practical limitations. 
To evaluate the progression and consequences of a disease, it is important to understand 
its pathophysiology. Research in vascular biology provides rapidly expanding 
knowledge on humoral and cellular mechanisms that are probably involved in vascular 
injury and vascular remodeling. However, the specific role of the various substances 
and mechanisms, their interactions and the sequence of the various events remains to 
be unravelled. Endothelial dysfunction is believed to playa key role in vascular 
remodeHng and various endothelial-derived vasoactive substances have been suggested 
to be involved in pulmonary vascular disease. 
Pulmonary plexogenic arteriopathy is a specific form of pulmonary vascular disease, 
with a charactedstic clinical course and unique morphological vascular lesions. 
Investigation of its pathophysiology is hampered by the lack of an adequate 
experi mental model of this disease. 
The aims of the studies described in this thesis were to determine the feasibility of a 
new technique, pulmonary intravascular ultrasound imaging, in children and infants 
and to investigate its potential to assess, ill vivo, morphological and functional chan-
ges of pulmonary arteries in the course of pulmonary vascular disease in children 
with congenital heart disease. Furthermore, in our search for specifIC cellular events 
and biologic modulators that are involved in the emergence of advanced lesions of 
plexogenic arteriopathy, and thus must be characteristic for this typical disease, we 
studied the vascular expression of two potential candidates, vascular endothelial growth 
factor and nitric oxide synthase, at different stages of the disease process. 
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The pulmonary circulation: 
Development, postnatal adaptation and disease 
R.M.F. Berger 
Department of Pediatrics, division of PediatIic Cardiology, 
Sophia Children's Hospital f University Hospital Rotterdam, 
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PULMONARY CIRCULATION, THE MATURE LUNG 
Introduction 
To define pulmonary hypertension and pulmonary vascular disease, whether relatecl 
to congenital heart disease, persistent pulmonary hypertension of the newborn or 
other conditions, insight into the nonnal pulmonary developmental changes in utero, 
at birth and during the postnatal period is necessary. Many mechanisms involved in 
pulmonary vascular remodeling in disease, are probably closely related, or may be 
even similar to mecilfUlisll1s involved in the normal development, growth and adaptation 
of the pulmonary vasculature. Therefore the pulmonary vascular anatomy, physiology 
and humoral and cellular regulation in characteristic conditions will be successively 
discussed. These conditions are (I) the normal mature lung, (2) lung development, 
(3) postnatal transition and, tinally, (4) pulmonary vascular disease. 
The mature lung 
AnllfOlIl), 
The human lung can be divided into two functionally different components: the 
conducting system (I), consisting of airways and blood vessels, which function is the 
distribution of air and blood to the basie unit of the lung, formed by the acinus (2), in 
which Ule gas exchange takes place. 
The conducting airways consist of the trachea, which originates at the larynx and 
after descending in the mediastinum branches into the left and tight main hronchi. 
Within the lung the bronchi branche dichotomously, giving rise to progressively smaller 
airways. The number of airway generations ti'om the main bronchus to UlC acini vW'ies 
fromS to 25, depending on the region of the lung. The branching pattern is asymmetric. 
Conducting airways I mm or more in diameter are reinforced by cartilage and are 
referred to as bronchi. Conducting airways without cw·tilage w'e named bronchioli. 
The terminal bronchiole is Ule most peripheral bronchiole, free of alveoli and not 
involved in gas exchange. The intra acinar airways of the adult lung consist of 
respiratory bronchioli, alveolar ducts and alveoli. The normal anatomy of the airways 
have been described in detail 1-",. 
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The pulmonary arteries accompany the bronchi, following the same branching pattern, 
until they reach the acini. The structure of these preacinar arteries can be predicted 
frOlll its size4.5: arteries with a diameter of approximately 1 mm or more are elastic 
arteries. In contrast to the pulmonary trunk and main arteries, in which the elastic 
laminae are irregular, disrupted and fragmented, in peripheral elastic arteries these 
laminae are regular, intact and parallel to one another. At the level of diameters bet-
ween approximately I and 0.5 mm there is a gradual transition to a muscular type of 
artery. The preacinar arteries between 0.5 mm and 150 micrometer are most II/use/dar 
arteries. The characteristic part of these arteries is its media or muscular coat. It is 
formed by vascular smooth muscle cells (VSMC's) with collagen and elastic fibers in 
between. The media is bounded by distinct internal and external elastic laminae5. 
In addition to the dichotomous branching pattern, following the airways, there are 
numerous additional branches, which do not follow the airways, but mise perpendicular 
or obliquely from elastic as well as from muscular arteries. These additional branches 
are known as supernumerary arteries and are muscular arteries6, 
Along the intra acinar arterial pathway the lilily muscular media gives way to a partially 
muscular region, where muscle is present only as a spiral, before it disappears. This 
results in a non-museulm' m'tery, still larger than a capillary, often controversially 
referred to as arteriole4, 5. In contrast to preacinar arteries in which the structure of 
the artery can be predicted from its size, in intra acinar arteries the transition from one 
type of artery to another does not always occur in arteries li'om the same size4. As 
described later, the proportion of arteries of a given size that shows a specinc type of 
structure changes with growth, but is also modilied by disease4. The non-muscular 
arterioles taper in calibre and give rise to dense alveolar capillary networks, The walls 
of alveolar C(lpillaries consist of a single endothelial layer resting upon a basal 
continuous layer. At the site of gas exchange the alveolar wall also consists of a single 
layer of alveolar epithelium resting upon a common basal laminas. 
Small pulmollllry veills, with a very thin wall consisting of an endothelial layer resting 
upon a basement membrane, collect the blood from the alveolar capillaries and merge 
with each other to form larger veins with a wall containing collagen and elastic libers 
and some VSMC's. These veins enter, independently from the bronchi, the 
mesenchyme of the interlobular septa and drain into the left atrium of the heartS. 7 
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Bronchial arteries provide nutrient blood supply to the bronchi, major vessels and 
part of the pleura and originate from the systemic circulation. As in systemic vessels, 
the media of bronchial arteries is considerably thicker than that of pulmonary arteries. 
Their caliber, however, is much smaller than that of the pulmonary artery accompanying 
the same bronchus. They show a distinct internal elastic lamina but the outer elastic 
lamina is usually interrupted or even absent. In general, the bronchial arteries 
accompany the bronchi as long as the latter contain cartilage5 
Physiology 
In the human circulation, the pulmonary vasculature is unique in receiving the total 
ventricular output, having a very active metabolism and producing, metabolizing and 
inactivating a variety of active substancess, The primary function of the pulmonary 
circulation is not the nutrition of an organ, but the exchange of oxygen and carbon 
dioxide. The pulmonary circulation is a high flow, low pressure and high capacitance, 
low resistance circuit and, thus, has unique functional and structural properties. 
The physiologic regulation of the pulmonary circulation, which involves many 
mechanisms, is very complex and far from elucidated completely". One of the 1I10st 
important mechanisms is the modulation of pulmonary vascular tone. Many interacting 
factors are responsible for this physiologic process, however, the tlnal common pathway 
by which the pulmonary VSMC constdcts apparently is the Ca2+-mcdiated stimulation 
of excitation-contraction coupling; whereas relaxation occurs mainly through either 
a cGMP- or cAMP-mediated mechanismS, In the normal pulmonary circulation the 
basal vascular tone is low and is the result of a subtle balance between vasoconstlictor 
and vasodilator activitl· ll . The normal pulmonary vasculature has the capacity to 
adapt to large fluctuations in pulmonm'y blood flow. During exercise, or in congenital 
heart disease with left-to-right shunt, pulmonary blood flow may increase enormously, 
without a rise in pulmonary artery pressure l2 . This can be achieved due to the great 
range of vascular tone modulation, high vascular compliance and the possibility to 
recruit "unopened" vessels. For studying the physiology of the pulmonary circulation, 
the use of hemodynamic variables and a simple formula for pulmonary vascular 
resistance (PVR), analogous to Ohm's law of electricity, has proved to be extremely 
useful from a clinical point of view 13.14: 
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meal/ PAP -meal/ LAP 
PVR ~ (eql/atiol/ 1) 
Qp 
in which: PVR ~ pulmonary vascular resistance (WU.m2) 
PAP pulmonary artery pressure (mmHg) 
LAP ~ left atrial pressure (mmHg) 
Qp ~ pulmonary blood flow (I/min/m') 
Pulmonary vascular resistance, corrected for body surface, is expresscd as Woods 
Units times m'. Although there is a wide range of normality, depending on various 
conditions at the time of the study, the normal pressure- and flow values in the young 
human are the following: mean PAP is around 15mmHg, about one-sixth of that in 
the systemic circulation, mean LAP approximately SnunHg. Qp around 4 ilmin/m' 
and, consequently, PVR approximately 1.5 Woods Units.m' 1.1. 16 
Poiseuille and Hagen, who both studied the now of liquids along narrow tubes, 
discovered independently that, once steady !low has started, the pressure drop (LIP), 
between two points L cm apart could be related to the now rate (Q), the radius of the 
tube (r) and the viscosity of the liquid (1]), by the expression I), 17 
L1P 8 L 
~--.--. 
Q 11 
(equatiol/ 2) 
Focusing on PVR, several aspects have to be taken into consideration. Although the 
compaJison of the complex pulmonary circulation to a simple rigid tube is a gross 
simplification, the relationship does indicate the importance of vessel radius. Because 
it is a fourth power function, a small change in radius alters resistance markedly in an 
individual vessel. The overall cross-sectional area of the pulmonary vascular bed 
undergoes dramatic changes in growth and diseaseD Another featurc of this formula 
that applies to clinical conditions is the factor viscosity. Even without pulmonary 
vascular changes, PVR will increase in conditions with polycythemia, associated with 
hyperviscosity. In children with cyanotic heart disease or pulmonary vascular disease 
this factor may not be neglected. Another t:1ctor, dlUt have to be taken into account 
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when interpreting PYR, is the critical closing pressure 16, 18, This is the pressure which 
results from the forces which tend to collapse a vessel. In the lung these may originate 
from the alveoli or from the vessel itself, in the latter case due to its elastic or muscular 
recoil. In the physiologic condition, LAP exceeds the clitical closing pressure and is 
the relevant downstream pressure, However, when critical closure pressure exceeds 
LAP, as may occur in pathologic conditions such as emphysema or pulmonary 
hypertension, the usual calculation of PYR becomes misleading because LAP is no 
longer the appropriate downstream pressure l8 
PYR as primary measure of the state of the pulmonary vasculature has conceptual 
limitations l5, 18 PYR as calculated above, represents the resistance to continuous 
flow from the main pulmonm'y mteries to the pulmonary veins, but does not take into 
account thc dynamic nature of pulsatile flOW l5,IS,I9, The pulmonary vascular system 
distends during systole and acts as a reservoir for blood, which will continue to flow 
during diastole, In this way, pulsatile flow is converted to virtually continuous now in 
the pulmonary capillaries, In the pulil10nmy capillaries pulsatile now can still be 
recognized, although the pulsations are relatively small and superimposed upon a 
strong mean flow 15, 16, 19, 20 ,The vascular reservoir capacity is called capacitance, and 
is determined by the distensibility or compliance of the pulmonary arteries, The 
pulmonary artery distensibility is determined by elastic properties of the arterial wall, 
the tone of its smooth muscle and environmental forces like, for instance, alveolar 
surface tension or excessive interstitial nuicJl5, 19, An additional chm'acteristic of 
pulsatile flow is inertia, due to viscous forces in the blood, which will oppose the 
action of the heart. Inertia vmies directly with the hem'! rate l5, 19, A third important 
component of pulsatile flow is the effect of reflected pulse waves!.I, IS, 19 In principle, 
pressure wave reflections originate from the pulmonary microcirculation, but also 
from the frequent branching of large vessels, In the normal pulmonary vasculature, 
wave retlections are of small amplitude because of excellent matching of impedances 
in the distal pulmonmy vessels 18, However, pulmonary hypertension may increase 
the amplitude of the retlected waves and ifpulmonary artelial compliance is decreased, 
their velocity will also be increased, These early reflection waves will enhance systolic 
pressure and the load on the right ventriclc l8 , Approximately 70% of the total right 
ventriculm work load is formed by the steady load and 30% by the pulsatile load IS, 
16 
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The pulsatile power is dissipated mainly in the large pulmonary arterial branches, 
while the steady work is lost in the small vcssels l9• 21. 
Finally, the resistance to pulmonary blood flow in the normal lung occurs not only 
upstream to the gas exchange vessels (30-50%), but also in the microcirculation itself 
(approximately 30%) as well as downstream in the venous component ofthc pulmonary 
vasculature (20-30%)15 
HlImoral al/d celllllal' mechal/isms il/ the matlll'e IllIIg 
Only recently thc pivotal role of the vascular endothelium in the homeostasis of 
pulmonary circulation has been recognized (4, 5, II). The functions of the pulmonary 
endothelium include biosynthesis and metabolism of circulating hormoncs and 
vasoactive substances, modulation of vascular tonc, regulation of hemostasis and 
thrombosis and influencing inflammatory processes. In recent years, in which 
molecular and cellular biology techniques have provided new insights in vascular 
biology, various mediators and growth factors have been shown to have vasoactive 
and growth modulating properties. The endothelial cell has been shown to be ablc to 
produce both vasoconstrictor (e.g. endothelin-I, platelet derived growth factor) and 
vasodilator (e.g. nitlic oxide, prostacycline) substances. l'vlany of these substances 
have been suggcstcd to playa role in the maintenance of basal pulmonary vascular 
tone9- 11 . 22.2.1. Although subject of extensive investigations, the roles of the various 
substances in the physiology of the pulmonary circulation has not been fully elucidated 
yet. 
The vascular endothelium produces a short lived dilator substance, which has been 
identified as nitric oxide (NO)24-26. NO is synthesized from L-arginine, by the cal-
cium-dependent, endothelial-specific isofonn of nitlic oxide synthase (ecNOS). A 
calcium-independent isoform of NOS can be induced by cytokines and lipopoly-
saccharides in endothelial cells and VSMC'S27-.10. This latter isoform is called inducible 
NOS (iNOS). After release by the endothelial cell, NO diffuses to the VSMC and 
stimulates soluble guanylate cyclase, incrcasing cGMP levels and lowering intracellular 
calcium. cGMP mediates vasodilatation, probably through GMP-kinase mcdiated 
activation of calcium-gated K+-channelsJ1 . In addition to its vasodilator properties, 
NO modulates vascular growth and structlll'e, decreases platelet aggregation, neutrophil 
17 
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adherence and vascular permeability30, 32, Physiologic stimuli, including increased 
p02 and hemodynamic forces, such as pulsatile flow or shear stress, are known to 
induce ecNOS activity, Basal NO formation has been demonstrated to contribute to 
the maintenance of basal pulmonary vascular tone and appear to augment the decline 
in PVR during exercise ll , 22, 33, 
Development 
AI/otom)' 
The pulmonary vasculature does not have only special features, but it also develops 
and mature in a specialway4, The embryonic development of the lungs starts in the 
4th week after conception, but is not yet completed at birth, Therefore, the lung of the 
newborn cannot be regarded as a miniature adult lung4 . The characteristics of airway 
development and differentiation have been extensively described34, 
At 4 wk of human development, an endodermal pair of lung buds originates from the 
esophagus and differentiates into bronchi 35.37, These bronchi multiply by branching 
until at 16 wk all non-respiratory airways are present4, 38, Respiratory airways develop 
between 16 wk of gestation and birth, The airspaces present at birth are referred to as 
primitive sacculi. At birth, approximately 20 million sacculi are present in both lungs4, 
38, Alveoli, as in the adult lung, are not present at birth. In mature infants they IIrst 
appear approximately 2 months after birth, then multiply fast. This multiplying is 
most prominent in the IIrst years of life, but continues until the age of 8 years, when 
approximately 300 million alveoli have developed. The alveoli keep growing in size 
until adulthood4, 
Pulmonary vascular development also starts early in the embryogenesis, probably 
simultaneously with the development of the airways, The mesenchyme surrounding 
the pair of lung buds contains a vascular network derived from the foregut36, Vessels 
following the branching airways differentiate into arteries and laterjoin the pulmonary 
arteries, which have grown toward the lung buds from the sixth branchial arch35,36, 
Two morphogenic processes contribute to the development of lung vasculature: 
vasculogenesis and angiogenesis36, 
18 
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In the process of vasculogenesis, preexisting endothelial cell precursors or angioblasts 
assemble in situ to form primitive vascular channels. These channels remodel, giving 
lise to arteries, veins and lymphatics, depending upon apparently local stimuli and 
information within the surrounding mesenchyme36 . 
In the process of angiogenesis, new vessels form by budding or sprouting from 
preexisting vascular channels, which have groups of migrating cells at their tip. 
Differences in endothelial cell properties between the proximal and distal lung 
vasculature have been contributed to both the differences in origin (i.e., sixth branchial 
arch and mesenchyme) and the different processes involved (vasculogenesis and 
angiogenesis) in lung vascular development36 •. 19. 
A close association of pulmonary arteries and airways starts early in development. 
During development preacinar arteries and airways show a synchronized branching 
pattern 40. Remaining separate, however, are the veins that arise within the loosc 
mesenchyme of the lung septa. All preacinar vessels are present at the 16 wk of intra 
uterine lit'c4.38. The intra acimu' blood vessels appear when the alveoli develop. They 
multiply and keep pace with the alveolar multiplication. The presence of muscula-
risation of the arterial wall lags behind the appearance of new vcssels4. 38 The 
proportion of arteries of a givcn size that show a muscular media changes with growth 
and development, but is also moditied with disease4• 41. Not only size, but also the 
position in the arterial tree determines wall structure in the intra acinar arteries. The 
extension of muscular arteries into the acinus progresses from fetus to adult. In the 
fetus, muscular arteries are not found with the respiratory bronchiole or beyond. 
Virtually all muscular arteries are found in the preacinar region. During childhood 
and adolescence, therc is extension of muscle, so that it appears in the arterial wall 
progressively further into the periphery of the respiratory unit. Respiratory bronchioli 
develop a muscular coat during the first year of lit'c. At the age of four years 
approximately all arteries accompanying alveolar ducts are muscular. At that time the 
majority of these arteries is partially muscularized and becomes completely 
muscularized by 7 years of age (tigure 1)4. 
Pulmonary arterial muscularity, defined as percentage medial thickness, is higher in 
the fetus than in the adult. After birth, perccntage medial thicknes decreases at tirst 
rapidly, and then morc gradually, to reach the low mature level at three months of age 
19 
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Figure 1. The distance or 'extension' within the acinus lJ{muscular arteries. In the 
fetus, musmlararteries are notfound with the respiratOJ)' bmnc/liolus (R.B.) 
or beyond. During childhood, they extend fllrther IIntil, in the adult, they 
reach the pleural level. The acinlls is the respiratOJ)' unit supplied by a 
terminal bronchiolus (IB.). A.D. = alveolar duct; All'. = alveolar region. 
Adaptedfmm Reid, LM. The pulmonar\' circulation: remodeling in growth 
and disease. 17le 1978 J. Bums Amberson lecture. Am. Rev Respir Dis 
1979; 119:531-46. 
in most normal infants (figure 2)4.42,4.1. As explained laler, Ihis first postnatal drop in 
muscularity is associated with changes in cell shape and position, without reduction 
of the amount of pulmonary vascular smooth muscie44, 45. 
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D- - -a 4 Months to Adult 
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Figure 2. Medial thicklless as a per Cellt o(external diallleter related to arterial dia-
lIIete!: Arteries of all sizes are thicker ill the fetus thall the adllit. By 3 days, 
the illcrease in compliance afsmall arteries is apparent by their decrease 
ill wall thicklless to adllit levels. 
Adaptedfrolll Reid, LM. The pullllollary circlIlllfioll: relllodelillg ill growth 
alld disease. The 19781. Burns Alllbersoll lecture. Alii. Rev Respir Dis 
1979; 119:531-46. 
If judged by the percentage medial thickness of a given artery, pulmonary arterial 
muscularity is larger in the fetal lung compared to the adult lung. However, judged by 
the level to which muscular arteries are found, muscularity in the fetus is strikingly 
less than in the adult lung. 
During maturation of the pulmonary vasculature, contractile, cytoskeletal and 
extracellular matrix protein production is subject to important changes, which will be 
discussed later36• 
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Physiology 
Most of our knowledge of the fetal circulation is derived from studies in fetal lambs 
and most of the data reviewed here refer to the fetal lamb. In utero, the pulmonary 
blood now is very low. DlIIing 2/3 of gestation the lungs receive approximately 4% 
of the combined ventricular output, rising to 8-10% at the end of gestation46-48 . Most 
of the right ventricular output is diverted away li'mn the lungs through the widely 
patent ductus arteriosus to the descending aorta and the placenta for oxygenation. 
Although the number of small blood vessels per unit of lung increases by 10-fold in 
the second half of gestation (i.e. the number of small vessels increases 40-fold, while 
the wet weight of the lung increases 4 fold), the blood tlow per unit of lung does not 
change in this period of gestation46. As many vasodilators can increase pulmonru'Y 
blood now dramatically in the near-term lamb, fetal blood now apparently is limited 
by vasoconstriction49• 5o. Fetal pulmonary circulation probably is modulated through 
a balance between vasoconstrictor and vasodilator stimUli, including endogenolls 
mediators and mechanical factors (e.g. lung volume). 
Sympathic chain stimulation, norepinephrine, arachidonic acid, prostaglandin F2, 
thromboxane A2 and endothelin-I (ET-I), an endothelium-de.ived vasoactive peptide, 
all are demonstrated to cause vasoconstriction in the fetal pulmonary circulation36.5 '. 
However, neither experimental sympathectomy nor alpha-adrenergic blockade 
decreased fetal PYR, indicating that the high PYI{ of the normal fetus is not caused 
by sympatic tone36. Similarly, blocking prostaglandin and thromboxane A2 synthesis 
does not decrease resistance, so prostaglandins or thromboxane do not appear to causc 
the high vascular tone in the fetallung3fi. 
In the late gestational ovine fetus, prolonged infusion of El~ I causes increase of 
PYR, whereas intrapulmonary blocking of the ETA receptor, localized at the YSMC, 
results in a decrease of vascular resistance. In contrast, selective stimulation of the 
ET B receptor causes pulmonary vasodilation through cndothelial cell NO release. It 
is suggested that endogenous ET-I production primarily contributes to the high basal 
puhllonru'y vascular tone in the fetus by its action on the A receptor of the YSMC52.53. 
Vasoconstriction in response to the low fetal oxygen tension (around 19 nUllHg) also 
does contributc to fetal pulmonary vasoconstriction. Decreasing oxygen tension in 
near-term fetal lambs doublcd PYR, whereas increasing oxygen tension markedly 
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decreased resistance and increased pulmonary blood flow to normal newborn 
levels46 ,54 
Prostaglandins, in particular prostaglandin-E2 (PGE) and prostacyclin (PGI2), havc 
shown to be potent vasodilators in the fetal lung55,56, PGI2 is produccd by endothelial 
cells and has its smooth muscle relaxing effect via cAMP. Acetylcholine, bradykinin 
and histamine are fetal pulmonary vasodilators, which act by stimulating the formation 
ofN026, 5HO, The presence of NO has been reported from in the lirst half of gestation 
in the fetal lamb. NO is formed in the endothelial cell during the conversion of L-
arginine to L-citrulline by NOS, Next, NO diffuses rapidly into the YSMC and 
stimulates soluble guanylate cyclase to produce cGMp.12, Despite high fetal PYR, 
NO modulates basal pulmonary vascular tone in the late-gestation fetus and postnatal 
adaptation (see later)6!, Recent studies suggest that high fetal cGMP-specit1c 
phosphodiesterase (POES) activity may limit NO activity62, 6.1. 
In the late gestational fetal circulation vasoconstrictor stimuli evidently dominate 
over the vasodilator stimuli, resulting in a high fetal pulmonary vascular tone and 
resistance. 
Humoral and cellular mechanisms ill pllllll()Il{{J~r v({scular development 
The close association of artelies and airways begins early in development, and as 
development proceeds, there is a synchronization of vessel and airway branching, 
implying that they respond to common mediators4o. The exact mechanisms that control 
vascular cell proliferation during lung development ill vivo are not known. However, 
circumstantial evidence from ill vifm studies of vascular cells from the lung or other 
organs suggest that the local production and action of growth factors are involved"", 
Growth factors who are likely to playa role in pulmonary vascular development are 
the fibroblast growth factor (FGF), both the basic and acidic type, the transforming 
growth factors J3 (TGFJ3), platelet derived growth factor (POGF), the insulin-like growth 
t~1ctors (IGF) type I and 2 and the vascular endothelial growth factor (VEGF)M 
I30th acidic and basic FGFs have been shown to be mitogcnic and chemotactic for 
vascular wall cells as well as a potent angiogenic factors""' 6'. Antibodies to FGF have 
been demonstrated to retard vascular development6". TGFIl increases production of 
collagens I and III and libronectin by lung libroblasts and is associated with angiogenic 
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activity)6, 67, It has been shown to be expressed in the developing lung in a specitlc 
spatial and temporal pattern and to have potent effects on cell proliferation36 POOF 
is also expressed at different stages in the developing lung and is shown to be mitogenic 
for YSMC's and fibroblasts, especially in combination with cyclic mechanical load, 
and to influence cell differentiation36, 68-70, The IOFs, both type I and 2, stimulate 
proliferation ofYSMC's and fibroblasts and also increase elastin and collagen synthesis 
in neonatal pulmonary vascular wall cells, IOF-I levels within the vascular walls are 
shown to vary with hemodynamic load and medial IOF-I expression parallels the 
expression of elastin36, 70. 
Mediators involved in the modulation of pulmonary vascular tone, also have effects 
on cell growth: ET-l, a potent vasoconstlictive peptide, has a mitogenic effect on 
pulmonary YSMC's, In contrast, the pulmonary vasodilators NO and prostacyclin 
inhibit proliferation ofYSMC'ss, 71, Hemodynamic factors are also of great importance 
in directing vascular growth, It has been suggested that the mechanical stress acting 
on vascular'endothelial cells after the onset of circulation is the major force responsible 
for the development of large vessels72 , A "shear stress responsive element" has been 
identitled in a progressive number of growth factors, suggesting that its production 
and activity can be altered by hemodynamic forces7J, 74, 
In the fetus and newborn, YSMC's are immature: synthetic and reproductive rather 
than contractile properties predominate75-78, In this stage, production of growth factors 
and deposition of connective tissue seems more important than contractility, During 
development, fetal YSMC's mature to an adult phenotype, characterized by increased 
concentration of myot1laments and predominantly contractile properties 79, This is 
accompanied by the acquisition of growth restrictive charactelistics, However in con-
trast to skeletal muscle, YSMC's do not show terminal differentiation when they loose 
the capacity to replicate)6, 79, In case of ill vivo vascular injury, apparently fully 
differentiated YSMC's are able to "redifferentiate" to the synthetic phenotype with 
great potential to replicate36, 
At all ages, the medial YSMC's form a phenotypically heterogeneous, highly organized 
cell population, The cells close to the adventitia contain a significantly greater 
concentration ofmyofilaments than those close to the intima76, 77, 79 Tltis gradient in 
YSMC differentiation is present at all age dcspite all the cells' showing an increase in 
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myofilament concentration with age, The predominantly secrctory properties of the 
VSMC's in the inner media may indicate a greater potential for growth and adaptation, 
which helps to explain the phenomena of intima proliferation, containing migrated 
VSMC's, in pulmonary vasculm'disease, Phenotypically different VSMC's also express 
genes for different growth factors45 , 
Production of extracellular matrix by cells of the developing vessel is also essential 
for vasculm integrity and continued cell differentiation, A major function of tile VSMC 
in the developing vessel is the production of connective tissue, particularly elastin 
and collagen, which ultimately constitute some 70% of tile mass of the large pulmonm')' 
m'terial walls36, The amount of connective tissue increases after birth in both media 
and adventitia, The proportion of the different types of interstitial connective tissue 
also changes with age, which directly affects the mechanical properties of the vessel 
wa1l80, 81, Elastin is largely produced during fetal development, with production 
essentially concluded by the first decade of life, In vitro experiments have demonstrated 
that TGFB, IGF-I and -2 and glucocorticoids increase tropoelastin-mRNA and elastin 
synthesis, whereas epidermal growth factor, interieukin-l B, phorbolesters and 1,25-
dihydroxyvitamin 03 suppress tropoelastin synthesis36, 8', Control of elastogenesis 
in vivo, however, is poorly understood, 
At birth, imnulllolocalization shows an abundance of collagen types III and V and a 
relative paucity of type 177,81, With age the proportion of type I collagen increases, 
mainly in the outer media and adventitia, Because collagen type I is the collagen of 
high tensile strength, this suggests that the newborn pulmonary vasculature is more 
plastic than that of the adult, facilitating rapid changes in cell shape and orien-
tation45, 75, 77, Factors assumed to be involved in collagen deposition include IGJ'-I, 
TGFB, leukotriene C4 and PDGF, which stimulate collagen synthesis, and PGE2, 
epidermal growth factor and gamma-interferon, inhibiting collagen synthesis3", 81, 84, 
Postnatal adaptation 
Anatomy 
Instantly after birth the lungs have to take care of the newborns gas exchange and 
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start immediately to adapt to extra-uterine life, This process, called neonatal transition, 
aims at an abrupt increase in pulmonary blood flow, It is accompanied by a rapid 
remodeling of the pulmonary vasculature and can be divided in two stages77 Stage I, 
the direct adaptation, that lasts from birth until approximately 4 days of age75, 77, 
Stage 2, the structural stabilization, that begins at birth and lasts until 3-4 weeks of 
age76, 77, As outlined before, postnatal pulmonary arterial development also comprise 
vascular growth, continuing until adulthood, 
In stage I, adaptation involves both the elastic conducting arteries and the resistance 
arteries, as the pulmonary vasculature behaves in a closely integrated manner75,76, 
The em'liest mld most prominent changes, however, are seen in the precapillary artedes, 
At birth the endothelial cells m'e squat and have a low surface/volume ratio, Already 
5 minutes after birth, these cells show stretching and spreading, leading to a thinning 
of the vascular wall and an increase in luminal diameter, while the external diameter 
is constant15, 77, Similar structural changes occur in the small muscular arteries, 
although slower. Many small, "unopened", muscular arteries are recruited into the 
pulmonary circulation dUling the tirst four days of life, Thus, direct stl1lctural adaptation 
to extra-uterine life consists of changes in cell shape and position, without reduction 
of the amount of pulmonary vascular smooth muscJe44,45 These changes may be 
facilitated by the lack of tixed interstitial connective tissue in the peripheral vascular 
wall at birth, 
In stage 2, after thc cells have taken their new position within the vessel wall, stl1lctural 
stabilization is accomplished by deposition of connective tissne77, The formation of 
the detinitive lamina elastica interna, consisting at birth of tiny amounts of amorphous 
elastin in the small muscular arteries, takes place in the tirst 3 weeks, In the larger 
arteries all elastic laminae increase in length and thickness and occasional collagen 
tibrils becomes substantial collagen tibers during the tirst 3 weeks of life76, Also the 
type of collagen changes: at birth there is mainly type III and V collagen, while poshlatal 
deposition is mainly type 181 , The increase in mcdial elastin is relatively greater than 
that of collagen, 
Physiology 
At birth there must be a sudden and complete transition from gas exchange by the 
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placenta to gas exchange by the lungs. Instantaneously, the newborn depends on 
pulmonary ventilation and perfusion. After the umbilical artery has been clamped, 
systemic resistance rises, partly caused by the removal of the low resistance vascular 
bed of the placenta. Immediately after birth a 8 to 10-fold increase in pulmonary 
blood now occurs, limn 30-35 ml/kg/min to 350-400 mllkg/min and is associated 
with a dramatic fall in PVR47 At 24 hours after birth the mean pulmonary artery 
pressure is only half systemic 85. After the initial, rapid fall in PVR and pulmonary 
artery pressure there is a gradual, progressive fall, with adult levels rcached in 2-6 
weeks86. 87. The rapid fall is mainly due to lowering vasculartone and modulations in 
cellular shape (see above), the gradual [111 to vascular remodeling, muscular involution 
and rheologic changes. 
The decrease in resistance is initiated by the rhythmic distension of the lungs by 
ventilation, increase of oxygen tension (p02) and the decrease of carbon dioxide tension 
(pC02)88.89. Experiments in lambs have shown that each of this stimuli separately 
lowers PVR, however, it has been demonstrated that the changes are predominantly 
due to the local vasodilatatory effects of increased pO/6.88. The mechanism through 
which 02 causes pulmonary vasodilation is not known. The rise in 02 could directly 
affect the pulmonary VSMC or it could stimulate the release of a substance or 
substances that, directly or indirectly, dilate the pulmonary circulation. 
Increasing oxygen tensions have been demonstrated to increase basal and stimulated 
NO release as well as bradykinin, a stimulator of NO synthesis9o. 9J. Another 
mechanism could he that the increase in 02 inhibits vasoconstriction, direct or via 
vasoactive substances. Finally and most likely, a combination of these may be 
responsible for the effect of p02 "2. 
Humoml lIlId cel/ulal' mechallisms ill the tmllsitioll process 
Variolls potential mediators of transition have been investigated, however, the com-
plex mechanisms of neonatal transition are not fully understood. 
Prostllglw/(/iIlS. One of the most extensively studied mediators have been the 
prostaglandins. The decrease in PVR caused by mechanical distension of the lung, 
without changing gas tensions, could be blocked completely by indomethacin, a 
prostaglandin synthesis inhibitor"3. 94. The particular prostaglandin involved, appears 
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to be prostacyclin (PGI2)95. However, the effect of pO, is not associated with an 
increase in PGI2 and cannot be blocked by indomethacin96• 97 Since in the intact 
lamb indomethacin only modestly disrupts the decline in PYR, but does not disrupt 
the transition to gas exchange by the lungs, the role of prostaglandins in transition is 
assumed to be modest.16 . 
Nitric oxide. Increasing expelimental data exist suggesting a central role of en doge no LIS 
NO in the perinatal peliod. Both basal and stimulated release of NO appear to peak in 
the immediate postnatal period98 L-NA, a blocker of NO production, blocks the 
increase in fetal pulmonary blood tlow caused by hyperbaric oxygenation without 
ventilation99. Infusion of a low dose L-NA for 10 days before delivery, did not increase 
basal PYR, but it markedly blunted the decrease in resistance and increase in flow at 
birth, minticking the physiology of persistent pulmonary hypertension of the newborn 
(PPHN) 100. Shear stress increases the synthesis of NO in the fetal pulmonary 
circulation, providing a positive feedback mechanism for increases in pulmonary blood 
flow at birthIOI. 
E"dollIe/ill. In the late gestation ovine fetal lung, brief infusions ofET- I cause transient 
vasodilatation; however, with prolonged infusion, PYR increasesIO'. The effects of 
ET-I on PYR in the normal fetus are mediated through distinct receptor subtypes 10.1. 
The ETA receptor has been identilled to the YSMCIO". The ET B receptor is present on 
the vascular endothelial cell 105 As summarized earlier, E1C I is suggested to contribute 
to high fetal basal pulmonary vascular tone. In human neonates with PPHN circulating 
ET-I levels are markedly elevated, correlate with disease severity and decline with 
the resolution ofPPHNI06. These lindings suggest that ET- I activity decreases during 
normal transition. 
Thus, summarizing, multiple mechanisms appear to independently and synergistically 
cause the crucial increase in pulmonary blood tlow at birth. 
Pulmonary vascular disease in congenital heart disease 
Pulmo/lary plexogenic llJ'feriojJafhy 
Pulmonary hypertension is not a disease in itself, but rather a symptom of underlying 
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disease. The underlying disease may havc its origin in the heart, the pulmonary 
vasculature or both. Secondarily, pulmonary hypertension will lead to pulmonary 
vascular disease, including functional and structural changes of the pulmonary vessels. 
Pulmonary hypertension caused by heart defects is associated with increased 
pulmonary blood flow andlor pulmonary venous congestion. Various types of 
pulmonary vascular disease (PVD) have been identitled with different etiologic 
factors 107. 108. 
I. Alveolar hypoxia, resulting from a variety of disorders, including exposure to high 
altitude, chronic obstructive airway disease and cystic tibrosis, will lead to hypoxic 
arteriopathy, characterized by pulmonary vasoconstriction and an increase in 
muscularization of all levels of the pulmonary arborization, cxcept the pulmonary 
veins. 
2. Left ventricular dysfunction, mitral or pulmonary venous stenosis, all may lead to 
pulmonary congestive vasculopathy, characterized by muscularization of the 
pulmonary veins and secondarily of the pulmonary arteries and hemosiderin-
containing macrophages in the alveoli. 
3. Congenital heart disease associated with increased pulmonary blood now will lead 
to pulmonary plexogenic arteriopathy (PPA). This is a characteristic type of 
pulmonary vascular disease, most frequently found in patients with congenital heart 
disease, but also occuning under various, apparently unrelated conditions, including 
hepatic disease, schistosomiasis, HIV and ingestion of anorexigenic drugs. lt also 
occurs without a recognized etiological t~1ctor, where it constitutes onc of the 
histological subtypes of the clinical entity called 'unexplained' or primary 
pulmonary hypertension. 
4. Other forms of pulmonary vascular disease include thromboembolic arteriopathy, 
pulmonary fibrosis, pulmonary vasculitis and pulmonary veno-occlusive disease. 
These types of pulmonary vascular disease arc out the scope of this study and will 
not be discussed here. 
When discussing pulmonary vascular disease, it is of eminent importance to distinguish 
the different types of pulmonary arteriopathy. Crucial differences in etiology, 
pathophysiology, morphology of vascular changes and, most important, in clinical 
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course distinguish plexogenic w"teriopathy from other vasculopathies, such as hypoxic 
or congestive vasculopathy l09. In the early stage of PPA, morphologic vascular chan-
ges may be similm to that in other arteriopathies. However, when PPA advances, 
characteristic lesions emerge, such as concentric laminar intimal fibrosis and plexi fOlln 
lesions, that are never seen in other types of pulmonmy arteriopathy. Also the clinical 
course distinguishes PPA from other pulmonary vasculopathies. Hypoxic and 
congestive pulmonary vasculopathies are reversible if the causing factor, the hypoxia 
or the venous congestion, can be removed. In contrast, PPA, if untreated, advances to 
a certain 'point of no return' at which the disease process has not only become 
irreversible, but even progresses when the underlying hew't defect is corrected 110. III. 
This review will further focus on plexogenic arteriopathy in congenital heart discase. 
Congenital hew't diseases that are associated with increased pulmonw'Y blood 11011', 
especially if combined with increased pulmonary artery pressure, will lead to PPA. 
The time course in which PPA develops seems related to hemodynamic vw·iabies. In 
heart defects with left-to-right shunts and increased pulmonary artery pressure 
persisting after birth, e.g. a large unrestrictive ventricular septal defect (VSD) or a 
complete atrioventricular septal defect, PPA commonly progresses to the advanced 
stage within the first yew's of life. In contrast, in cW'diac anomalies with substantially 
increased pulmonary blood flow but normal pulmonary w·tery pressure, e.g an atrial 
septal defect, PPA generally advances slowly and, untreated, may lead to severe, 
irreversible disease associated with pulmonary hypertension and death, after the third 
decade of lifc in more than 50% of the cases ll2 . Although advanced PPA in the latter 
type of defects has been reported in the pediatric age group, this is rarelo'.IIJ. Besides 
the hemodynamic charactelistics, the anatomical defect has been suggested to affect 
the time course in which advanced PPA develops77. 114 For example, both an isolated 
VSD and one associated with a transposition of the great arteries (TGA) cause a left-
to-right shunt and pul monary hypertension, but, if untreated, the fonner rarely causes 
advanced PPA during the lirst year, whilst the latter usually has developed irreversible 
PPA beforc patients are one year old77. 115 
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AI/lltomy 
Pulmonary plexogenic arteriopathy is named after its most charactelistic lesion, the 
so called plexiform lesion, which occurs, however, ouly iu the tinal stage of the disease, 
Plexogenic m'teriopathy, i.e, potentially leading to plexiform lesions, is thus a vascular 
disease with a sequence of vascular changes, that may eventually include plexiform 
lesions, From a histological point of view, the most prominent vascular changes are 
localized in the small, muscular pulmonary arteries, 
ENDOTflELIAL CELL ALTERATIONS 
Ultrastructural studies, by scanning and transmission electron microscopy (EM), of 
lung biopsy material of patients with congenital heart disease revealed alterations in 
endothelial cell appearance as the vessel becomes thick-wallcd II6, By scanning EM, 
the normal "corduroy-appearance" of the arterial inner surface texture, consisting of 
cells in neat, even, aligned ridges, changed to "cable-like" with twisted hulls and 
gulleys, On transmission EM, compared to control Jlulmonm'y m'teries, the cytoplasm 
of endothelial cells showed an increased concentration of rough endoplasmatic 
reticulum and microfilament bundles, Further it was observed that the internal elastic 
lamina of the muscular arteries appem'ed li'agmented in patients with early PYD, 
MEDIAL HYPERTROPHY AND i\IUSCULARIZATION OF ARTERIOLES 
If elevated pulmonary artery pressure persists after birth the pulmonary vasculature 
fails to remodel nonnally77, 117, 118, In the presence of an increased pulmonary blood 
tlow, pericytes and intermediate cells in precapillary vessels differentiate to YSMC, 
giving rise to extension of muscle into more peripheral arteries than nonnal" 9, 120. 
This "ll1l1scularization of arterioles" occurs almost always in association with 
thickening of the media of the muscular arteries77, lOS, 120, This thickening is due to an 
increase in number and size of the YSMC's, Although it is clear that both hypertrophy 
and hyperplasia are involved, this is usually referrcd to as medial hypertrophy, In 
congenital heart disease medial hypertrophy ah'eady occurs dllling the tirst two months 
of life, probably when the YSMC's are in their least differentiated state and 
consequently highly responsive to inj uryJ6, 77, lIS, The YSlvlC's, which are relatively 
undift'erentiated at birth, show an accelerated maturation in the presence of elevated 
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puhnonary artery pressure, associated with an increase in myofilament concentration 
and an increase in contractilc capability79, This is further enhanccd by a premature 
innervation of these thick-walled arteries by sympathic, vasoconstIictive nerves n 
This stage of increased muscularity of the pulmonary arterial tree is accompanied by 
an cxtensive modulation of thc extracellular matrix composition, including increased 
deposition of collagen and glycoprotcinsJ6, 77, 120, 
INTIMAL THICKENING 
Intimal thickening is the formation of a de novo laycr in a normally non-cellular 
stratum between endothelium and internal elastic lamina lOR, Although various types 
of intimal thickening may occur in plexogenic arteriopathy, two forms, representing 
two successive stages of disease, are the most common and characteristic for this 
arteriopathy: 
CELLULAR JNTI~'IAL PROLIFERATION 
This constitutes the tirst stage in the development of intimal thickening and is most 
striking in muscular arteries smaller than 100 ~un in diameter lOS, Ultrastucturally, the 
proliferated cells within the intima have the appearance of "myoJlbroblasts" and are 
suggested to be VSMC's that have migrated ti'om the media, through gaps in the 
internal elastic lamina to the subendothcliulll 12', The VSMC's of the inner media 
have a predominance of secrctory over contractile organelles indicating a great potential 
to growth, adaptation and migration36, 76, 79, Within the layer of proliferating cells, 
there is accumulation of mucopolysaccharides, but collagen fibers are scarce 
initiallylO7, Cellular proliferation of the intima may cause considerable narrowing of 
muscular pulmonary arteries, 
CONCENTRIC-LAl\,t[NAR INTIt-.·lAL FIBROSIS 
Deposition of collagen and, usually to a lesser extent, elastin within the layers of 
proliferatcd intimal cell leads to the stage of intimal tibrosis, This process starts within 
the layer of cellular proliferation close to the internal elastic lamina, In the course of 
time the intimal thickening becomes more and more Jlbrotic and lacking in cells, 
Concentric layers are formed by which the intimal thickening acquires a peculiar 
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onion-skin appearance. This lesion may be considered pathognomic for plexogenic 
arteriopathylO8. As with cellular proliferation, concentric-laminar intimal librosis is 
most severe in the proximal segments of supernumerary branches near their origin 
from larger arteries and eventually may completely occlude the arterial lumen and 
may protrude into the parent artery as a thick collar around the orilice J08 Severe 
intimal librosis may cause secondary medial atrophy by lack of medial nutrition, 
nonnally supplied by blood flowing through the lumen, or by lack of persistence of 
the high blood flow and/or pressure in the more peripheral artery segments, resolving 
the stimuli for VSMC proliteration IOJ. 122. 
DILATATION LESIONS 
Sustained elevation of pulmonary arterial transmural pressure may lead to localized 
dilatation of pulmonary arteries, so that the lumen becomes wider and the wall thinner. 
Consequently, preexisting medial hypertrophy seems to diminish or to disappear in 
some arteries, in spite of sustained pulmonary hypertension. Usually, dilatation leads 
to extreme thinning of the wall of muscular arteries and their branches, in combination 
with pronounced widening of lumina, producing the so called "vein-like branches of 
arteries", that arise from thick-walled arteries I 10 These branches may form clusters 
of wide, thin-walled vessels, that occasionally become so large and compact as to 
resemble small angiomas, refel1'ed to as "angiomatoid lesions"110 Vein-like branches, 
clusters of vessels and angiomatoid lesions are collectively known as dilatation lesions. 
The place of dilatation lesions in the sequence of changes of plexogenic arteriopathy 
is not beyond doubt lO8- 11O It is ccrtainly one of the advanced lesions and most likely 
the development of dilatation lesions generally precedes that of fibrinoYd necrosis 
and plexiform lesions lO8• 109. 
FIBRINOiD NECROSIS AND ARTERITIS 
In fibrinoYd necrosis, the wall of muscular pulmonary arteries, and particularly the 
medial smooth muscle cells, degenerate and become necrotic, probably preceded by 
imbibition of the wall with fibrin lOJ • lOS. This process usually occurs over short stretches 
of small arterial branches, preferably shortly after their origin from a larger artery. In 
such n segment the media is swollen with an eosinophilic, ground glass appearance, 
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while the VSMC's become unrecognizable due to karyolysis, In some cases fibrinoid 
necrosis is complicated by an inflammatory response, leading to necrotizing arteritis, 
Experimental evidence suggests that the injury to the arterial wall leading to fibrino'id 
necrosis is related to severe, spastic contraction of the medial2.l, 
PLEXIFORM LESIONS 
Plexiform lesions are very cbaracteIistic arterial alterations that develop in the tlnal 
stage of plexogenic arteriopathy, The predilection place is, again, in the small arterial 
branches, the supernumerary arteries, directly after their origin from larger arteries, A 
plexiform lesion consist, in its most typical form, of a circumscript dilatation of a 
branche with destl1lction of the arterial thinning of the media, loss of VSMC's and 
rupture or even disappearance of elastic laminae, Within the dilated lumen a plexus of 
narrow slit-like channels develops, These channels communicate with each other and 
with the proximal and distal lumen of the branch, the latter being very dilated and 
thin-walled over some distancelO~, 110, The proliferated cells within a plexiform lesion 
are numerous and show characteristic hyperchromatic nuclei. Active proliferation of 
endothelial cells and active collagen synthesis have been demonstrated within 
plexiformlesions l24,125 
SUlllmarizing, in the early stages ofPPA, increased muscularization of the pulmonary 
arterial tree is found, constituted by medial thickening of the pulmonary muscular 
arteries and musculmization of normally non-musculm'ized arterioles, This is followed 
by cellular intimal proliferation, As plexogenic arteriopathy advances, characteristic 
lesions emerge, such as concentric laminar intimal fibrosis, angiomatoid dilation 
lesions, tlbrinoid necrosis and plexiform lesions, These advanced lesions are associated 
with in'eversible disease lll , 
In the larger, elastic puhnonmy arteries, structural changes are less prominent. However, 
these arteries are not exluded from the disease process, The media of the elastic arteries 
increases in thici"less, due to an increase in size of the solitary VSMC's and changes 
in the extracellular matrix, including an increase in collagen and glycoprotein 
deposition 126, Intimal fibrosis occurs in the larger elastic arteries, but is not 
charactetistic for plexogenic ar'teriopathy and, in pathological studies, did not correlate 
with the histological changes of the vascular bedlO8, 126, 
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Physiology 
The equation for PYR (eql/ation 1) can be reananged to givc: 
PAP = LAP + PVR x Qp 
It can be derived that pulmonary hypertension may be due to three basic physiologic 
phenomena. Firstly, if pulmonary blood flow is incrcased, whereas the PYR is 
unchanged, this will result in an increased pressure gradient over the pulmonary 
vascular bed and thus an elevated pulmonary arterie pressure. This may be the case in 
young children with congenital heart disease with left-to-right shunting, before 
advanced PYD has developed. Secondly, if the downstream pressure (LAP or PWP) 
is elevated and pulmonary blood !low and PYR are unchanged, pulmonary artery 
pressure has to rise to maintain the required pressure gradient over the vascular bed. 
This may be the case in mitral stenosis or left ventricular dysfunction. And thirdly, 
PYR is increased, and consequently more pressure is needed to maintain equal 
pulmonary blood !low. This will be the case in PYD. Obviously, various combinations 
of the described conditions are possible. 
It is important to realize that flow per se is not a cause of pulmOlHu'Y hypertension. 
Large increases in pulmonary blood flow due to excersise or atrial septal defect cause 
almost no increase in mean pulmonary artery pressure because, as outlined earlier, 
previously closed arteries are recmited and existing open vessels dilate Ll . Consequently, 
PYR is below normal in these conditions. Therefore the finding of pulmonary 
hypertension, when there is a large pulmonary blood Ilow implies that PYR has not 
fallen appropriately and indicates some PYDLl. 127. 128. 
PYR rises in pulmonary vascular disease. Evaluated from the Poiseuille equation 
(eqllation 2), this may be caused by changes in vessel diameter, length of the vessels 
or blood viscosity. In PYD, the pulmonruy arterial lumen will narrow becausc of 
vasoconsttiction, due to increased muscularization, and because of cellular intimal 
proliferation; in advanced stages the arteriallumclI may even obliterate completely. 
This will result in a decrease in the overall cross-sectional area of the vascular bed. To 
differentiate between the vasoconstrictive and structural component of vessel 
narrowing, PYR can be determined, subsequently, during administration of 
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-pulmonary- vasodilators. Although not based on adequate follow-up data, the res-
ponse of the vascular bed to vasodilators, such as inhalation of 100% oxygen andlor 
NO, has been assumed to indicate the reversibility of the disease process 14.129.131. 
Independent from vessel na11"owing, the number of pulmonary vessels affects the 
total cross-sectional area of the pulmonary vascular bed. In certain conditions it is 
known that the pulmonary vascular bed may be hypoplastic, such as congenital 
diaphragmatic hernia and anomalies with decreased fetal bloodtlow, like pulmonary 
atresia. This may increase PYR, however independent from vascular hindrance and 
thus from the degree of vascular disease 13• 128. The number of pulmonary vesscls is a 
variable that is difticult to evaluate. 
An increase in blood viscosity will increase PYR by increasing the pressure gradient 
across the vascular bed for a given flow 13• 132. Since hematocrit may be increased in 
patients with cyanotic heart disease or decreased in children with large shunts, this 
variable should be taken into account. For example, a hematocrit of about 70% can 
roughly double PYR 133 The exact increase will depend on the hematocrit, the flow 
rate and the LAP. Therefore, with a high hematocrit, an increased PYR should not be 
interpreted only in terms of nan·owed resistance vessels. 
The length of the vessel seems a relatively unimportant variable in PYD bccause it 
seems unlikely that the small resistance vessels will changes much in length during 
the disease process 13. 
In the presence of pulmonary hypertension the distensibility of the elastic pulmonary 
arteries decreases, probably due both to structural and functional changes in the arterial 
wall and to the artery operating on a steeper part of its pressure-volume relation-
shipls. 1J4. Reflected pressure ,vaves will be increased in pulmonary hypertension. 
The decreased distensibility, and thus decreased capacitance of the pulmonary arteries 
may hamper the smooth conversion of pulsatile flow to virtually continuous perfusion 
of the pulmonary capillaries, and will lead to an accelerated return of the reflect 
waves 18.134. Both these physical phenomena will increase the mechanical, potentially 
damaging forces on the vasculature. 
Consequently, in the course of PYD both the steady load and the pulsatile load of the 
subpulmonary ventricle will increase dramatically, evcntually resulting in ventricular 
failure. 
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Humoral (l11l1 cellular mechanisms ;'1 plllmollWT vascular disease 
Recent research in vascular biology has demonstrated that a large variety of growth 
t~1ctors and mediators are likely to be involved in vascular remodeling. One has to 
realize, however, that our current knowledge has largely evolved from experiments 
using cultured vascular cells ill viflV. Although this simplitied experimental approach 
is necessary to determine capabilities of cells and to elucidate the mechanisms 
responsible for regulation of cell to cell interactions, these methods carry unavoidable 
limitations. Cells in culture may dedifferentiate and be removed of a myriad of blood-
b0111e and cell-derived controlling elements that are present ill vivo, with unknown 
consequences. A second indispensible source of our knowledge are experiments using 
animal models of pulmonary vascular disease. However, these experiments have 
demonstrated that the effects and actions of growth factors and their receptors show 
important inter-species diIIerences Ll5 . And, last but not least, thesc expelimentalmodels 
often use hypoxia, air-emboli or chemicals, such as monocrotaline, to inducc 
pulmonary vascular disease L1fi . These factors, however, do not lead to pulmonary 
plexogenic arteriopathy. Unfortunately, no well-functioning animal model for this 
characteristic arteriopathy is currently in usc. So, the results of these experiments 
must be interpreted cautiously and can not simply be translated to humans with 
pulmonary vascular disease associated with congenital heart defects. 
The pulmonary vascular remodeling process is associated with excessive cell 
proliferation and extracellular matrix modulation. Marked changcs in cellular 
phenotypes occur during the remodeling process. Precursor cells in precapillary vessels 
differentiate into VSMC's resulting in muscularization of arterioles 77. In the presence 
of neonatal pulmonary hypertension, accelerated maturation of VSMC from the 
immature, synthetic phenotype to the adult-like, predominantly contractile phenotype 
has been demonstrated36• 79. On the other hand, a subset of VSMC's increase their 
replicating and matrix protein synthetizing propertiesl.17·I.19.lmmature VSMC's migrate 
from the confines of the media into the subendothelium where they produce a new 
extracellular matrix. Further, apparently fully differentiated VSl'vIC's may "rediffe-
rentiate" to a secretory phenotypy in the course of pulmonary vascular disease36. 79, 
The pulmonary vascular endothelium, with its unique location, lining the inner vessel 
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wall, seems pre-eminently suited to detect changes in mechanical forces, such as 
stretch and shear stress, and is assumed to play an important role in the initiation of 
PVD associated with increased pulmonary blood flow and/or pulmonary hypertensions, 
A shear stress responsive element (SSRE) has recently been identified in the promo-
tor region of genes, encoding for various vascular modulators, including ecNOS, PDGF 
and endothelin29, 140, Endothelial cell release of vasoactive substances, including PGI2, 
ET-l and NO, was increased by cyclic strain on cultured human endothelial cell 
layers74, Shear-stress has heen demonstrated to induce the endothelial release of 
substances, including PDGF, NO and PGI/2, 141, 
Endothelial injury appears to be an important mechanism of enhanced release of ET-l 
in animal models l42, lung ET-I production is increased in rats with idiopathic 
pulmonary hypertension l43 and the pulmonary arterial-to-venous ratio of inununo-
reactive ET-I was increased in patients with pulmonary hypertension compared to 
controls l44, Finally, increased expression of ET-l in pulmonary endothelial cells has 
been demonstrated in adults with pulmonary hypertension l45 
NOS activity is stimulated by hemodynamic forces, such as pulsatile flow and shear 
stress32, However, in patients with plexogenic arteriopathy, expression of ecNOS 
appeared to be diminished in the course of the disease l46, In adolescents with advanced 
PVD, but also in babies with potentially reversible PVD, the excretion ofprostacyclin 
metabolites was reduced, whereas that ofthromboxane metabolites was increased 147, 
Already in an early stage of pulmonary vascular disease in children with congenital 
heart disease and increased pulmonary blood flow, impaired endothelium-dependent 
pulmonary vasorelaxation has been demonstrated l48 
In short, numerous observations suggest that PVD is the consequence of imbalance 
between substances with vasoconstlictor/growth promoting properties on the one hand, 
and vasodilator/growul inhibiting properties on the other; either by an increased release 
of the former or by an inhibited release of the latter, The net result will be pulmonary 
vasoconstriction and proliferation of pulmonary vascular cells, 
During the process of vascular remodeling there is extensive extracellular matrix 
modulation, associated with changes in proteolytic, chemotactic and synthetic activity, 
Alteration of extracellularmatdx can change cell phenotype 120, so it has been suggested 
that release or activation of proteolytic enzymes may be responsible for initiating the 
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series of switches in cell phenotypes l49, 1'0, Increased activity of an endogenous 
vascular elastase (EVE) has been observed in VSMC's of rats with both hypoxia and 
lllonocrotaline induced pulmonary hypertension l ,I-I,3, Elastase-inhibitor studies 
strongly suggest that increased activity of EVE leads to proliferation and migration 
ofVSMC's and increased production of extracellular matrix 1'4, Other growth factors 
and mediators that have been suggested to be involved in the pulmonary vascular 
remodeling process include TGFB, bFGF, lGF-l, IGF-2, VEGF, protoglycans and 
glycoproteins36, 71,120,149, TGFB and IGF-l and -2, induce the synthesis of collagen 
and other extracellular matrix proteins, such as fibronectinM , 67, The expression of 
isoforms TGFB-2 and TGFIl-3 apeared to be incrcased in the media and intima of 
pulmonary arteries in patients with PPA 155, Increases in IGF-l and IGF-2 mRNA 
expression have been demonstrated in experimental pulmonary hypertension I,,,, bFGF 
not only induces proliferation of vascular cells, but also the synthesis of proteases, 
These activities, in combination with its chemotactic properties, make bFGF suitable 
to playa role in the migration o[VSMC' S64, Finally, hFGF is directly upregulated by 
mechanical forces, 
In advanced PPA, exuberant endothelial cell proliferation has been demonstrated in 
plexiformlesions l24 VEGF, an important mitogen for endothelial cells and mediator 
of angiogenesis, is induced byTGFIl and has been suggested to playa role in pulmonary 
vascular disease, In an ex vivo rat model, hypoxia enhanced VEGF-synthesis and 
upregulated VEGF-receptor mRNA expression in alveolar cells and pulmonary 
macrophages l ,7,I,8 
The growth factors under study in PVD, are similar to thc factors involved in pulmonary 
vasculardevelopmcllt and growth. It is unclear whether vascular remodeling in disease 
results from a recapitulation of mechanisms associated with normal vascular 
development or Ii-OIl! entirely different pathological mecha-nisms3", Up to now, the 
pathophysiology of pulmonary plexogenic arteriopathy is poorly understood, The 
sequence of activation or inhibition of the various factors in the time course of the 
disease, so crucial to obtain insight in pathophysiology, remains to be elucidated, 
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Aims of the studies 
Pulmonary vascular disease is an lmportant determinant in the management and prog-
nosis of children with congenital heart disease. The assessment of the progression of 
plexogenic arteriopathy in these children is hampered by the limited knowledge of 
the pathophysiology of the disease. 
In the early stage of pulmonary vascular disease, the functional consequences of the 
alterations in contractile properties and the proliferation ofYSMC's and the modulation 
of extracellular matrix, for the integrated, pulsatile pulmonary circulation are only 
partly understood. This is due to the difficulties in studying the intrinsic, biomechanical 
arterial wall properties in vivo. 
We sought for new diagnostic variables that include both structural and functional 
properties of a pulsatile circulation. Intravascular ultrasound has the potential to 
evaluate both the structnral appearance of the pulmonary artery ill vivo and functional 
properties of the arterial wall itself. 
The aims of the described intravascular ultrasound studies in patients with congenital 
heart diseases were; 
I. To assess the feasibility of pulmonary intravascular ultrasound in infants and children 
and the ability to measure vascular dynamics accurately. 
2. To assess the ability of pulmonary intravascular ultrasound to detect changes in the 
appearance of elastic arteries in pulmonary vascular disease. 
3. To study vascular pulsatility and arterial wall distensibility, which may be new 
functional variables of the pulmonary vasculature, in patients with and without 
pulmonary vascular disease. 
4. To assess how these variables are associated with hemodynamic data, with structural 
changes of the pulmonary vascular bed and with the progression of the vascular 
disease. 
In plexogenic pulmonary arteriopathy, characteristic lesions emerge in the course of 
the disease process, that are associated with severe, irreversible disease, and will 
progress cven when the underlying heart defect is corrected. Determination of this so 
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called "point of no return" is hazardous: the techniques til at are currently in use to 
evaluate the pulmonary vasculature leave a grey zone between reversible and 
ineversible disease. This is due to our lack of knowledge on how the pathognomic 
lesions of plexogenic arteriopathy develop and at what point in the time course of the 
disease, plexogenic arteriopathy distinghuish itself from other pulmonary arterio-
patllies. 
Chamctetistic features of the advanced lesions of plexogenic arteriopathy include 
endothelial cell proliferation, abnormal angiogenesis and dilatation. We sought for 
factors that could be involved in these specific processes and therefore may playa 
role in the development of the characteristic lesions of plexogenic pulmonary 
arteriopathy. VEGF has been demonstmted to induce endothelial proli leration and 
angiogenesis, including abnormal angiogenesis in malignancies. The properties of 
NO include vasodilatatory activity, inhibition ofVSMC proliteration and stimulation 
of endothelial cell proliferation. Large amounts of NO, as produced by the inducible 
isofonn of NOS, may lead to oxidative vascular injury. 
The immunohistochemical studies, using lung biopsy tissue of children with congenital 
heart diseases, were aimed to answer the following questions: 
1. Is Vascular Endothelial Growth Factor involved in the development of the charac-
teristic lesions of PPA and if so, at which stage of the disease? 
2. Is increased nitric oxide production likely to playa role in the development of the 
charactetistic lesions of PPA? 
3. Is the inducible isofonn of nitric oxide synthase involved in pUlmonary vascular 
remodeling and is there a differentiated expression of the different isoforms? 
4. Is the expression of vascular endothelial growth factor and nitric oxide synthase in 
the pulmonary vasculature associated with mechanical forces, retlected by 
pulmonary hemodynamic data? 
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Abstract 
To determine the correlation between hemodynamic and histological evaluation of the 
pulmonary vasculature and clinical outcome, we retrospectively studied contemporaneous 
hemodynamic and histological data and outcome in a selected group of 47 children with 
complex congenital heml disease. 
Pulmonary artery pressures con'elated weakly with increased muscuhU'ity of the pulmonary 
arIeriallree (r = .4610 .67; p < .05) aod wilh Ihe presence of advanced plcxogenic arleriopalhy 
(p < .01). Diastolic pulmonary m-tery pressure:5: 25mmHg or pulmonary vascular resistance 
::;; 6 WU.m2 excluded features of advanced plexogenic artel"iopathy. Perioperalivc mortality, 
associated with acute pulmonary hypertensive crises. was conelated with increased arterial 
musculmity (p :::: .OI). Pulmonary hypertensive crises were not correlated with prcoperative 
hemodynamics. Of 15 survivors, 5 showed persistent pulmonary hypertension at follow up 
(69 ± 39 months; mean ± SD). No correlation existed between preoperative hemodynamics or 
the histologic presence of advanced plexogenic arleriopathy and persistent pulmonary 
hypertension aftcr surgery. All 3 patients with plexifofmlesions showed persistent pulmonary 
hypertension (p = .02). 
Conclusions: We found merely limited con·elations between hemodynamic and histological 
assessment of pulmonary plexogenic arteriopathy. Perioperative mortalily due to acute 
pulmonary hypertensive crises was associated with increased muscularity of the pulmonary 
arterial tree, but could not he predicted from preoperative hemodynamics. Both hemodynamic 
and histologic assessment of plexogenic mteriopathy were of limited value in predicting per-
sistent pulmonary hypertension after corrective surgery. Only plexiform lesions were inevitably 
predictive for persisting pulmonary hypertension. 
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Introduction 
Pulmonary plexogenic arteriopathy constitutes a serious threat to children with 
congenital heart disease and increased pulmonary blood tlow or increased pulmonary 
artery pressures. The state of the pulmonary vasculature is an important determinator 
of the management and prognosis of these children!' 2. As long as increased pulmonary 
blood tlow or elevated pressure in the pulmonary arteries pcrsists, the process of 
plexogenic arteriopathy may progress towards a "point of no return", at which the 
process becomes irreversible and precludes a curative effect of surgical repair of the 
cardiac disease3. 4• In addition, earlier and potentially reversible stages ofplexogenic 
arteriopathy can jeopardize the outcome of surgical procedures because of acute 
pulmonary hypertensive crises direct postoperatively5. In Fontan or Norwood-like 
procedures, even a slight postoperative increase in the resistance of the pulmonary 
vascular bed will cause pulmonary hypoperfusion, which may easily result in clinical 
detoriation. The techniques most commonly used to assess the state of the pulmonary 
vasculature and to determinc operability in children with congenital hcart disease arc 
hemodynamic evaluation by cardiac catheterization 1, 2 and histological evaluation of 
an open lung biopsy}-7. However, important discrepancies between the results of both 
techniques have been reported in individual patients with pulmonary vascular 
disease7-!!, hampering the interpretation of such findings. Furthermore, although 
widely used for over thirty years, data on the predictive value of both techniques with 
regards to outcome are scarce4• 8. !2.13 The purpose of the present study is to correlatc 
pulmonary vascular morphology and hemodynamic data, and relate the findings to 
clinical outcome in infants and children with complex congenital heart disease. 
Methods 
Patiellls 
Patients with congenital heart disease. of whom contemporaneous hemodynamic and 
histological data, obtained between 1983 and 1994, were available. formed the 
population of this retrospective stUdy. 
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Lung fissue specimens 
Biopsy specimens were taken as an isolated procedure or during cardiac surgery in 
children judged to be at risk for pulmonary vascular disease (biopsy group). In addition, 
specimens taken at autopsy were included in tile study (autopsy group). The indication 
for taking these latter specimens was not necessarily based on the suspicion of 
pulmonary vascular disease. Specimens were formalin fixed under vacuum, cut in 
2 nHn thick blocks and embedded totally in paraffin. Five pm sections were cut at 
various levels and stained with hematoxylin-eosin. Elastic van Gieson stain and Perls' 
iron stain were included in all cases. All specimens were re-examined independently 
by two pathologists (CAW, RJS), who were unaware of the diagnosis and hemodynamic 
data. Only the age of the patient was revealed. Pulmonary vascular lesions were 
described according to Wagenvoort and Mooi-'. Morphologic features such as medial 
hypertrophy, musculruisation of arterioles, cellular intimal proliferation and concentJic-
laminar intimal librosis were scored semi-quantitatively with regard to severity and 
frequency (0 = absent, I = mild, 2 = moderate, 3 = severe), as described earlier3. In 
evaluating the muscularity of the pulmonary arterial tree, the scores for medial 
hypertrophy and muscularisation of arterioles were adjusted to the age of the pa-
tient I4-16• Subsequently, a concensus session produced the delinite scores. For the 
overall degree of muscularity a single composite score, the total musculru'ity score 
(TMS, 0 = normal, I = mildly increased, 2 = moderately increased, 3 = severely 
increased), was obtained on the basis of tile scores for medial hypertrophy and arteriolru' 
muscularisation. The presence or absence of arterial tortuosity, longitudinal smooth 
muscle cells in arterioles and sphincters at the origin of branches were used as 
secondary indices to turn the balance in cases where the results were borderline. 
Dilatation lesions, librinoid necrosis and plexiform lesions were documented as pre-
sent or absent. The presence of plexiform lesions, Iibrinoid necrosis, dilatation lesions 
or concentric-laminar intimal tibrosis was considered as "advanced pulmonary 
plexogenic ruteriopathy". 
Hemodynamic dafa 
Cardiac catheterization was performed in all patients under general anesthesia. Data 
on pulmonary and systemic arterial and venous pressures, pulmonary blood flow, 
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shunt size and pulmonary and systemic vascular resistance were collected. Pulmonary 
vascular resistance was determined using pulmonary blood now, calculated with the 
Fick principle using assumed oxygen consumption. Pulse pressure and the ratios of 
pulmolUu'y-to-systemic pressure and pulmonary-to-systemic vascular resistance were 
calculated. Pulmonary vasodilator capacity was studied in II cases as the response of 
pulmonary vascular resistance to 100% oxygen inhalation. 
Follow "I' data 
Outcomc was assigned to short-term and mid-term outcome. Peri operative death 
associated with pulmonary hypertensive crises was studied as short-term outcome 
variable. Peri operative death was defined as death during cardiac surgery or within 
21 days after the procedure. Acute pulmonary hypertensive crises were defined as 
events of progressive and profound pulmonary hypertension and/or systemic 
desaturation, in the absence of obstruction of the pulmonary artery, combined with a 
decreased systemic circulation. In patients who underwent a univentricular repair, 
peri operative death associated with pulmonary hypoperfusion was studied as outcome 
variable. As mid-term outcome variable was studied the persistence of pulmonary 
hypertension after corrective surgery. Persistent pulmonary hypertension was de tined 
as a loud second hemt sound at physical examination, electrocardiographical evidence 
of right ventricular hypertrophy and echocardiographical features suggestive for 
elevated pulmonary m'tery pressure, in the absence of residual cardiac lesions. 
Statistical aI/a lysis 
Patients in the autopsy and biopsy groups were analysed seperately because the 
indications to obtain lung tissue were dissimilar in both groups. Hemodynamic data 
were correlated with histologic findings using Pearson's correlation coefticient. 
Categorical data were compared by Fisher's exact test. Statistical comparisons of 
hemodynamic and histologic data between groups of patients were made using the 
Student's t test or Mann-Whitney U test when distribution was not normal. In the 
biopsy group comparisons of data were made between patients with and without 
clinical features of pulmonary hypertension during follow up, using thc same tests. A 
value of p < .05 was considered significant. 
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Table 1 Anatomical Diagnosis 
VSD • isolated 
• with leftsided obstructive lesions 
cAVSD • isolated 
• complex 
TGA • complex 
Truncus arteriosus 
ASD with/without PAPVe 
TAPVe 
Tricuspid atresia • complex 
Fallot 
Others 
n 
6 
5 
6 
3 
9 
5 
3 
6 
2 
47 
ASD indicates atrial septal defect; cA VSD, complete atrioventricular septal defect; 
PAPVe, partial abnormal pulmonm'y venous connection; TAPVe, total abnormal 
pulmonary venous connection; TGA, transposition of the great arteries; VSD, 
ventticular septal defect; complex indicates with associated lesions; n, number of 
patients. 
Results 
In the study period, 47 patients underwent concomitant histologic and hemodynamic 
evaluation of the pulmonary vasculature. The total study group consisted of 29 males 
and 18 females, with a variety of complex congenital heart diseases (table I). 
The median age at lung biopsy was 6.5 months with a range from I day to 16.8 years. 
The age disttibution and the distribution of histological features in relation to age are 
shown in fig. l. 
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One patient had two lung biopsies with concomitant cardiac catheterizations. Three 
biopsies were taken as an isolated procedure and 14 during cardiac surgery (biopsy 
group, n = 17). 31 Specimens were taken at autopsy (autopsy group, n = 31). The 
median time period between collection ofiung specimen and hemodynamic data was 
1,0 month, ranging from 3 days - 24 months. In 4 patients this period exceeded 6 
months. 
number of patients 
MH 8 15 2 4 3 
MA 7 15 2 4 4 
ICP 0 3 0 0 0 2 
CLIF 0 2 0 0 
DL 0 0 0 0 I 
FN 0 2 0 0 0 
PL 0 0 0 
20 
MH = Medial Hypertrophy 
tvlA :::: lvluscuiarisalion of Arterioles 
15 ICP :::: Intimal Cellular Proliferation 
CLIP :::: Concentric Laminar Intimal Fibrosis 
~ DL :::: Dilatation Lesions 
" '0 
'" co. 
FN :::: Fibronoid Necrosis 
PL :::: Plexiform Lesions 
~ 10 0 
~ 
.8 
8 
'" 
" 
5 
o l ~ n ~ 
0-3 3-12 1-2 2-4 4-6 >6 
age months months year year year yem 
Figure 1 Age distribution and the distriiJlIIion 0/ histological/eatllres in re/ation to 
age. 0: Autops)' patiellfs; D: BioI'S), patients 
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Table 2 P({tiel/t characteristics of the ({utopsy ({I/d biopsy groups 
group autopsy biopsy 
n* 31 17 
median age (mo) 4.5 8.5 ns 
(range) (0.1-192) (3.1-20 I) 
M:F 2.8 : 1 0.9: 1 ns 
hemodynamics 
(mean ± SO) (mean ± SO) 
syst PAP 43 ± 22 60 ± 20 p = 0.016 
diast PAP 21 ± 11 26 ± 10 ns 
mean PAP 30 ± 15 41 ± 15 p =0.02 
pulse pressure 22 ± 14 34 ± 12 p= 0.006 
PAP/SAP ratio 0.56 ± 0.34 0.64 ± 0.27 ns 
PVR 4.6 ± 4.5 8.0 ± 3.5 P = 0.01 
PVR/SVR ratio 0.49 ± 0.99 0.32 ± 0.14 ns 
histology 
MH 1.3±1.I 1.5 ± 1.1 ns 
MA 1.2 ± 1.I 1.3 ± 1.0 ns 
TMS 1.3±1.2 1.6 ± 1.1 ns 
APA 0/31 5117 P = 0.003 
APA indicates features of advanced plexogenic arteriopathy; MA, arteriolar muscu-
larisation; M : F, sex ratio; MH, medial hypertrophy; n, number of specimens; PAP, 
pulmonary artery pressure (mlllHg); syst, systolic; diast, diastolic; PVR, pulmonary 
vascular resistance (WU.m2); SAP, systemic arterial pressure; TMS, total muscu-
larity score; 
* one patient had two lung tissue specimens with concomitant hemodynamic data, 
see text. 
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Table 3 Pllimol/([J)' hemodYl/amic characteristics (!f the total stlldy populatiol/ 
2 3 4 Total 
n 10 28 4 6 48'[ 
Qp (shuntsize) t 28 3 31 
t 4 5 
= 10 2 12 
mean ± SD 1.l±0.1 4.0 ±4.3* 0.6 ± 0.2* 1.5 ± 0.8 2.8 ± 3.6 
mPAP (mmHg) t 5 25 2 5 37 
= 5 3 2 II 
mean ± SD 19 ± 6 38 ± 14* 31 ±22 48 ± 15* 35 ± 16 
PVR (WU.m2) 
<4 4 9 2 15 
4-7 4 8 2 14 
>7 9 4 15 
mean ± SD 3.9 ± 2.6 6.4 ± 5.1 8.1 ± 5.8 9.2 ±7.1 6.3 ±5.1 
mPVP (mmHg) i 6 6 
= 10 28 4 42 
mean ± SD 8±3 9±2 6±1 21 ± 3* 9±5 
I, indicates normal pulmonary blood flow (Qp/Qs ratio: 0.8-1.2); 2, increased 
pulmonary blood flow (Qp/Qs ratio> 1.2); 3, decreased pulmonary blood tlow 
(Qp/Qs ratio < 0.8); 4, pulmonary venous congestion (pulmonary venous pressure 
> 17 mmHg). mPAP indicates mean pulmonary artery pressure (I > 20 mmHg); 
mPVP, mean pulmonary venous pressure (1' > 17 nunHg); n, number of patients; 
PVR, pulmonaty vasculat· resistance; Qp, pulmonary blood flow; 
* significant difference with group I (p < .05). 
t one patient had two lung tissue specimens with concomitant hemodynamic data, 
see text. 
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By reanalysis, excluding the latter 4 patients, it was verified that the findings were not 
essentially affected by these cases. Baseline characteristics of the autopsy biopsy 
goups are shown in table 2. Pulmonary hemodynamics of the total study population 
are summarized in table 3. Medial hypertrophy and arteriolar l11uscularisation were 
present in patients with increased, decreased as well as normal pulmonary blood flow, 
but were significantly more frequent in patients with increased pulmonary blood flow 
and/or pulmonary venous congestion (p = .03). Intimal cellular proliferation, concentric 
laminar intimal fibrosis, dilatation lesions, fibrinoid necrosis and plexiform lesions 
were present only in patients with increased pulmonary blood flow, with or without 
pulmonary venous congestion. 
Hemodynamic-histologic correlation 
In the autopsy group, systolic, diastolic and mean pulmonary artery pressure, 
pulmonary pulse pressure and the pulmonary-to-systemic pressure ratio correlated 
significantly with the severity of medial hypertrophy (I' = .55, I' = .46, r = .51, r = .60 
and I' = .60 respectively; all p < .05), arteriolar musculadsation (r = .53, r = .46, I' = .50, 
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e: aflfopsy patients; 0: biopsy patients. 
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l' = .57 and l' = .56 respectively; all p < .05) and total muscularisation score (1' = .59, 
r = .46, r = .54, l' = .67 and l' = .64 respectively; all p < .05). Pulmonary vascular 
resistance was correlated significantly only with medial hypertrophy (1' = .39, P < .05). 
Pulmonary blood flow, shunt size, pulmonary-to-systemic resistance ratio and 
puhnonary venous pressures showed no correlation with the featmes of arterial 
musculru·ity. Cellular intimal proliferation or features of advanced plexogenic 
arteriopathy were not present in this group. In the biopsy group, none of the 
hemodynamic parameters correlated significantly with the featmes of arterial 
musculru'isation or the presence of cellular intimal proliferation. Pulmonary rutery 
pressmes and pulmonary-to-systemic pressme ratio were significantly higher in 
patients with histologic lesions of "advanced plexogenic ruteriopathy" compru'ed to 
those without these features: systolic pulmonary artery pressure, 75 ± 18 vs. 53 ± 18 
mmHg (p = .03); diastolic pulmonary artery pressure, 36 ± II vs. 21 ± 5 nllnHg 
(p = .002); mean pulmonru'Y artery pressme, 53 ± 14 vs 36 ± 12 mmHg (p = .02); 
pulmonary-to-systemic pressure ratio, 0.94 ± 0.19 vs. 0.51 ± 0.18 (p = .01, mean 
± SO). Pulmonary vascular resistance, pulmonary-to-systemic resistance ratio, 
pulmonru'Y blood flow or shunt size did not differ signiticantly in patients with or 
without features of advanced plexogenic arteriopathy. 
None out of 7 patients with pulmonary vascular resistance'; 6WU.m2 and none out 
of 9 patients with diastolic pulmonary artery pressure'; 25mmHg, cut-off values 
reported in earlier studies8• II, 17 showed features of advanced plexogenic arteriopathy 
in the lung biopsy, whereas 5 out of 10 patients with pulmonary vasculru' resistance 
> 6WU.m2 and 5 out of 8 patients with a diastolic pulmonary artery pressure 
> 25nllnHg did show these features (p = .04 and p = .009 rcspectively; analysed for 
biopsy and autopsy groups together: p = .003 and p = .002 respectively; tlg. 2). The 
respons of pulmonary vascular resistance to inhalation of 100% oxygen showed no 
significant correlation with any of the histological variables in the II studied patients. 
Perioperative mortality 
In the autopsy group, 26 of 31 patients had undergone cardiac smgery. In 5 this 
concerned a univentriculru·repail'. Sixteen patients had died perioperatively. Ten patients 
had died after the peJioperative period without clinical involvement of pulmonary 
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vascular disease. In 9 out of the 21 patients who had undergone a biventricular repair, 
periopcrative death was associated with pulmonary hypertensive crises. Preoperative 
hemodynamic parameters of these 9 patients did not differ significantly with that 
from patients who died peri operatively without pulmonary hypertensive crises (n = 4) 
or patients who died after the peri operative period (n = 8). Of the 5 patients who had 
a univenltieular repair, 3 died petioperatively due to pulmonary hypopelfusion, whereas 
2 died after the perioperative period. Preoperative hemodynamic data did not differ 
between the former and the latter patients. Patients who died pelioperatively associated 
with pulmonary hypertensive crises, showed significantly increased medial 
hypertrophy, arteriolar muscularisation and a higher muscularisation score compared 
to those who died perioperatively without such crises (medial hypertrophy: 2.1 ± 0.9 
vs. 0.5 ± 1.0 (p = .01); arteriolar muscularisation: 1.8 ± l.l vs. 0.5 ± 1.0 (p = .04); 
muscularisation score: 2.2 ± 1.0 vs. 0.5 ± 1.0 (p = .0 I, mean ± SO). In patients with a 
univentricular repair, no difference in arterial muscularity could be demonstrated be-
tween patients who died with and patients who died without pulmonary hypoperfusion. 
The features of pulmonary arterial muscularisation tended to be lower in patients 
who underwent a univentricular repair compared to those who underwent biventricular 
repair, however, these differences did not reach statistical significance. In the biopsy 
group. no patient had undergone a univentricular repair and no peri operative mortality 
had occurred. 
Mid term outcome 
In the biopsy group, 2 of the 17 patients died of causes not related to pulmonary 
vascular disease (l infectious disease, I during a later surgical procedure) after 55 
and II months respectively. The remaining IS patients are still alive with a mean 
follow up of 69 ± 39 months (mean ± SO), ranging from 14 months to 12.3 years. 
Five of these patients showed clinical features of persistent pulmonary hypertension 
in the absence of residual cardiac lesions. No significant differences in age at biopsy, 
time period between collection of lung specimen and hcmodynamic data and follow 
up period could be demonstrated between children with and without features of 
pulmonary hypertension at follow up. Preoperative hemodynamic data from children 
with persistent pulmonary hypertension did not differ signiticantly li'orn those with-
62 
CHAPTER 3 
out persistent pulmonary hypertension: mean pulmonary artery pressure: 50 ± 18 vs. 
41 ± 9 mmHg (p = .22), diastolic pulmonary artery pressure 32 ± 15 vs. 24 ± 6 mmHg 
(p = .38), pulmonary-to-systemic pressure ratio 0.81 ± 0.32 vs. 0.58 ± 0.15 (p = .17), 
pulmonruy vasculm resistance 10.1 ± 4.7 vs. 7.7 ± 2.2 WU.m2 (p = .20) and pulmonary-
to-systemic resistance ratio 0.31 ± 0.18 vs. 0.34 ± 0.13 (p = .82, mean ± SD). Of the 
histological features studied, only the presence of plexiform lesions was signiticantly 
associated with signs of persistent pulmonary hypertension: all 3 patients with 
plexiform lesions showed persistent pulmonary hypertension (p = .02, positive 
predictive value 100%). The histological classification "features of advanced 
plexogenic ruteriopathy" did not correlate signiticantly with signs of pulmonru'y 
hypertension at follow up (p = .26, positive predictive value 60%). Two out of 10 
patients without features of advanced plexogenic arteriopathy in their original lung 
biopsy showed persistent pulmonary hypertension at follow-up which could not be 
explained by residual anatomical lesions. However, 2 out of 5 patients with histological 
features of advanced plexogenic arteriopathy showed no evidence of persistent 
pulmonmy hypertension after 69 and 77 months, respectively. At the time of the lung 
biopsy, one of these 2 patients showed severe concentric laminar intimal fibrosis with 
some tibrinoid necrosis, the other also showed tibrinoid necrosis next to severe cellullar 
intimal proliferation. The remaining 3 patients who did develop persistent pulmonary 
hypertension all showed concentric laminru' intimal tibrosis and plexifonn lesions, 2 
of them also showed dilatation lesions and I additionally showed fibrinoid necrosis. 
Discussion 
The present study demonstrates merely limited correlations between hemodynamic 
and histologic assessment of the pulmonary vascular bed in a highly selected group 
of children with complex congenital heru·t disease. In this patient group, both techniques 
appem'ed of limited value in predicting persistent pulmonary hypertension after 
corrective surgery at midterm follow up. Only plexiform lesions in the lung biopsy 
were inevitably predictive for persisting pulmonary hypertension. 
Lung specimens were obtained from biopsies or autopsies. Pulmonru'y ru'tery pressures 
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and pulmonary vascular resistance were significantly higher and histological advanced 
vascular lesions significantly more frequent in biopsy compared to autopsy patients 
(table 2). This may be the result of tIlC fact that patients in the biopsy group were 
selected on the suspicion of pulmonary vascular disease. In the autopsy grouP. the 
hemodynamic variables pulmonary artery pressure, pulmonary-to-systemic arterial 
pressure ratio and pulmonary vascular resistance showed significant correlations only 
with the muscularity of the pulmonary arterial tree. Correlation coefiicients, however, 
were not high, indicating that, in the individual patient, muscularity could not be 
predicted accurately fi'OlIl hemodynamic data, or vice versa. In contrast to tIle findings 
in the autopsy group, no significant correlation between pulmonary artery pressures 
and muscularity could be demonstrated in the biopsy group. The grades of medial 
hypertrophy, arteriolar muscularisation and total muscularity score, however, did not 
difter significantly in both groups. One could speculate that, in the biopsy group, 
containing patients with more advanced vascular disease, this lack of correlation could 
be caused by the cffcct of pre-acinar obstructive intimal proliferation, resulting in a 
decreased muscularity of the intra-acinar arteries, as suggested by Haworth II, However 
in our material we found no support for this explanation. 
Patients with features of advanced plexogenic arteriopathy had signiticantly higher 
pulmonary artery pressures. However, again the scatter was wide, so no accurate 
predictions could be made in the individual patient. In our study, a diastolic pulmonary 
artery pressure s 25 mmHg or a pulmonary vascular resistance s 6 WU.m2 was never 
associated with histological features of advanced plexogenic arteriopathy in the lung 
biopsy. A high diastolic pulmonary artery pressure or pulmonary vascular resistance, 
however, were not predictive for the presencc of advanced lesions. 
Discrepancies betwcen the interpretation of hemodynamic and histological data in 
the individual patient, as frequently found in our patients, are not surprising if one 
realises that the information obtained by both tcchniques is far from identical. 
Histologic examination of lung biopsy is a static, ill vitro, description of morphologic 
vascular changes, which does not take into account the functional activity of the 
endothelium and smooth musclc cells l6• IX. 19. Although a lung biopsy of adequate 
size is thought to be representative of tIle entire pulmonary vascular bed211, the vascular 
changes may be distributed heterogenously in the lung. On the other hand, hemo-
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dynamic data are derived data, which retlect merely indirect the functional conse-
quences of changes in the vascular bed, Moreover, various assumptions have to be 
made in calculating /lows and resistances, resulting in potential errors 1 , Realising 
that both diagnostic techniques reveal different aspects of the state of the pulmonary 
vasculature, the question is which of both methods reveals the most accurate 
information on clinical outcome in the individual patient. Do we have a gold standm'd? 
The value of the information has to be weighed against the risks of both diagnostic 
procedures, which are not equal. While the risks of pediatric cardiac catheterisation 
are relatively low21 , the mortality rate of a lung biopsy as an isolated procedure has 
been reported to reach 20%17, Although both diagnostic tools are in clinical use for 
over 30 years, reports on mid and long term follow up are few4, 8,11,13 
Perioperative mortality 
Patients with early, potentially reversible, stages of pulmonmy plexogenic arteriopathy 
may develop pulmonary hypertensive crises in perioperative periods, Although 
treatment results have improved with the introduction of vasodilators like epoprostenol 
and, more recently, inhaled nitric oxide, these life-threatening events continue to lead 
to signitlcant peri operative mortality, In our study, preoperative hemodynamic data 
did not allow the prediction of peri operative mortality associated with pulmonary 
hypertensive crises, From the histologic features, increased muscularity of the pul-
monary tree, expressed as medial hypertrophy, muscularisation of arterioles 01' the 
combined total muscularity score, was associated signiticantly with peri operative 
pulmonary hypertensive crises. In univentricuiar heart repairs, which create a 
circulation without a ventricle facing the pulmonary vasculature, already a mildly 
elevated pulmonary resistance can cause pulmonary hypopertilsion and clinical 
detoriation, In these patients neither preoperative hemodynmllics nor musculatity could 
predict perioperative death with pulmonm'y hypoperfusion, This is of major concern 
now that Fontan- and Norwood-procedures are performed with increasing fre-
quency5, 10,12, How then, if hemodynamic data do not allow an accurate prediction for 
the risk of postoperative pulmonm'y hypoperfusion after univentricular repair or for 
the risk of peri operative death by pulmonm'y hypertensive crises after bivcntricular 
repair, can we determine the optimal time for surgery, other than just operate at young 
age? 
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Furthermore, if this optimal time has passed, can benificial effects still be expected 
from postoperative supportive therapy, like nitric oxide or other vasodilators? Our 
current diagnostic tools do not provide answers to these questions. 
Mid /el'm oil/come 
The main aim of evaluating the state of the pulmonary vasculature is the assessment 
of reversibility of the disease process. Although the il1'eversible stage of plexogenic 
arteriopathy most commonly occurs in older patients, with sustained pulmonary 
hypertension, it may also occur in infants younger than one year of age, hampering 
surgical decision-making9. IJ, 22. Data on the predictive value, however, of both 
preoperative histologic and hemodynamic evaluation, with respect to the progression 
of plexogenic arteriopathy after corrective surgery, are scarce. Severe concentric 
laminar intimal fibrosis, fibrinoid necrosis, dilatation lesions and plexiform lesions 
are features of advanced plexogenic arteriopathy and are generally regarded as signs 
of irreversible disease}' 4, 6. We found morphologic features of advanced plexogenic 
arteriopathy under the age of one year (fig. I). No significant correlation between age 
and any of the hemodynamic or histologic variables could be demonstrated. At follow 
up, 2 of our patients showed to have persisting pulmonary hypertension after cOl1'ective 
surgery, despite the absence of advanced vascular lesions in their preoperative biopsy. 
On the other hand, the presence of these features did not predict accurately the 
persistence of pulmonary hypertension at a mean follow up of almost 6 years. In our 
series, only plexiform lesions were inevitably predictive of pulmonary hypertension 
at follow up. Although one should realize that patients with advanced lesions of 
plexogenic arteriopathy in their lung biopsy may develop pulmonary hypertension at 
longer follow up, these findings lead to hesitation in accepting histologic assessment 
as the gold standard with respect to long term prognosis. Especially since recent 
reports suggest that chronic therapy with vasodilatory and antiproliferative agents, 
such as continuous intravenous epoprostenol, may result in a rcmodeling of vascular 
changes in primary pulmonary hypertension, including reversal ofplexogenic lesions23 . 
These suggestions challenge the cUl1'ently used concept of irreversibility of advanced 
plexogenic arteriopathy. Similarly, hemodynamic evaluation did not allow an accu-
rate prediction of persistent pulmonary hypertension at follow up. Reactivity of the 
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pulmonmy vasculm' bed to vasodilators is a commonly used tool to assess reversibility 
of plexogenic m"teriopathy24-26, However, in our study, response of pulmonary vascular 
resistance to 100% oxygen inhalation, a very potent pulmonary vasodilator, was 
assessed in 9 of the 15 survivors and showed no signitIcant correlation with pulmonary 
hypertension at follow up. Response to other vasodilators was not studied in our 
series. 
Stl/dy limitatiolls 
A retrospective study has inevitably shortcomings. Lung biopsies were not performed 
routinely in our institution, but in patients judged to be at risk for puhnonm'y vascular 
disease. Thirty-one samples were obtained at autopsy. As a result, the patients in this 
study represent a highly selected group with a variety of complex cardiac anomalies. 
However, it is the subset of patients with complex congenital heart disease, like the 
study population, in which the assessment of the pnhnonm'y vasculm' bed becomes 
especially crucial, when correction is delayed because of a staged approach or whcn 
Fontan-Iike procedures will be involved. In this retrospective study hemodynamic 
evaluation of the pulmonmy vascular bed included acute vasodilator testing in only 
II patients. Although inhaled oxygen is one of the most powerful pulmonary vaso-
dilators, additional vasodilator testing with epoprostenol or inhaled nitric oxide in a 
larger number of patients might have provided additional information26. The follow 
up data on the presence of pulmonary hypertension in our study are based on clinical, 
electro- and echocardiographical IIndings suggestive for pulmonary hypertension. 
Obviously, these findings are not synonymous with the actual presence of plexogenic 
arteriopathy. However, pulmonary hypertension as a long term sequel after cardiac 
repair, is the main, clinically important consequence of plexogenic arteriopathy, Cases 
were not classified on the basis of anatomical diagnosis because we feel that mechmlical 
forces, acting on the pulmonary vasculature and resulting from abnormal pulmonary 
hemodynamics caused by the anomaly, rather than Ule anatomical diagnosis itself, 
are responsible for the initiation of this specific vascular disease process in children 
with congenital heart disease. 
Both hemodynamic and histologic assessment of thc pulmonary vasculature have 
proved to be of great value in the management of children with congenital hem't disease. 
67 
HEMODYNAMIC VS. HISTOLOGIC EVALUATION 
However, our study indicates the limitations of both techniques. In our opinion, an 
effort bas to be made to develop additional tools to assess ill vivo the functional status 
of the pulmonary vascular bed. The intravasculm' ultrasound imaging technique may 
contribute to tllis ultimate goal. It has the potential to assess directly and simultaneously, 
in vivo, functional and morphological features of the pulmonary arteties. Intravasculm' 
ultrasound imaging has shown to be feasible in infants and children and has shown to 
be able to assess "real tinle" pulmonary vascular dynamics in vipo27, In addition, 
current resem'ch on modulators and growth factors involved in pulmonary vascular 
disease will extend our insight in the pathophysiology of the process of vascular 
remodeling l9• 28. 29. Molecular biology may hand new clues with respect to the 
progression and functional consequences of the pulmonary vascular disease process 
in children with congenital hemt disease, and may thus aid the clinician in choosing 
the optimal therapy and its timing. 
We conclude that, in the selected patients of the present study, correlation between 
hemodynamic and histological evaluation of the pulmonm'y vascular bed was merely 
limited. Patients with a diastolic pulmonmy artery pressure s 25nunHg or a pulmonary 
vascular resistance s 6WU.m2 did not show concentric laminar intimal tibrosis, 
dilatation lesions, fibtinoid necrosis or plexiform lesions in their lung tissue. However, 
in patients with a diastolic pulmonary artery pressure> 25mmHg and a pulmonm'y 
vascular resistance> 6WU.m2 histology of the lung biopsy could not bc predicted 
from hemodynamic variables. No hemodynamic parameter was predictive for 
peri operative death associated with pulmonary hypertensive crises. Increased 
pulmonary arteterial muscularisation was associated with an increased risk of 
perioperative death associated with pulmonmy hypertensive crises. This was not the 
case in patients who had undergone a univentricular repair. In our study both 
hemodynamic and histologic assessment of the pulmonm'y vasculm' bed were oflimited 
value in predicting persistent pulmonmy hypertension after corrective surgery. Only 
plexiform lesions were inevitably predictive for persisting pulmonary hypertension. 
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Introduction 
Increased pulmonary blood flow and pulmonary hypertension in congenital heart 
disease will lead to structural and functional changes in the pulmonary vasculature I-3• 
These changes include an increased IHllscuiarisation, altered vasoconstrictive and 
impaired vasodilatatory responses of the arterial tree, extensive extracellular matrix 
modulation, including increased collagen deposition, and gradual occlusion of the 
small pulmonary arteries by intima proliferation and tibrosis4-o. These alterations 
will result in a decreased compliance of the pulmonary vessels and, thus, a stiffening 
of the arterial wa1l7,8. In plexogenic pulmonary arteriopathy, characteristic lesions 
emerge in the course of the disease process, including concentric laminar intimal 
fibrosis, fibrinoid necrosis and plexiform lcsions. The combined vascular changes 
wiIllead to an increase in bOtll steady and pulsatile hydraulic load of the subpulmonary 
ventricle. Depending on the progression of the process and the type of surgical proce-
dure, they may jeopardize surgical correction of the heart defect or seriously affect 
the patients' prognosis. In plexogenic pulmonary arteriopathy, the early vascular chan-
ges are reversible after tlle underlying heart defect has been corrected". However, if 
untreated, plexogcnic pulmonary arteriopathy advances to a certain 'point of no re-
turn' at which the disease process has not only become irreversible, but progresscs 
even when the underlying heart defcct is corrected"-
In patients with congenital heart disease, the state of the pulmonary vasculature is, 
thus, an important determinant of management, clinical course and prognosis. Various 
diagnostic techniques are available to evaluate the progression of pulmonary vascular 
disease (PVD) in the clinical setting. However, although all these techniques have 
undisputable value, they all have specitic drawbacks and intrinsic lim.itations 10. Ii. 
The purpose of this paper is to review these currently available diagnostic techniques. 
Non-invasivc techniqucs to evaluate the pulmonary vasculature 
Clinical examination, chest X-ray and electrocardiographic evaluation may suggest 
the presence of pulmonary hypertension, however sensitivity is very 10l"i2. 13. 
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Echocardiography with pulsed doppler is more reliable in determining the presence 
of pulmonary hypertension, using tricuspid- or pulmonary regurgitation velocity 
measurements l4-17 However, in congenital heart disease thc presence of pulmonary 
hypertension provides limited information on the state of the pulmonary vascular bed 
and, in general, the progression of PVD cannot be assessed with these diagnostic 
tools, 
Estimation ofleft-to-right intracardiac shunting and measurement of pulmonary blood 
flow using velocity-encoded, phase-difference magnetic resonance imaging havc been 
reported 18-20, However, its value in the evaluation of PVD remains to bc investigated, 
Hemodynamic evaluation of the pulmonary vasculature 
The technique most frequently used to evaluate the pulmonary vascular bed in 
congenital heart disease is cardiac catheterization 21 -2), In this procedure the pulmonary 
artery pressures and pulmonary wedge pressure or left atrial pressure are measured, 
shunt size and pulmonary blood now are determined and, subsequently, pulmonary 
vascular resistance is calculated by dividing the pressure gradient across the lungs by 
the pulmonary blood flow, The pulmonary vascular resistance constitutes a key para-
meter in the prcoperative cvaluation of the pulmonary vasculature22 It is regarded as 
a measure for the functional state of the vascular bed, and its reaction to vasodilators 
as a measure for reversibility of the disease process, Although hemodynamic evaluation 
of the pulmonary vascular bed has proven to be extremely valuable in clinical practice, 
it has both conceptual and practicallimitation24, 
Pl'(lc/ic(I{ ('onsidem/ions, Like any other invasive technique, cardiac catheterization 
has celtain risks, especially in patients with PV025, 26, However, with the cUl1'ently 
available techniques and materials, including nonionic contrast media, the risks of 
pediatdc cardiac catheterization are relatively lown , 2X, The conditions under which 
the hemodynamic measurements are performed, such as position of the patient and 
level of agitation, may influence the results of the measuremcnts 29, Standardized 
conditions during the complete procedure are imperative in order to obtain reliable 
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and comparable hemodynamic data. A serious drawback of the hemodynamic 
evaluation, however, is the difticulty to determine accurately blood flow in the clinical 
setting. Various methods exist to quantitate cardiac output and intracardiac shunting. 
These methods are based on the Fick principle: a known amount of a specific indicator 
is added to a volume of fluid. If the concentrations of the indicator in the blood before 
and after this addition is known, the volume of tluid can be calculated26 . .10, J I. The 
Fick method uses the physiologic uptake of oxygen as indicator. Pulmonary blood 
flow can be calculated by dividing oxygen consumption throngh the difference in 
oxygen content between the pulmonary artery and the veins. The oxygen content of 
the blood is calculated using measured oxygen satnration, hemoglobin concentration, 
oxygen binding capacity and dissolved oxygen. The advantagcs of oximetry are that 
it is easy to perform, results are available immediately and it allows one to ascertain 
the site and magnitude of the shunt. However, in patients without intracardiac shunts, 
the oxygen content has been demonstrated to gradually increase from the caval veins, 
right atlium (RA), right ventricle (RV) to the pulmonary artery.12 . .15. Dexter et al. 
detined criteria for normal right-sided oxygen step-ups, which resulted in a normal 
oxygen content difference of maximal 1.9 mlldl between superior caval vein and RA, 
0.9 mlldl between RA and RV and 0.5 mg/dl between RV and pulmonary artery.12. 
This means that the minimal ratio of pulmonary-to-systemic flow (Qp/Qs) that can be 
reliable detected by oximetry is 1.5-1.9 at the atrial level, 1.3-1.5 at the ventricular 
level and 1.3 at the level of the great arteriesl6 . .16. Measuring oxygen saturations 
nowadays can be petformed relatively easy lIsing paramagnetic oxygen sensors, within 
an accuracy of approximately 2%.11. However, in heart defects with large left to right 
shunts, pulmonary arterial oxygen saturation is high, and variations in oxygen 
saturations of 2% may result in a change in calculated blood tlow of 25% or morel". 
Measurement of the patient's oxygen consumption is another potential source of er-
ror. In the past, rather cumbersome methods, like the douglas bag method, have been 
used for this purpose. However, procedural complexity prohibited its wide use in 
routine catheterization laboratories. In recent years more practical instrumentation 
has become available, that can be used routinely.1~. However, measuring oxygen 
consumption is based on measuring the difference in oxygen content between inspired 
and expired air. In contrast to metabolic studies, determination of cardiac output 
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requires an absolute value for oxygen consumption. This, in turn requires precise, 
absolute measurements of respiratory gas volumes, so that leakage of respiratory 
gasses has to be precluded. This is cumbersome in most pediatric patients, but is 
virtually impossible in small, intubated children. For this reason, many routine 
catheterization laboratories continue to use assumed oxygen consumption, based on 
body weight or surface area, derived from predictive tables, like that of LaFarge and 
Miettinen39. This is a serious limitation since these tlgures may not be reliable, 
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Figure 1. a. Relatiollship betweell time alld dye COllcelltratioll at the jemoral artery 
oj a 1I0rmal slll~iect, {(fter illjectioll 'if" a bollls (d· dye ill to the p,t/mO//([I), 
artery. The doffed lille is the reploffillg}i"Om the lillear extrapolatioll ojthe 
descending limb Oil a semilogarithmic scale. 
b. Relationship between time liflll dye COllcentration lit thefemoJ"(tf arIel)' 
«fter illjectioll of dye illfo the right heart. A pre-llormal so-called x-peak is 
dlle to a right-to-I~ft Shllllt. A post-llormaly-peak is dlle to a left-to-right 
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especially in congenital heart disease, where oxygen consumption may be int1uenced 
by intracardiac shunts26, 40, 41, Finally, when 100% oxygen inhalation is used to test 
pulmonary vasoreactivity, measuring oxygen consumption as desclibed is not possible 
because the Haldane equation cannot be applied42 
The dye dilution technique, tirst described by Stewart, is often regarded as the gold 
standard in measuring blood t10w in patients"', A bolus of dye, most frequently 
indocyanine green, is injected into one part of the circulation (e,g, pulmonary artery) 
and sampled at another site (e,g, femoral artery) by continuous withdrawal through a 
densitometer cuvette, leading to a concentration-time curve, characterized by a primary 
peak and a recirculation peak (figure la)30, 31, In left-to-right shunts the curve 
demonstrates a prominent early recirculation (tigure I b)43 The area of the primary 
curve is proportional to Qp, whereas the area of the em'ly recirculation curve is 
proportional to shunt tlow. Both can be calculated by different mathematical 
techniques44.47, These techniques require a complex analysis of the inscribed curve, a 
process that may be especially difticult in the setting of very large or small shunts, A 
method developed by Cmter et al. is much simpler but restricts itself to quantitating 
the intracardiac shunt4S, To detect a left-to-right shunt using the direct mathematical 
analysis of the indocyanine green curve, the Qp/Qs ratio has to be at least l.lS49, 
whereas the method of Cm'ter can reliably detect left-to-right shunts only when 
Qp/Qs 2: 1,35 50,51, Limitations of the indocyanine green dilution technique include 
further: I) the complexity and time-consuming nature of the procedure, 2) thc need 
for -temporary- withdrawal of fairly large volumes of blood from the systemic 
circulation, which may constitute a potential hazard in int~1nts, 3) problems in cuvette 
sterilisation and 4) very important in patients with congenital heart disease: the rapid 
recirculation in large left-to-right shunts may hamper the description of the primary 
circulation curve, int1uencing the accuracy of the calculation 26, 36, 52, 
The thermodilution technique, that uses temperature difterence after injection of a 
bolus of a cold solution as indicator, is found to be quite reliable in patients without 
shunts, but is not accurate in the presence of left to right shunts21 , 23, The difticulties 
in quantitative determination of blood t10ws are illustrated by the limited correlations 
between the different methods,3, 54, When reviewing the inttinsic limitations of the 
various techniques, it has to be acknowledged that the determination of shunt size 
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and pulmonary blood now, and thus pulmonary vascular resistance, are at bcst 
estimations. 
COl/ceptual cOl/sideratiol/s. The equation used to calculate pulmonary vascular 
resistance, analogous to Ohm's law in electrical resistance, assumes a constant, steady 
now. The Poiseuill-Hagen equation, derived ti'om a Iigid tube, indicates tile importance 
of the vessel radius, or cross sectional area of the vascular bed, to steady tlow 
resistance55 ,56: 
meal/ PAP -meal/ LAP 8 L 
PVR = • I} 
Qp 7[ ," 
in which: PVR = pulrnonury vascular resistance (WU.m2) 
PAP = pulmonary artery pressure (mmHg) 
LAP = left atrial pressure (mmHg) 
Qp pulmonary blood now (l/min/m2) 
L = length of the vessel(s) 
r radius 
I} viscosity of the nuid 
The differences between the steady now of water throuh a long straight glass tube on 
the one hand and the pulmonary circulation on the other, are very clearly lined out by 
Hoffman in 197256. Several considerations have to be taken into account, when 
interpreting pulmonary vascular resistance in children with congenital heart disease: 
I) The total cross-sectional area of the pulmonary vascular bed may be diminished 
due to other reasons than vasoconstriction or structural vascular changes, occurring 
in PVD. For instance, vascular underdevelopment in congenital diaphragmatic her-
nia, or pulmonary thrombi may cause a decrease in total cross-sectional area. The 
increased pulmonary vascular resistance in these conditions docs not represent a 
decreased vascular hindrance due to vascular disease, but a reduced number of vessels. 
Narrowing of arteries may be due to extrinsic pressure, for instance in case of 
pedvascular edema tluid. 2) Blood viscosity, a factor in the equation that applies to 
clinical conditions, may be increased due to polycythemia in children with cyanotic 
heart disease or PVD, and may raise pulmonary vascular resistance, independent from 
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pulmonary vascular changes. 3) A third factor to take into account is the ctitical closing 
pressure, resulting from the forces which tend to collapse a vessel. In the lung these 
may Oliginate from the alveoli or from the vessel itself, in the latter case due to its 
elastic or muscular recoil57. In physiologic conditions, left atrial pressure exceeds the 
critical closing pressure. However, when critical closure pressure exceeds left atrial 
pressure, as may occur in pathologic conditions such as emphysema or pulmonary 
hypertension, the usual calculation of pulmonary vascular resistance becomes 
misleading because left atrial pressure is no longer the appropriate downstream 
pressure57 • Finally, a conceptual limitation of pulmonary vascular resistance, 
rcpresenting the resistance of the pulmonary vasculature to steady flow, is that it 
neglects tbe pulsatile nature of the pulmonary circulation. In this context one has to 
realize that in normal conditions approximately 30% of the work load of the right 
ventricle consists of pulsatile load57 . In pulmonary hypertension this load increases, 
because of decreased distensibility oftbe pulmonary arteries and increased amplitude 
and velocity of retlected pulse waves57 However, this cannot be evaluated using 
pulmonary vascular resistance. 
The response of the vascular bed to vasodilators is regarded as a measure for 
reversibility of the disease process58.60• This is based on the concept that changes in 
PVD consist of a vasoconstrictive component and structural component26 Many stu-
dies focus on the question which pharmacological substances produce the most 
powerfull and selective pulmonary vasodilation 10. However, it has to be acknowledged 
that the predictive value of pulmonary vasoreactivity with regards to operability of 
the cardiac defect, the likelihood for peri operative pulmonmy hypertensive crises, 
and the likelihood of persistent pulmonary hypertension following repair, has never 
been convincingly demonstrated in children with congenital heart disease. Furthermore, 
recent observations in patients with advanced primary pulmonar·y hypertension, who 
did not respond to acute vasoclilator testing, showed that long-term continuous 
prostacyclin therapy improved the clinical status and hemodynamic data61 • 62. These 
observations seriously challenge the concept of reversibility and irreversibility of 
PVD63. 
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Histologic evaluation of lung biopsy 
Although the value of this medlOd is also defined by its ability to determine the type 
of pulmonary arteriopathy and the morphological substrate for clinically unexplained 
pulmonary hypertension, we will focus here on its use in assessing plexogenic 
pulmonary arteriopathy in congenital heart defects. From a histological point of view, 
the most prominent vascular changes are localized in the small, muscular pulmonary 
arteries (figure 2, see page 180). 
In 1958, Heath an Edwards described six grades of progressive structural changes in 
the small pulmonary arteries in congenital cardiac defects64 ; In grade I there was 
medial hypertrophy of arteries and arterioles, but no intimal changes; In grade Il, 
additional cellular intima proliferation was present; In gJ'llde Ill, intimal llbrosis was 
present, in addition to medial hypertrophy. Grade IV showed progressive generalized 
vascular dilatation and plexiform lesions. In grade V, other dilatation lesions werc 
present, including vein-like branches and angiomatoid lesions. Finally, gJ'llde VI, was 
the stage in which necrotizing arteritis occurred. This grading system has been widely 
used for assessment of the severity of hypertensive PVD. However, with the increasing 
awareness of dIe complexity of the vascular lesions, the sequence of the vascular 
changes in the course of the disease process and their biological meaning, have been 
debated65• Wagenvoort advocated to abandon the grading principle, because the degree 
and extent of the various lesions, the different types of intimal llbrosis and additional 
features should all be assessed, not only for arteries but also for other vessels65.67 . 
Careful consideration and weighing of all these features are necessary in order to 
form an opinion on reversibility and prognosis of PVD. In general, severe conccntric 
laminar intimal fibrosis, angiomatoid dilatation lesion, fibrinoid necrosis and plexiform 
lesions are considered advanced vascular lesions, associated with irreversible 
disease9• 68. Finally, Rabinovitch and Haworth suggested a morphometric approach, 
in which they judged the extension of muscle into peJiphereral arteries which are 
normally non-muscularized, quantified medial thickening and assessed the number 
of small arteries by the alveolar-artery ratio69. 
The natural history of the various vascular changes has been assessed in patients with 
shunts at the ventricular level, who had first undergone a pulmonary artery banding 
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and subsequent surgical repair of their cardiac anomalies. However, systematic stu-
dies of long-term follow-up of patients evaluated by any method are scarce9, 58, 70, 71, 
Practical cO/lsidemtio/ls, To assess PVO, a lung biopsy of adequate size requires an 
open lung biopsy and, thus, a thoracotomy, The amount of lung tissue obtained by 
transbronchial biopsies or transthoracic needle biopsies is too small and the vessels 
are often severely damaged, precluding adequate evaluation67, Inadequate lung biopsy 
sizc, that may be caused by the concern to take away too much tissue or by pleural 
thickening, means that the patient is subjected to the risks of the proccdure without 
benelit67 , An open lung biopsy as isolated procedure carries a certain risk, that 
substantially increases in patients with PY072, The processing of biopsy specimcns 
is important for a reliable evaluation, For example, handling by the surgeon or the 
pathologist may easily result in collapse of tissue, whereas intravascular injection of 
fixative may lead to unpredictable dilatation of vessels, both leading to qualitative 
and quantitative misinterpretation of the pulmonary blood vesscls, Fixation of lung 
tissue under vacuum has been recommended67 
CO/lceptual cO/lsideratio/ls, Histologic examination of lung biopsy yields a static 
description of morphologic changes in the vascular bed and does not take into ac-
count the functional activity of tile vascular endothelium and smooth muscle cells7J-75, 
Controversy exists on the predictivc value of evaluation of lung biopsy, since it has 
been suggested that the vascular changes in PVO, especially the advanced lesions, 
may be distributed unequally in the lung and thus may be missed in a lung bi opsy69, 76 
Also, the presence of these advanced lesions is unusual in the first two years of life, 
even in the presence of severely, elevated, non-responsive pulmonary vascular 
resistance69, The c1assilication of Rabinovitch et aI., studying features that are 
distributed uniformely through the lung, is based on the concept that small arteries 
becomc reduced in size and number in the course of PV069, 77, 78, However, this 
concept has been seriously challenged79, 80, 
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Pulmonary wedge angiography 
The pulmonary wedge angiogram provides an angiographic visualisation of pulmonary 
mteries as small as 100 J.Ull and allows definition of tapering and tortuosity of muscular 
mteries, supernumerary arteries and of the background capillary blush, representing 
the perfusion of intraacinm' vessels (figure 3)SI-84. These variables can be described 
and quantitated and have been demonstrated to con'elate with both hemodynamic 
data and structural tindings in lung biopsies82-84. It has been suggested that the presence 
of obstructive, ilTeversible PVD can be detcrmined by wedge angiograph y82. Two 
techniques of pulmonary wedge angiography have been described. In the tirst, an 
end-hole catheter is placed in wedge position and 0.5-3 ml contrast medium is injected 
slowly by hand until most of the small arteries and some of the interlobular veins are 
seen. Then 5-10ml flush solution is flushed through the catheter until the major 
pulmonary veins till and the lobular capillary blush disappear·s82. In the second method, 
a balloon-tipped, cnd-hole catheter is used. The catheter is placed in a segment artery 
and after the artery is occluded by inflation of the balloon, 0.3mllkg contrast medium 
(with a minimum of 2ml) is injected at a flow rate of approximately 5 mIls. After the 
injection, the balloon is deflated and the venophase can be examined separately8J 
Practical considerations. The risks of the procedure consist of the risk of lung 
parenchymal damage, pulmonary infarction and hemoptysis after injection of con-
trast medium at a such peripheral localisation, and of the general Iisks of pulmonary 
angiography in patients with PVD25.SI. However, with the currently available mateIials, 
such as non ionic contrast t1uids, and with the described techniques, these risks ar'e 
lows2-84. A limitation of the method is that features such as abrupt termination of 
vessels, tortuosity, arborization and background flush are largely qualitative and rat-
her subjective. This has been accommodated par·t!y by Rabinovitch et aI., who provided 
quantitative variables, like tapering rate and circulation timeSJ High resolution 
angiography facilities are required in the catheterization laboratory. 
Conceptllal considemtions. The tapering rate ofa vessel may be decreased by dilatation 
of the proximal part of the artery, as is the case in high flow states, or by narrowing of 
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a b 
Figure 3 Pulmonary wedge angiography in a 6 years old child wilh nO/7nal plllmonGl), 
circllialion (a) and in a 5 years old child wilh a palenl duci and advanced 
plIlmonw)' plexogenic arteriopathy (b). Nole the dilated arteries with 
increased tapering rale, tile redllced nllmber o/monopedial brallches alld 
a markedly redllced backglVlIlld haze. 
the distal part of the artery as occurs in obstructive disease, or by vasoconstriction of 
the distal part of the artery or, finally, by a combination of these phenomena. These 
cannot bc distinguished by angiography. Circulation time may reflect a structurally 
reduced pulmonary vascular bed, due to partially or completely obstructed vessels. 
However, circulation time may be also directly related to flow, and consequently Illay 
reflect just pulmonary blood flow. Indeed, circulation time appeared to be decreased 
in patients with pulmonary stenosis83• 
Evaluation of pulmonary vascular compliance 
In the eonccpt of pulsatile flow, the total forces opposing the blood flow consist of the 
vascular resistance component, the vascular elasticity component and the blood vo-
lume related inertia componentSs • Although blood flow through the pulmonary 
vasculature is equal to that through the systemic vasculature, the pulmonary pressure 
wave is more rounded and of lower amplitude. This means that the compliance of the 
puhnonary arteries is substantially higher than that of its systemic counterpartsss. 
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In the normal pulmonary vasculature elastic arteries extend to arteIies of approximately 
I nllll in size and have much thinner walls than systemic arteries67 . In PVD, the 
compliance of the elastic pulmonary arteIies decreases, probably due both to structural 
changes in the arterial wall and, when pulmonary hypertension is present, to the artery 
operating on a steeper part of its pressure-volume relationship. Consequently, forces 
opposing the pulsatile now, such as arterial compliance and renected pulse waves, 
which have little importance in the normal pulmonary circulation, may become ma-
jor components of the right ventricular load in pulmonary vascular disease57. 
Using harmonic analysis of pressure and now waves, pulmonary vascular impedance 
can be studied. However, until now its use has been restricted to animals and 
experimental models86·88. In systemic arteries, vascular' compliance bas been studied 
using pulse wave velocity, however this has not been feasible in pulmonar,)' arteries. 
Recently, pulsatility and distensibility of pulmonary arteries have been studied, using 
ultrasound or magnetic resonance techniques89, 90, These data, however, remain to be 
validated and interpreted in the clinical context. 
Discussion 
The techniques described, all evaluate different properties of the pulmonary 
vasculature. As lined ollt, the hemodynamic evaluation describes functional aspects 
of the pulmonary vascular bed associated with the total cross-sectional area of that 
bed, whereas lung biopsy describes morphological, structural changes of the small 
pulmonary arteries. Pulmonar'y wedge angiography describes changes in the course, 
the luminal diameter and the perfusion of peripheral pulmonary arteries. Puhnonar'y 
arterial distensibility describes the functional behaviour and properties of the larger 
pulmonary ar·teries and its consequences for the pulsatile circulation. Although, all 
these different aspects of the pulmonary vasculature are subject to changes in the 
course of PVD, the infonnation obtained by the various tecbniques is far from identical. 
And therefore it may not be surprising, that although the results of the different 
teChniques are cOlTelated, these correlations are limited and results may appear 
conflicting in the individual patient56. 58.69.79.82.83,91. 
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No doubt, hemodynamic evaluation, lung biopsy and pulmonary wedge angiography 
have contributed greatly to our knowledge ofPYO and to the management of children 
with congenital heart disease at risk for this disease. However, realizing the different 
aspects that are evaluated by each technique and its intrinsic limitations, we are still 
not confident on how to explain and how to handle discrepancies between the diffe-
rent technique results in individual patients. Clinicians each have developed their 
own preferences and strategies in evaluating the pulmonary vasculature in children 
with congenital heart disease, frequently dictated by institutional experience and 
facilities. A three-pronged approach has been suggested to determine surgical risk 
aud outcome!!. However, although in use for over 30 years now, reliable data on the 
predictive values of the different techniques, with regard to reversibility and long 
term prognosis are scarce9• 58.70. Jl. 92. This is especially the case when the results 
indicate that the disease process is in the grey zone between reversible and irreversible 
disease. fvloreover, in the current era, in which univcntricular heart repairs, slIch as 
Fontan- and Norwood procedures, are performed in an increasing frequency, the 
evaluation of the pulmonary vasculature faces higher demands. For instance, on the 
pathologic functional activity of the pulmonary arteries in early stages of PYO. Efforts 
should be made to develop new clinical, diagnostic tools, that provide additional 
information on the state of the pulmonary vasculature, with special attention for aspects 
of the pulsatile nature of the pulmonary circulation. 
Our limited capability of a relIned assessment of the pulmonary vasculature in PYO, 
may be explained by the acknowledgemcnt that the pathophysiology of this charac-
teristic vascular disease process is still largely unknown. In the last decade, due to the 
emerging research in vascular cell biology, a signitlcant progress has bcen made in 
our insights in mechanisms on cellular and molecular level that appear to be involved 
in PY05. 6. 74. 75, 93 The vascular disease process is characterized by excessive cell 
proliferation, changes in cellular phenotype and extracellular matrix modulation, 
directed by various vasoactive modulators and growth factors. The unraveling of these 
mechanisms may not only provide insight in the progression and functional 
consequences of the disease process, but may also lead to novel therapeutic strategies 
directed to prevent or reverse the vascular disease'" (,3. 74. 
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In conclusion, each of the diagnostic techniques to evaluate PYD in patients with 
congenital heart disease, describes specific aspects of the pulmonary vasculature and 
each has its specific practical and conceptual limitations, Data on the predictive value 
of the techniques regarding reversibility and long term outcom are scarce. The value 
of the obtained information has to be weighed against the risks of the diagnostic 
procedure. The results of the different techniques may provide discrepancies in 
individual patients, hampering the interpretation of the tindings. Research focused on 
the pathophysiology ofPYD in congenital herut disease will increase our understanding 
of these patients and may aid the clinician to ascertain optimal management and its 
timing. 
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Abstract 
The ability to assess the pulmonary vasculature in pulmonary vasculru' disease by hemodynamic 
or histological evaluation is limited. 
We sought to determine the feasibility of intravascular uilrasound techniques in infants and 
children and to assess simultaneollsly the morphology and dynamics of pulmonary arteries. 
Patients were seen in the department of Pediatrics, division of Pediatric Cardiology, Sophia 
Children's Hospilal, Rotterdam, The Nelherlands. 
\Vc perfanned intravascular ultrasound imaging in II pediatric patients with congenital heart 
disease undergoing cardiac catheterization. Luminal diameter, area and pulsatility were 
detcnnincd at two to nyC sites in the pulmonary branches. Pulmonary vascuhu' reaction to 
100% oxygen inhalation was studied. 
Patients weighed 4.1 to 5 1.0 kg (21.8 ± 16.3 kg, mean ± SD). Luminal diameters. areas and 
pulsatilities could be determined reproducibly in arteries with diameters from 1.6 to 9.3 111111. 
In total 39 sites were studied in 11 patients. Pulsatility was related to vessel size (r::: 0.81). 
aHhough a substantial interindividual variation was presenl. After 100% oxygen inhalation 
pulsatility increased in all arteries (from 20.0 ± 3.3% to 25.9 ± 2.9(k!, P < 0.05) and a 
vasodilatation could be directly visualised, most prominently in the smallest m-teries (percen-
tage change in diameter mean 7.4 ± 2.8£.«, vs. -2.8 ± 3. I % in the hU'gest mteries. r < 0.00 I). 
Measurement of wall thickness was not feasible, but specinc changes in the appearance of the 
wall structure could be recognized in a patient with severely elevated pulmonary vascuhu' 
resistance. 
The specil1c advantages of intravascular ultrasound in assessing pulmonary vascular disease 
arc discussed. 
Conclusions: Intravascular ullrasound imaging of the pulmonary vasculature is feasible in 
infants and children and provides a unique opporlllnity to assess directly pulmonary dynamics 
in vivo. Therefore it may he a valuable tool in evaluating the pulmonmy vasculature and its 
responses to normal and pathological conditions. 
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Introduction 
The state of the pulmonary vasculature plays a crucial role in the management and 
prognosis of children with congenital heart disease l . 2. To assess the pulmonary 
vasculature, mainly two diagnostic tools are currently in use; haemoclynamic evaluation 
by cardiac catheterization and examination ofiung histology. Although both techniques 
provide valuable information, both also have important limitations. One must realise 
that, on the one hand, hemodynamic data, like pulmonary artcry prcssure, blood tlow, 
and resistance, reflect merely indirect consequences of the vascular process; more-
over, they are based on various assumptions and, thus, inevitably are accompanied by 
potential errors2. On the other hand, histologic examination of lung biopsy tissue 
provides a qualitative and quantitative description of morphologic changes in the 
vascular wall, but remains a static, ill vitro examination without functional validation3, 4. 
Furthermore, it requires a thoracotomy. Thcsc limitations arc illustratcd by rcports of 
the correlation of the two techniques, showing important discrepancies in individual 
patients with pulmonary vascular disease (PVD)'·s. 
It has been shown that by mcans of intravasculru' ultrasound (IVUS) imaging vascular 
luminal diameter, area and pulsatility can be determined accurately, as well as 
qualitative and quantitative aspects of the vascular wall"·I'. We hypothesized that 
with this technique it is possible to assess directly and simultaneously vessel wall 
appearance and "real time" vessel wall dynamics. ill \'ivo, in peripheral pulmonary 
mteries of children with congenital heart disease. This would give direct, unique 
information on the apperu'ance and functional state of the pulmonary vascular bed, 
which is directly available during cardiac catheterization and might obviate the need 
for a thoracotomy. 
We therefore performed a study to determine the feasibility of I VUS techniques in 
infants and children and to assess the appearance and the dynamics of the pulmonmy 
vasculature ill vivo. 
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Methods 
Eleven patients, requiring diagnostic or therapeutic cardiac catheterization because 
of congenital heart disease in the Sophia Children's Hospital, Rotterdam, the 
Netherlands, underwent simultaneous IVUS imaging of the pulmonary arteries. IV US 
was performed using disposable ultrasound catheters, 4.2F CVIS (Cmdiovascular 
Imaging Systems Inc., Sunnyvale, CAl or 3.5F Sonicath (Boston Scientific Corp., 
Watertown, MA), both having a 30MHz transducer at its tip. These were connected to 
the CVIS Insight system or the HP Sonos Intravascular Imaging System (Hewlett 
Packard, Andover, MA) respectively. All patients underwent complete right heart 
catheterization, under general anesthesia, including determination of pulmonary artery 
pressure, capillary wedge pressure, pulmonary blood tlow calculated by the Fick 
principle, and pulmonary vasculm resistance. A 6F, 70cmlong sheath (Cordis, Miami, 
FL) was advanced from the femoral vein into the proximal pulmonary artery. Through 
this sheath the ultrasound catheter was directed along the pulmonary branch, towards 
a wedged position. At consecutive sites, from the proximal artery, via the segment 
arteries to the peripheral arteries, identified and detined by tluoroscopy", ultrasound 
images were recorded, simultaneously with the ECG, and analyzed off-line. Pulmonary 
artery diameter and area were measured at end-diastolic (minimal) and peak-systolic 
(maximal) dimensions. Vascular pulsatility was dell ned as the difference between 
planimetered peak-systolic and end-diastolic areas divided by end-diastolic area x 
100%. The average value of 3 cardiac cycles was used for analysis. In 6 of II patients 
all measurements were repeated at identical sites after inhalation of 100% oxygen as 
pulmonary vasodilator. Written informed consent was obtained li'Dlll the parents of 
all children. The study protocol was approved by the Medical Ethical Comittee of the 
University Hospital Rotterdam. 
Statistical aI/a lysis 
Data are expressed as mean values and standard deviations. Correlations were 
calculated using linear rcgression and correlation coefficient. Student's t-test and 
Wilcoxon rank sum test were used to evaluate the effect of oxygen inhalation. A p value 
< 0.05 was considered signitlcant. 
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Results 
IVUS imaging of the pulmonary arteries was performed in II children. Patients 
characteristics arc shown in table I. Pulmonary vascular resistance was normal in 
eight patients, slightly to moderately elevated in two and severely elevated in one 
patient. In all patients the positioning of the long sheath in the proximal pulmonary 
artery and guiding of the ultrasound cathcter through tltis sheath along the pulmonary 
branch could be achieved easily. Once the catheter lVas placed in a stable, non-
branclting position, the obtained images were or good quality in all patients (fig I). 
There was a clear delineation between blood and the inner vessel wall, allowing 
reproducible measurements of systolic and diastolic vessel dimensions in all recordings. 
Measurements sites are shown in figure 2. End-diastolic diameter of the vessels 
Figure 1 Illtravascular ultrasoulld illlage of a peripheral pullllollary artel)' of 
patiellt I I. *: ultrasoulld catheta Note the gray layer (/t the illller border 
of the vessel wall (anvw). Distallce belll'een two white poillts is I /11111. 
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Table 1 Patiellts c/wracferislics 
patient age weight diagnosis mPAP Qp PYR PYR 
30% 100% 
yrs kg mmHg 1/ minI m2 WU. m2 WU. m2 
3.1 15.6 PDA 12 4.3 1.0 0.2 
2 11.4 51.0 PDA 17 6.0 1.2 * 
3 3.3 15.4 PDA II 6.7 0.2 
4 3.0 15.8 PDA II 5.3 0.8 
5 6.5 24.7 PDA 13 4.4 0.9 
6 0.7 5.3 YSO 24 8.6 1.6 1.7 
7 11.5 48.0 AS OIl 13 4.4 1.6 
8 5.0 12.0 ASDII 12 7.3 1.0 
9 16.0 36.5 ASDI 24 4.3 4.2 2.3 
10 0.4 4.1 AYSO 33 4.2 5.5 2.8 
II 4.4 11.7 AYSD 72 4.4 15.0 19.0 
mean 6.0 21.8 22 5.5 3.0 
(SO) 5.1 16.3 18 1.5 4.3 
ASDII illdicates atrial septal d~fect ,!f the seculldum type; A FSD, atriovelltricular 
septal d~fect; PDA, patellt ductus arteriosus; FSD, velltricular septal d~lect; mPAP, 
meall pulmO//(/I:)' artel), pressure; Qp, pulmollal')' bloodfiow; PVR 30%, puill/(Jl/ar)' 
vascular resistallce with 30% oxygell illhalatioll; PVR 100%, idemlVith 100% oxygell 
illhalatioll. WU, !!'<)()d '.I ullits; *, IVUS study, but I/O hemodYllamic data durillg 100% 
oxygell inhalatioll. 
reached, varied from 1.6 to 9.3 nun. Lm'ger m·teries could not be visualised adequately 
because of limited penetration power of the 30 MHz transducer. The pulsatility of the 
pulmonary artery varied at different sites in the arterial branch and showed a relation 
with the size of the vessel, expressed as end-diastolic area. In all patients but one 
(patient 11) the pulsatility increased in the more proximal vessels. The relation for 
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Figure 2 kJeasliremenl sites iJ1 the jJulmollm:v vasclilar Iree~ A: plvximal arteries, 
IUlllillal diallleter 4.2 to 9.3 111111 (6.4 ± 1.3111111, lIIeclll ± SD), 11 = 15; 
B: seglllellt arteries, IUlllillal diallleters 2.3-5.911111/ (3.9 ± 1.1111111),1/ = 12; 
C: peripheral arteries, IUlllil/al diallleters 1.6-2.9 111111 ( 2.3 ± 0.4 111111), 
11 = 12. 1/: II/llIIber of lIIeaSUrelllellt sites. 
the total patient group (I' = 0.81; p < 0.05) is shown in fig. 3a. Between the individual 
patients there was a substantial variation in pllisatility per vessel diameter and in the 
extent of pulsatility increase (tig. 3b). In 6 patients the reaction to 100% oxygen 
inhalation was studied. Pulsatility increascd in all vessels. The larger vessels tended 
to show the largest increase in pulsatility (fig. 4). Only patient II showed a different 
rcaction pattern. The mean pulsatility in this patient was smaller than the mean 
pulsatility in the other patients (9.5 ± 0.7%, n = 2 vs. 21.5 ± 13.6%, n = 14). 
Furthermore, the increase in pulsatility after oxygen inhalation tended to be diminished 
(13.5 ± 0.7% vs. 27.6 ± 13.5%). End-diastolic diameters increased after oxygen 
inhalation. This reaction was most prominent in the smallest vessels (percentage change 
in diameter 4-11 %, mean 7.4 ± 2.8%, P = 0.001) and was less prominent in the medium 
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Figure 3 Pulsatility ill relatioll to vessel sile ill 11 patiellfs. II: measuremellts (!fthe 
total patiellt grollI', e.\pressed as meall ± SD. (11) = 1I11mbero!measuremellfs. 
B: measuremellts of the illdividualpatieJIts. (11) = patieJIt 11 umber as SflOIVII 
ill table 1. 
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Figure 4 Effect of100% oxygen illhalatioll Oil pliisatility ill 6 patiellts. FiO" percell-
tage of illspired ""ygen. Vessel end-diastolic diall/eter: 1-311/11/, 11=7 (0); 
3-611/11/,11=6 (1::.); 6-911/11/, 11=3 (0); total gmllp, 11=16 (III). II, IIl1/llber of 
measllrements. Pliisatility is e.\pressed as mean ± SEMp)r tlte towl gmllp. 
The increase ill II/eall pliisatility at 100% illspired oxygen collcelltratioll 
was statistically sigllificallt (I' < 0.05, Wilcoxoll siglled rallk Slllll test for 
total gmllp). 
sized vessels (2-6%, mean 4.2 ± 1.8%, P = 0.002). There was a slight decrease in 
diameter in the largest vessels (-6 to -2%, mean -2.8 ± 3.1 %, p = 0.047) (fig. 5). 
Again, this reaction pattern was similm' in all patients except patient II. In this patient 
the end-diastolic diameter of the largest vessels increased 2%. 
The adventitial border could not be delineated adequately. Consequently, wall thickness 
could not be measured. However, there was a specific appearance of the wall aspect 
in patient II, in whom a grey layer could be distinguished at the inner border of the 
vessel wall (fig. I). Such layer was not seen in the other patients. There were no 
procedure related complications in any of the patients. 
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Figure 5 Effect of 100% oxygen inhalation on end-diastolic vessel dia/lletCl: Per-
centage c/tange in diameter expressed as /IIeans ± SD. Vessels of various 
diameters s/tolVed a statistical/y significant different effect of 1 00% oxygen 
inhalation (t-test: * p < 0.05; ** p = 0.001). 
Discussion 
Our data show that IVUS imaging of the pulmonary arteries in infants and children is 
feasible. There was a clear delineation between blood and the inner vessel wall, 
allowing reproducible measurements of systolic and diastolic vessel dimensions. 
Accuracy of vascular luminal diameter and area measurements with IVUS has been 
demonstrated9- I2• Measurements of luminal diameters and areas during the cardiac 
cycle provide the possibility of studying pulmonary vascular dynamics in vivo in a 
unique, direct way. 
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The pulsatility of the pulmonary artery is one expression of this dynamics. We found 
a significant relationship between vessel size and pulsatility. Although the pattern of 
increasing pulsatility towards the proximal arteries was present in all patients, the 
variation between the individual patients was considerable. One might speculate that 
the diminished pUlsatility in the smaller vessels is caused by a progressive obstruction 
by the ultrasound catheter in these vessels, thus affeCting their responses. However, 
the intedndividual variation, specifically in vessels at similar sites, with similar area 
in patients with similar weights, makes this hypothesis unlikely. This t;1r more suggests 
that, as expected, there are more factors than size that affect pulsatility. Pulsatility 
will be determined by two major components: (I) mechanical forces working on the 
vessel wall and (2) intrinsic viscomechanical properties of the vessel wall. 
Mechallical forces 
III vivo, various mechanical forces have their effects on the vascular wall. Radially 
directed forces, such as pulmonary artery or pulse pressure and the contradirected 
intrapulmonary pressure, will affect wall dynamics. Also pressure wave reflections, 
originating from the pulmonary microcirculation and branching of larger vessels, 
will contribute to the pulsatility, varying with propagation down the pulmonary 
branches14. Next, tangential forces, in both longitudinal and circumferential directions, 
such as shear stress, will affect the mechanics of the vascular wallIS, 16. In pulmonary 
vascular disease these mechanical forees'and their effect on wall dynamics will alter. 
For instance, in the normal pulmonary circulation wave reflections are of small 
amplitude because of excellent matching of impedances in the distal pulmonary vessels. 
However, in pulmonary vascular disease these reflection waves will increase in 
amplitude as well as in velocity with which they return, resulting in an increasing 
effect on vessel wall dynamics'" 17 It has been demonstrated thatmcchanical forces 
have their effects on the metabolic activity in the vascular wall, resulting, on the short 
term, in adaptation of vascular tone and, on the longcr term, changes in the elastic 
properties of the wall itself18·20• 
Properties of the vessel wall 
Refel1"ing to the vessel wall itself, this exhibits an anisotropic, nonlinear, viscoclastic 
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are using indirect parameters to estimate dilatatory vascular effects or less reliable 
methods like angiogratlc diameter determination 2• 20. 
In our experience, the adventitial border could not be delineated well, probably because 
the pulmonmy vessels are embedded in air, frustrating quantitative assessment of the 
vessel wall thickness. This confirms the limited expetience reported in adult patients 22. 
However, qualitative aspects of the vascldm' wall could be studied. The inability to 
distinguish the three layer structure of the wall corresponds with the fact that we 
studied elastic m'teries I2 . B. However, a grey inner layer was identified at the inner 
border ofthe vessel wall of the one patient with irreversible PYD, which might retlect 
intima thickening. A congruency may exist with IYUS aspects of coronm'y intima 
proliferation in adult patients24. 25. However, histological validation was not performed 
in this patient. Few em'lier reports claim to distinguish qualitative changes in the 
vessel wall in pulmonary hypertension22. 26. n We think Im'ger series, including nor-
mal pulmonary m'teries, are needed to evaluate the value of this qualitative vessel 
wall assessment. 
The smallest vessels we reached with the ultrasound catheter had a diameter of 1.6 
mm. In PYD the most striking changes, from a morphological point of view, occur in 
the muscular arteries and smaller m'terioles, which are vessels with a diameter of less 
than 111111123. Although new ultrasound catheters, with a diameter less than I mm, m'e 
about to become available, the vessels accessible for ultrasound imaging will not be 
the "resistance vessels". However, as stated before, PYD is a process of the whole 
pulmonary vasculature, which is not restricted to the small peripheral vessels, but 
also affects the larger puh11onm'y m'teries I9 . 21 Every functional change in the pul-
monary microcirculation will directly affect the dynamic behaviour of the more 
proximal vessels. The large and medium sized pulmonary arteries are not just passive 
conduit vessels, but represent an important determinant of integrated pulmonary 
circulation 14. 17. So, their mechanical behaviour in PYD is of major interest. In con-
trast to both hemodynamic and histological evaluation, IYUS imaging has the 
possibility to assess vessels of different sizes separately. 
In this feasibility study, the patient number was too small, with regard to the number 
of hemodynamic parameters, to perform adequate analysis of possible relationships 
between hemodynamic variables and ultrasound data. However, there \vas a tendency 
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of less pulsatile arteries in the patients with elevated pulmonary vascular resistance. 
Furthermore, in all previously described relations and responses, patient II, with 
severe, irreversible PVO, showed abe11'ant patterns. This suggests the ability of 
intravascular ultrasound to assess altered vascular dynamic behaviour in pulmonary 
vascular disease. 
At the moment we are performing a prospective study in children with congenital 
heart disease, including not only the vruious stages ofPVD but also normal pulmonru'y 
vasculature, in which we will correlate IVUS data with complete hemodynamic, 
angiographical and histological evaluation. This study will demonstrate whether the 
described advantages of IVUS imaging will have additional value to the currently 
available diagnostic techniques, in assessing the state of the pulmonru'y vasculature 
for clinical as well as research purposes. 
We conclude that IVUS imaging of the proximal and peripheral pulmonary arteries is 
feasible in children and infants using routine catheter techniques. This technique 
provides a unique opportunity to assess the state of the pulmonary vasculature and its 
dynamics ill vivo directly. Therefore it may be a valuable tool in evaluating the 
pulmonary vasculature and its changes and responses in normal and pathological 
conditions. The additional value with regard to conventional techniques, such as hemo-
dynamic and histologic evaluation, remains to be determined. A prospective, 
comparative study to answer this question is in progress at our department. 
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IVUS ASSESSMENT OF PULMONARY ARTERIAL WALL APPEARANCE 
Abstract 
Assessment of the progression of pulmonary vascular disease (PVD) associated with congenital 
heart disease is limited with current techniques. This study aimed lO assess the ability of 
intravascular ultrasound (IVUS) to visualize changes in the pulmonary arterial wall associated 
with PVD in children. 
Pulmonary rvus was performed in 35 patients with moderate PVD, 12 with advanced PVD 
and in 14 controls. The I1ntlings were compmed with hemodynamic variables and, in 31 patients, 
with lung biopsy lintlings. In controls, the arterial lumen was most frequently (71 %) surrounded 
by an echo dense ring with a dearly tlcl1ncd inner bonIer, but without a dearly dcl1llcd ollter 
border. This pattern was founo less frequently in patients with moderate (p < .01) and advanced 
(p < .05) PVD. In patients with moderate PVD an inner layer of soft echo reflections was 
recognized more frequcntly than in controls (p < .0 I). The thickness of this layer con'elated 
wilh shunl size (r = .39; p < .01), pulmonary ancry pressure (I' = .31; p < .(5) and percent 
mcdial thickness as determined in lung biopsies (r = .44; p < .05). \Vhcn adjacent structurcs 
allowed the ollter border of the arterial wall to he delincd, wall thickness conelated with 
pulmonary artery pressure (r = .52; p < .(5) and pulmonm-y vaseularresistance (r = .65; p < .01). 
The ultrasound appearance of the arterial wall did not correlate with advanced lesions iniul1g 
hiopsies. 
Conclusions: IVUS is able to visualize changes in the wall of elastic pulmonary arteries in 
PVD. Quantitative assessment of these changes cDlTciated with hemodynamics and quantitative 
data on medial hypertrophy in lung hiopsy. The ultrasound changes of the arterial wall did not 
correlate with the presence of advanced lesions in lung hiopsy. 
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Introduction 
Congenital heart disease associated with pulmonary hypertension or puhnonary 
overflow leads to functional and morphological changes in the pulmonary vascular 
bed l -5 .This pulmonary vascular disease (PVD). referred to as plexogenic arteriopathy, 
is an important determinant in the management and prognosis of children with this 
type of heart disease2, J. 6.8. As long as plexogenic arteriopathy has not progressed 
beyond a certain stage, surgical correction of the heart defect will result in regression 
of vascular changes. Howevcr, when the arteriopathy has progressed beyond a "point 
of no retul11," the disease process becomes irreversible and will progress despite 
cOll'ective surgery7. Current diagnostic techniques, used to assess the state of the 
pulmonary vasculature, i.e. cardiac catheterization and lung biopsy, have intrinsic 
limitations I. 5-7. 9-12. Interpretation of the results of both techniques leaves a "grey" 
zone between reversible and irreversible disease7. 
It has been suggested that intravascular ultrasound imaging (IVUS) of the pulmonary 
arteries may complement the assessment of pulmonary vascular diseaseD. 14. IVUS 
has been shown to provide accurate measurements of vascular area, wall characteristics 
and pulsatility ill l'il'ol3· 15-17. The cUl1'ently available ultrasound catheters have dia-
meters down to 3.0 French and can reach vessels of 1.4 mm diameter. In the pulmonary 
vasculatlll'e, where the transition to a muscular type of artery occurs at a diameter of 
approximately I mm, this means that only clastic artel1es are accessible for inves-
tigation by IVUS. This may be a potential limitation, since histologically the most 
prominent vascular changes arc localized in the smallcr, muscular pulmonary arteries. 
However, anecdotal data, suggesting changes of the echographic appearance of the 
vascular wall in patients with pulmonary hypertension, have been reported [4, 18-20. 
To assess, systematically, the ability of IVUS to visualize changes in the pulmonary 
mterial wall associated with PVD, we prospectively studied tile echographic appearance 
of the pulmonary artetial wall, ill vivo, in control children and in patients with diffe-
rent stages of pulmonary vascular disease and correlated the findings with hemo-
dynamic and histologic evaluation of the pulmonary vasculature. 
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Materials and Methods 
Parients 
This study was approved by the Medical Ethical Committee of the University Hospital 
Rotterdam. After wlitten informed consent of the parents, patients who required cardiac 
cathetelization and had increased pulmonary blood flow (pulmonruy-to-systemic blood 
flow ratio> 1.2) and/or pulmonary hypertension (mean pulmonary artery pressure 
> 20 mmHg), were prospectively enrolled in the study. Children with a normal 
pulmonary circulation, who underwent cm'diac catheterization to exclude cardiac 
disease or with mild left-sided obstructive lesions and a normal left ventricular end-
diastolic pressure and pulmonary wedge pressures, served as controls. 
Catheterization and IVUS pmcedure 
All procedures were performed under standmdized general anaesthesia21 • Hemo-
dynamic evaluation and IVUS imaging of the pulmonary aI'teries were performed in 
the same procedure according to a protocol previously reportedI3. Briet1y, all patients 
underwent complete hemodynamic evaluation of the puhnonm'y and systemic vascular 
beds, including vasodilator response to inhalation of 100% oxygen, as a powerful 
pulmonm'y vasodilator. An HP Sonos Intravasculm' Imaging System (Hewlett Packard, 
Andover, MA) was used. Sonicath 3.5 r or Spy 3.0 F ultrasound catheters (Boston 
Scientific Corp., Watertown, MA) were used, both having a 30 MHz transducer at its 
tip. The ultrasound catheter was directed through a 6 F long sheath along the pulmonary 
branch. At consecutive sites in the proximal artery, the segment arteries and the 
peripheral artelies, identified and defined by t1uoroscopyB. 22, ultrasound images were 
obtained and recorded on S-YHS videotape simultaneously with the ECG. 
Histologic evaluation 
In patients who underwent subsequent cardiac surgery, an open lung biopsy was ta-
ken dnring the surgical procedure. In one patient an open lung biopsy was taken as 
isolated procedure for diagnostic purposes. Tissue was formalin tlxed under vacuum. 
After slicing and routine paraftin embedding, histological sections were cut at 3 dif-
ferent levels of each slice. Sections from each level were stained by hematoxylin-
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eosin, elastic- van Gieson stain and iron stain, Vascular changes were described 
according to Wagenvoort5, 7, The medial thickness of the muscular arteries was 
calculated as a percentage of the total artery diameter, excluding the adventitial layer. 
The presence or absence of intimal proliferation, concentric laminar intimal fibrosis, 
angiomatoid dilatation lesions, fibrinoid necrosis or plexiform lesions was recorded, 
Patimt classificatioll 
Patients were classified on the basis of hemodynamic data and, separately, on the 
basis of histologic data, 
HEMODYNAMIC CLASSIFICATION: patients with nonnal pnlmonary vascular resistance 
(PVR baseline < 4 WU,m2) or responsive PVR (PVR al IIK)% oxygen inhalalion < 4 WU,m2 
or vasodilator response 2 50%) were classilied as having mild-to-moderate PVD, 
Patients with an increased PVR, not responsive to 100% oxygen (PVR al 100% oxygen 
inhalation 2 4 WU,m 2 and vasodilator response < 50%) were classilied as having 
advanced PVD, Vasodilator response was deli ned as 100 x (PVR baseline - PVR al 
100% oxygen inhalation) / PYR baseline. 
HISTOLOGIC CLASSIFICATION: patients with a Inng biopsy showing one ore more of the 
advanced lesions of plexogenic arteriopathy: concentric laminar intimal tibrosis, 
angiomatoid dilatation lesions, librinoid necrosis or plexiform lesions, were classified 
as having il1'eversible PVD7, In the absence of any of these lesions, the patients were 
classified as having reversible PVD, 
Illtravascular ultrasoul/d (Il/(Ilysis 
The ultrasound cross-sections were analyzed at end-diastole, independently by two 
observers blinded for diagnosis, hemodynamic and histological data, For qualitative 
and qnantitative analysis the cross-sections were divided in four quadrants (each 90°), 
Based on ultrasound appearance the pulmonary arterial wall was categorized in tive 
patterns: A, an echodense ring with a clearly deli ned inner border, but without a 
clearly deli ned outer border (Fig, I A); B, an inner layer of soft echo retlections within 
the echodense outer layer (Fig, I B); C, two layers separated by a thin echolucent 
layer witllminimal reflection (Fig, I C); D, a well-deli ned outer border of the arterial 
wall (Fig, I D); E, a three-layered arterial wall, as described in systemic muscular 
III 
IVUS ASSESSMENT OF PULMONARY ARTERIAL WALL APPEARANCE 
A 
B 
Figure 1 PlIllIIOIIGlY arterial wall chamcteristics as d~filled by illtmvasclilar 1Iltm-
sound. 
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A. Pattern A: ({II ec/wdmse rillg with a clearly defilled illller borde/; bllt 
withollt a clearly defilled aliter borda 
B. Pattern B: all illller layer of soft echo reflectiolls lVithill the ec/wdellse 
oliter fayel: 
c 
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C. Pattern C: 2 layers separated by a thin echolucent layer with minimal 
reflectioll. 
D. Pattern D: a well-defined outer border of the arterial wall, due to 
adjacent stmctures. 
a = arterial lumen diameter; b = layer thickness; The distance between 
two white dots is 1 111111 
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arteries 16 and in vitro in pulmonary arteries l4. The wall characteristics were described 
for each quadrant. The mean number of quadrants with a specitic pattern per vessel 
was calculated for each patient. Quantitative analysis was performed using a pro-
tractor. The vessel diameter, bounded by the leading edge of the outer echodense 
ring, and the maximum layer thickness per cross-section were measured for each 
artery. The layer thickness was determined as the perpendicular distance between the 
leading edge of the inner layer and the leading edge of the outer layer (Fig. I b-d). A 
layer was measured only if the distance was 2 0.1 mm. In the absence of a distinct 
layer (pattern A) no layer thickness was measured. The percentage of layer thickness 
of a vessel was calculated as (maximum layer thickness / vessel diameter) x I 00. The 
mean percentage of layer thickness was calculated for each pattern in each patient. 
Because the resolution of the ultrasound catheter may influence the findings in arteries 
of different size, Ule IVUS cross-sections were divided in small (diameter < 2.5 mIll), 
medium-sized (diameter 2.5-6.5 mm) and large (diameter> 6.5 mIll) arteries. 
Statistical analysis 
The interobserver variability for the presence or absence of each qualitative parame-
ter was assessed using the unweighted Cohen's Kappa coefficient 23.24. Kappa values 
range from -I to + I. Kappa equals + I when there is complete agreement between 
two observers. Kappa equals 0 when observed agreement is equal to that expected by 
chance alone. The number of quadrants with each pattern per vessel, as determined 
by the two observers, was compared using the Wilcoxon matched-pairs signed-ranks 
test. The interobserver agreement for the quantitative parameters was determined by 
calculating correlation coefficients. The Student's t-test for paired observations was 
used to test whether there were systematic differences between the observers. 
The incidence of the different wall charactelistics was compared between patient 
groups using Chi-square test, followed by Fisher's Exact test. The correlations bet-
ween continuous variables were calculated using linear regression. A p-value < 0.05 
was considered statistically significant. 
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Table 1 Di(/glloses ({{the stlldy patiellts 
Diagnosis n 
L~{t-to-right "hlllll 
VSD with or without ASD or PDA 
ASD 
PDA 
cAVSD 
Truncus arterioslIs 
No left-to-right Shllllt 
Persistent PH after corrected heart defect 
Unexplained PH 
Left sided obstructive lesions with PVC 
Controls 
Total 
23 
6 
3 
2 
2 
9 
14 
61 
ASD indicates atdal septal defect; cAVSD, complete atrioventricular septal defect; n, 
number of patients; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PVC, 
pulmonary venous congestion; VSD, ventricular septal defect. 
Results 
Patiellts 
In total 61 children were ern-oIled in tbe study. These included 47 patients with PVD 
and 14 controls. Diagnoses are shown in table I. Based on hemodynamic evaluation 
35 patients had mild-to-moderate PVD and 12 patients had advanced PVD. Lung 
biopsies were obtained in 31 children. Based on histological evaluation 23 patients 
had reversible PVD and 4 patients had irreversible PVD. In 4 controls, biopsies were 
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Table 2 Patients classification based on hemodynamics and histology. 
n 
age 
mean PAP 
shunt ratio 
PVRBASELlNE 
PVRAT 100% O2 
n 
age 
medial thickness 
(years) 
(mmHg) 
(Qp/Qs) 
(WU.m2) 
(WU.m2) 
(years) 
(%) 
Hemodynamics 
moderate PVD advanced PVD 
35 12 
3.6 2.1 
(0.2-30.7) (0.2-15.8) 
22±9 50± 12 
2.6 ± 1.5 1.2 ± 0.3 
2.0 ± 1.2 9.7 ± 3.S 
1.6 ± l.l 9.S ±4.1 
Histology 
reversible PVD irreversible PVD 
23 4 
1.2 2.0 
(0.3-IS.2) (0.3-30.7) 
11.0±S.1 13.0± 1.4 
control 
14 
6.3 
(0.5-16.9) 
12 ± 3 
1.0± 0.0 
1.2 ± 0.5 
0.7 ± 0.3 
control 
4 
3.3 
(1.8-4.8) 
9.8 ± 2.9 
PAP indicates pulmonary artery pressure; PVD, pulmonary vascular disease; PVR, 
pulmonary vascular resistance; Qp/Qs, pulmonary-to-systemic blood flow ratio; 
WU.m2, Woods units times square meter. Age is expressed as median (range), other 
data are expressed as mean ± standard deviation. 
available. Patient characteristics, hemodynamic and histological data are summarized 
in table 2. 
Illfravascular ultrasound analysis 
A total of 229 pulmonmy arterial lVUS cross-sections was analyzed. Image quality 
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Table 3 EcilOgraphic wall characteristics re/ated to vessel diameter 
vessel diameter 
small medium-sized large 
« 2.5 mm) (2.5-6.5 mm) (> 6.5 mm) 
n (%) n (%) n (%) 
pattern A 143 ( 71) 116*'i' ( 54) 43 ( 73) 
pattern B 38 ( 19) 59*t ( 28) 6 ( 10) 
pattern C 7 ( 4) 21* ( 10) 6 ( 10) 
pattern D 12 ( 6) 18 ( 8) 4 ( 7) 
200 (100) 214 (100) 59 (100) 
n indicates the sum of the mean numbers of quadrants per vessel per patient; 
*p < .05 compared to small arteries; t p < .0 I compared to large arteries. 
For the description of pattel11s sec text. 
was moderate or good in 220 cross-sections and poor in 9 cross-sections. The latter 9 
cross-sections were excluded for analysis. Of the cross-sections selected, all 4 quadrants 
could be analyzed in 84.5%, 3 quadrants in 10%,2 quadrants in 5% and only I quadrant 
could be analyzed in 0.5%. In 62% of the analyzed quadrants pattern A was identified, 
in 22% pattern B, in 8% pattern C and in 8% pattern D. Pattern E could not be identified 
in any of the cross-sections. 
Vessel diameter ranged from 1.4 to 10.4 mm. As shown in table 3, the frequency of 
the described patterns differed between small, medium-sized and large arteries 
(p < .001). Pattern A presented less frequently in medium-sized arteries compared to 
both small (p < .001) and large arteries (p < .05). In contrast, pattern B occurred more 
frequently in the medium-sized arteries compared to the other diameter categories 
(p < .05). No differences in echographic wall characteristics were demonstrated 
between the small and large pulmonary arteries. 
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Table 4 Echogmphic lVall paltems ill the patiellt groups based Oil hemodYllamics 
pattern moderate PVD advanced PVD control 
n (%) n (%) n (%) 
diameter A 78.1 ( 69) 30.7 ( 76) 34.5 ( 73) 
< 2.5 nlln B 25.3 ( 22) 5.5 ( 14) 7.5 ( 16) 
C 5.0 ( 4) 0.8 ( 2) 1.0 ( 2) 
D 5.3 ( 5) 3.0 ( 8) 4.0 ( 9) 
Total 113.7 (100) 40.0 (100) 47.0 (100) 
diameter A 56.4** ( 48) 21.0* ( 49) 38.3 ( 69) 
2.5-6.5 mm 13 41.2** ( 36) 10.5 ( 25) 7.0 ( 13) 
C 11.6 ( 10) 5.0 ( 12) 4.8 ( 9) 
D 7.3 ( 6) 6.0 ( 14) 5.0 ( 9) 
Total 116.5 (100) 42.5 (100) 55.1 (100) 
diameter A 32.5 ( 75) 2.0 ( 67) 8.0 ( 67) 
> 6.5 nlln B 4.0 ( 9) 1.0 ( 33) 1.0 ( 8) 
C 4.0 ( 9) 2.0 ( 17) 
D 3.0 ( 7) 1.0 ( 8) 
Total 43.5 (100) 3.0 (100) 12.0 (100) 
n indicates the sum of the mean numbers of quadrants per vessel per patient; 
PVD, pulmonary vascular disease. *p < .05 and Mp < .0 I compared to controls. 
The interobserver agreement for the qualitative ultrasound parameters revealed kappa 
values of .82 for the descIibed pattern in quadrant I, .79 in quadrant 2, .88 in quadrant 
3 and .78 in quadrant 4. No systematic differences were demonstrated between the 
number of quadrants with each pattern per vessel, as determined by the two observers. 
Correlation coefficients for the quantitative ultrasound parameters, as determined by 
both observers, were .99 for vessel diameter, .95 for percentage wall thickness in 
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Table 5 Ec/lOgraphic wall f1atfems ill the f1atiell1 groups based all histology 
pattern reversible PVD irreversible PVD control 
n (%) Il (%) n 
diameter A 51.6 ( 61) 1l.2 ( 83) JO.5 
< 2.5 nun B 24.3 ( 28) 1.0 ( 7) 2.5 
C 3.5 ( 4) I.3 ( 10) 
D 6.3 ( 7) ( - ) 2.0 
Total 85.7 (I 00) 13.5 (100) 15.0 
diameter A 44.0 ( 54) 8.0 ( 53) 7.0 
2.5-6.5 mm B 28.0 ( 34) 3.0 ( 20) 5.0 
C 6.0 ( 7) 1.0 ( 7) 1.0 
D 4.0 ( 5) 3.0 ( 20) 3.0 
Total 82.0 (I 00) 15.0 (100) 26.0 
n indicates the Slim of the mean numbers of quadrants per vessel per patient; 
PVD, pulmonary vascular disease. 
(%) 
( 70) 
( 17) 
( - ) 
( 13) 
(100) 
( 44) 
( 3 J) 
( 6) 
( 19) 
(100) 
pattern B, .94 for percentage wall thickness in pattern C and .89 for percentage wall 
thickness in pattern D. No systematic differences between the observers for these 
quantitative parameters were demonstrated. 
Corre/atiolls be/ween JVUS and hemodynamic evaluatiol1 
In the controJ group, predominantly pattern A was found in small (73%), medium-
sized (69%) and large (67%) arteries. The incidence of the ultrasollnd wall patterns in 
the "hemodynamics-based" patient groups is given in table 4. 
In the small « 2.5 mm) and large (> 6.5 mm) arteries no differences in cchographic 
wall patterns could be demonstrated between patients with mild-to-moderate PVD, 
patients with advanced PVD and controls. No signitlcant correlations between the 
mean percent layer thickness and hemodynamic data could be demonstrated in the 
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small and large arteries. In the medium-sized arteries, pattern A was fOllnd less 
ti'equently in patients with mild-to-moderate and advanced PYD compared to controls 
(p < .01 and p < .05, respectively), whereas pattern 13 was seen more frequcntly in 
patients with mild-to-moderate PYD compared to controls (p < .01). The mean per-
cent layer thickness in pattern B correlated with the mean pulmonary artery pressure 
(r = .31; P < .05) and with the size of the left-to-right shunt (I' = .39; p < .0 I). In the 
medium-sized arteries, patte 111 D was found in similar frequencies in all patient groups. 
However, the mean percent layer thickness in this pattern correlated with mean 
pulmonary artery pressure (I' = .52; p < .05) and with pulmonary vascular resistance 
(r = .65; p < .01). 
Corre/ations between II'US ant! histologic evaluation 
In the patients with irreversible PYD and in the controls, arteries with a diameter 
> 6.5 mm were not studied. In the small and medium-sized arteries, no differences in 
the incidence of echographic wall patterns nor in layer thickness could be demonstrated 
between the "histology-based" patient groups (table 5). The percentage of medial 
thickness of muscular arteries, as determined in lung biopsy, cOITelated with the layer 
thickness in pattern B only in the medium-sized arteries (I' = 0.44; p = 0.02). The 
echographically discernible layers in elastic arteries were not correlated with the 
presence of intima hyperplasia or fibrosis in lung biopsy. 
Discussion 
The present study demonstrates differences in the echographic appearance of the elastic 
pulmonmy arteries between children with and without PYD. Quantitative measurement 
of echographic layers in the arterial wall correlated with both hemodynamic data and 
the media thickness of musculm' arteries in lung biopsy. The interobserver agreement 
for qualitative and quantitative assessment of IYUS images was good. As far as we 
know, this is the first study that correlates IVUS imaging of the pulmonary arteries in 
vivo, both in controls and in patients with PYD, with contemporaneous hemodynamic 
and histologic evaluation. 
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Although IVUS imaging has heen extensively described in systemic and coronary 
arterial disease, it has not been studied systematically in PV025-JO. In PVO, the 
muscular arteries and arterioles, with a diameter smaller than 0.5-1 mm, may show 
medial thickening, muscularisation of arterioles and intima proliferation. In plexogenic 
arteriopathy, characteristic lesions may emerge, such as concenttic laminar intimal 
fibrosis, angiomatoid dilation lesions, llbrinoid necrosis and plexiform lesions. These 
advanced lesions are associated with irreversible disease. However, slich small arteries 
can be assessed only in lung biopsy tissue4, 7 Structural changes in the larger, elastic 
pulmonary arteries are less prominent, but increased medial thickness, with an altered 
elastin arrangement and changes in extracellular matrix composition, such as an 
increased collagen content and deposition of glycoproteins, have been demonstrated 
in PV031. 
In this study, IVUS in children with a normal pulmonary circulation, predominantly 
showed an arterial lumen surrounded by a single, echodense ring, with no discernible 
separate layers. This is in concordance with previous llndings 13. 15. IS. The media of 
elastic arteries mainly consists of densely packed, concentrically arranged elastin 
tlbers and some sole smooth muscle cells. The acoustic impedance of elastin tibers is 
more or less comparable to that of intima and adventitia. Thcrefore, in normal elastic 
arteries it is expected that no separate layers can be discerned echographicallyl6. 
However, in autopsy specimens of patients with pulmonary hypertension, Ishii et a!., 
using a 20 MHz ultrasound catheter, described a three-layer appearance, with a thick 
echodense inner layer, an echolucent zone and an echodense outer layerl4 Scott et 
a!., also using a 20 MHz ultrasound catheter, reported another type of three-Iayer-
appearance in three adults with systemic pulmonary hypertension and described a 
thin echodense layer visible at the intima media interl;1ce ls. Although we used 30 MHz 
ultrasound catheters, allowing for greater delineation of structural anatomy, we found 
no three-layer appearance as reported by Ishii, in any of our patients ill vil'o. 
When evaluating the arterial wall with IVUS, onc has to acknowlcdgc that acoustic 
factors, gain setting and catheter position may cause visualization of an cchodense 
layer at the intima-media interface, that provide no anatomic information per se·12 . In 
our experience, increasing the gain setting sometimes created an echodense line at 
the luminal border of the pulmonary arterial wall, leading to an artincial three-layer 
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appearance. The wall charactc!istics, in the present study described as pattern C and 
seen in a similar frequency in all patient groups, is comparable to the description of 
Scott et al. and may be such a nOll-anatomic layer. 
In our series, IYUS showed differences in the appearance of the pulmonary arterial 
wall in medium-sized arteties between controls, patients with hemodynamically mild-
to-moderate PYD and those with severe PYD. Pattern A, most frequently found in 
controls, occurred significantly less ti'equent in patients witl! mild-to-moderate and 
advanced PYD. An inner layer with soft echo retlections (pattern B, Fig. I b) was seen 
more frequently in patients with mild-to-moderate PYD compared to controls. The 
thickness of this layer correlated positively with the size of the left-to-right shunt and 
with mean PAP. It also correlated with the medial thickness of muscular arteries, as 
assessed in lung biopsy. The morphologic substrate of this "soft" layer is not clear. In 
elastic vessels of this size the solitary vascular smooth muscle cells, located between 
the elastic laminae, will increase in size in the course of PYD, but it is unlikely that 
this willleacl to this echographic layer.ll. One may speculate that the acoustic properties 
of the intima-media complex change because of modulation of the extracellular ma-
trix or intima proliferation. Then the layer could retlect medial thickening or intima 
proliferation, as suggested earlier'4. 18. The finding that the occurrence of this pattern 
appears to diminish in patients with advanced PYD, might be explained by the increase 
in collagen deposition and fibrosis in media and intima at this stage of the disease, 
increasing again the echodensity of the layer. 
In most IYUS cross-sections the outer border of the arterial wall could not be defined, 
presumably because of ail' in adjacent tissue, hampering echo transmission. In cross-
sections with pattern D (Fig. I d) it was possible to detine the outer border of the 
arterial wall. This characteristic pattern was recognized in similar frequencies in the 
diffcrent patient groups. The possibility to delineate thc outer border of the arterial 
wall may be due to the presence of adjacent structures, such as arterial branches or 
bronchial vessels, taking the place of air-filled lung parenchyma. The thickness of the 
wall, as determined in this pattern, was correlated with mean pulmonary artery pressure 
and PYR. 
No differences in the appearance of the arterial wall could be demonstrated in the 
small and large arteries. This may be explained by the limited penetration of the 
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30 MHz catheters in the large arteries and the limited image resolution in the small 
arteries. The use of lower frequency ultrasound catheters in the large arteries and 
higher frequency catheters in the small ones, may demonstrate whether structural 
changes can he identified by IVUS in these arteries. 
In contrast to the in vitro findings of Ishii et a1. 14, we found no signitlcant correlation 
between qualitative echographic wall characteristics and the histological features of 
the pulmonary vascular bed. Of the quantitative ultrasound findings, only the percent 
layer thickness of pattern B correlated with medial thickness in muscular arteries. 
Pulmonary IVUS and lung biopsy evaluate the pulmonary vasculature at different 
levels. In early pathologic studies, medial thickness of elastic arteries did not correlate 
with hypertensive changes in the vascular bed, nor did non-specific intimal changes, 
such as atheroma31 . 
Limitatiolls of the stlldy. 
The design of this ill vivo study allowed no con'esponding histologic sections of the 
pulmonary arteries studied with IVUS. Therefore, the echographic appearance of the 
arterial wall could not be cOll'elated directly with anatomic structures. The number of 
patients with irreversible PVD in whom a lung biopsy was available, was relatively 
small. Functional vascular changes have been reported in both small and large 
pulmonary arteries in the course of pulmonary vascular disease.lJ· .14. IVUS of the 
pulmonary arteries also has the potential to assess functional properties of the 
pulmonary vasculature ill vivo by investigating pulsatility and arterial wall 
distensibility13· 35. However, this was not the focus of the present study. 
We conclude that IVUS has the ability to visualize changes in the wall of elastic 
pulmonary arteries in the course ofPVD. Quantitative assessment of these echographic 
changes correlated with hemodynamic data, pulmonary artery pressure, shunt size 
and PVR, and also with the quantitative assessment of medial hypertrophy in lung 
biopsy. The echographic changes in the pulmonary arterial wall did not correlate with 
the histologic presence of advanced lesions in lung biopsy. Therefore, we demonstrated 
that IVUS of the pulmonary vasculature provides additional information in the 
assessment of progression of pulmonary vascular disease. Long-term outcome analysis 
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is needed to determine the predictive value and, with that, the clinical utility of 
echographic assessment of the pulmonary arterial wall in children with congenital 
heart disease associated PVD. 
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Abstract 
Vascular remodeling in pulmonary hypertension leads to functional and structural changes in 
the pulmonary vasculature. The available techniques to evaluate the pulmonary vasculature in 
congenital he,ll't disease have practical and conccpllmllimitations. 
We investigated whether pulmonary arterial wall properties. assessed with intravascular ultra-
sound. arc altered in children with congenital heart disease and pulmonary vasculm disease 
and whether these are associated with the progression of the disease. 
Pulmonary arterial pulsatility and distensibility were determined. using intravascuhu' ultra-
sound, in 43 children with congenital heart disease, associated with mild to moderate (n = 31) 
or advanced (n = 12) pulmonary vascular disease, and in 12 children wilh normal pulmonary 
circulation. Vascular pulsatiIity cOll'elated independently with pulmonary pulse pressure, 
pulmonary-to-systemic vascular resistance ratio and hemoglobin concentration. Adjusted for 
these variables, pulsatility did not differ between patient groups. In contrast, arterial wall 
distensibility decreased with the sevcrity of vascular disease and cOlTelatcd with the ratios of 
pulmonary-to-systemic pressure and resistance and with hemoglobin concentration. Adjusted 
for hemodynamic vm-iables, distensibility was still decreased in patients with pulmonary 
vascular disease compared to controls. This difference was most pronounccd aftcr inhalation 
of 100% oxygen. 
Conclusions: These data demonsIrate that distensibility is progressively decreased in pulmonmy 
vascular disease and suggest that this decrease is, in part, related to an increased distending 
pressure as a result of pulmonary hypertension and, in part, to a stiffening of the arterial wall 
in the disease process. Arterial waH distensibilily may be a variable of additional valuc in thc 
evaluation of the pulmonary vasculaturc. 
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Introduction 
Pulmonary hypertension, with or without increased pulmonary blood now, in children 
with congenital heart disease, will lead to functional and structural changes of the 
pubnonary vasculature l-4, The progression and reversibility of these vascular chan-
ges, referred to as pulmonary vascular disease (PYD), are important determinants of 
management and prognosis of these patients l ", In the clinical setting, the state of the 
pulmonary vasculature is currently evaluated at cardiac catheterization by calculating 
pulmonary vascular resistance and its response to vasodilators, Although these 
hemodynamic data provide valuable information, they are conceptual restricted to 
the resistance of the pulmonary vasculature to continuous !low and, thus, neglect the 
essentials of a pulsatile circulation 5. However, with the increasing recognition of the 
importance of the pulsatile component of blood pressure in the pathogenesis of various 
cardiovascular diseases, this aspect of pulmonary blood now has become of major 
interest6-8, In normal conditions, approximately 30% of the work load of the right 
ventricle is formed by the pulsatile load and this will increase in pulmonary 
hypertensions, 9 A major determinant of this load is the capacitance of the pulmonruy 
vasculature. That is, the reservoir capacity of the pulmonary vasculature that distends 
during systole, absorbing the energy in the elastic components of the arterial walls, 
and releases this energy during diastole to continue blood now"' 10, The capacitance 
of the pulmonary vasculature depends of tile compliance or distensibility of the vessel 
wall. The functional and structural changes of the large pulmonary arteries in 
puhllonary hypertension may lead to stiffening of the arterial wall and may affect 
arterial wall dynamics ll -1J 
Intravascular ultrasound (IYUS) of the pulmonary vasculature can visualize vasculru-
dynamics ill vivo, is feasible in int;1nts and children and has been suggested to docu-
ment changes in arterial wall properties in pulmonary hypertension l4 - lo, The 
appearance of the rutetial wall, as determined ill vitm by IYUS in patients with 
congenital heart disease and PYD, has been reported to correlate with histopathologic 
grade l7 However, vasculru'dynamies and pulmonary arterial wall properties in children 
with congenital herut disease and dilTerent stages of PYD have not been reported 
earlier. The purpose of this study was to assess pulmonary arterial wall dynamics in 
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children with a normal and abnormal pulmonary circulation. We sought for the 
correlation of these tindings with hemodynamic data and the progression of the vascular 
disease. 
Methods 
Patiellfs 
This study was approved by the institutional Medical Ethical Committee. After written 
infonned consent of the parents, patients who required cardiac catheterization and 
had increased pulmonary blood flow (pulmonary-to-systemic blood tlow ratio> 1.2) 
and/or pulmonary hypertension (mean pulmonary artery pressure> 20mmHg), were 
prospectively enrolled in the study. Children with a normal pulmonary circulation, 
who underwent cardiac catheterization to exclude cardiac disease or with mild left-
sided obstructive lesions and a normal left ventricular end-diastolic pressure and 
pulmonary wedge pressures, served as controls. Patients with hemoglobinopathies, 
interstitial pulmonary disease, liver or renal dystilllction or unstable condition were 
excluded. 
Catheterizatioll alld IVUS procedure 
All procedures were performed under standardized general anacsthesia18 Hemo-
dynamic evaluation and IVUS imaging of the pulmonary arteries were performed in 
the same procedure according to a protocol previously reported l4 Briefly, all patients 
underwent complete hemodynamic evaluation of the pulmonary and systemic vascular 
beds, including vasodilator response to inhalation of 100% oxygen, as a powerful 
pulmonary vasodilator. Pulmonary blood flow was determined using dye dilution 
technique, the shunt size was determined by oximetry. Before, during and after the 
procedure blood gas analyses were performed to maintain metabolic stability. An HP 
Sonos Intravascular Imaging System (Hewlett Packard, Andover, MA) was used. 
Sonicath 3.5 F or Spy 3.0 F ultrasound catheters (Boston Scientific Corp., Watertown, 
MA) were used, both having a 30 MHz transducer at its tip. The ultrasound catheter 
was directed through a 6 F long sheath along the pulmonary branch. At consecutive 
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sites in the proximal artery, the segment arteries and the peripheral arteries, identified 
and defined by tluoroscopyl4. 19, ultrasound images were obtained and recorded on 
S-VHS videotape, simultaneously with the ECG. IVUS imaging of the pulmonary 
arteries was performed, during 30% and 100% oxygen inhalation. The images were 
analyzed off-line independently by two observers, blinded for clinical and 
hemodynamic data (AC,RB). Pulillonary arterial luminal diameters and areas were 
measured at end-diastolic (minimal) and peak-systolic (maximal) dimensions. The 
values of three cardiac cycles were averaged for each observer and the mean of both 
averages was used for further analyses. Vascular' pulsatility was detined as the difference 
between planimetered peak-systolic (ESA) and end-diastolic ar'ea (EDA), divided by 
EDA x 100%15. Arterial wall distensibility, the inverse of the stress/strain elastic 
modulus and a measure of arterial wall compliance, was calculated by dividing 
pulsatility by pulmonary pulse pressure (pulsatility / systolic minus diastolic pulmonary 
artery pressure?' 20. Because adequate measurement of wall dynamics was not feasible 
in arteries with an end-diastolic diameter < 2.0 mm, these ar·teries were excluded 
from pulsatility and distensibility analyses. 
Patiellf classification 
The enrolled children were classified into three groups. Children with a norillal 
pulmonary circulation formed the control group (group I). Patients with normal 
pulmonary vascular resistance ( PVR baseline < 4 WU.m2) or responsive PVR ( PVR 
al 100% oxygen iIdlalation < 4 WU.m2 or vasodilator response;:> 50%) were classitied as 
having mild-to-moderate PVD (group 2). Patients with an increased PVR, not 
responsive to 100% oxygen (PVR at 100% oxygen inhalation;:> 4 WU.m 2 and vasodilator 
response < 50%) were classitied as having advanced PVD (group 3). Vasodilator 
response was detined as 100 x (PVR baseline - PVR at 100% oxygen inhalation) / 
PVR baseline. 
Statistical analysis 
Interobserver agreement was determined by calculating intraclass correlation 
coefticients (R). Pulsatility and distensibility outcomes, taking account of differences 
between as well within patients, were evaluated using regression analysis for repeatcd 
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measurements using the BMDP-statistical software package 21. Both outcomes were 
logarythmically transfonned in order to obtain approximate nonnal distributions. 
Univariate comparison of IVUS data between the patient groups was done using mlxed-
model analysis of variance. Using bacbvard elimination, the clinical and hemodynamic 
vlll'iables, most predictive for pulsatility and distensibility, respectively, were deter-
mined. To allow a comparison between results at baseline and at 100% oxygen 
inhalation, however, regression coefficients are given for both conditions if one of 
them proved to be significant. In the multivariate analysis we have chosen pulmonary-
to-systemic pressure ratio and pulmonary-to-systemic vascular resistance ratio to 
represent measures for pulmonary pressure and resistance respectively. The limit of 
signit1cance was set at p = 0.05 (two-sided). 
Results 
Clinical and hemodynamic dala 
In total 55 patients were enrolled in the study. These included 12 controls, 31 patients 
with mild to moderate PVD and 12 patients with advanced PYD. Patient characteristics 
are shown in table l. 
[nlral'ascular ullrasound dala 
IVUS studies were pelformed in 2-7 consecutive sites along the the pulmonary arterial 
tree per patient. In total, 199 artery segments were studied. There was an adequate 
delineation between blood and the inner vessel wall, allowing reproducible 
measurements of vessel dimensions during the cardiac cycle in 196 recordings. Three 
recordings were excluded from the analysis because of poor image quality. End-
diastolic diameter of the studied vessels varied from 1.4 mm to 10.4 nUll. 148 Vessels 
were;:" 2 mm in diameter. There was a high degree of agreement between both 
observers. The intraclass correlation coefficients for the measurements ofEDD, ESD, 
EDA, and ESA were 0.997, 0.998, 0.998 and 0.998 respectively. The sizes of the 
studied m·teries, determined by end-diastolic diameter, were similar in the three patient 
groups (p = .20). 
132 
CHAPTER 7 
Table 1 PlIfiellf chal'llcfcl'isfics 
control mild to moderate advanced 
PVD PVD 
n 12 31 12 
age (yrs) 5.6 3.7 2.6 
(0.5-16.9) (0.2-30.7) (0.2-15.8) 
weight (kg) 21.0 13.0 11.4 
(8.2-51.9) (3.0-76) (4.3-44) 
Hemodynamics 
meanPAP (nuuHg) 13 ± 3 22±9 50 ± 12 
PWP (mmHg) 8±3 9±4 II ± 7 
shunt size (Qp:Qs) 1.0 ± 0.0 2.6 ± 1.5 1.2 ± 0.4 
PVR (WU.m2) 1.2 ± 0.6 1.9 ± 1.2 10.2 ± 3.5 
PAP indicates pulmonary artery pressure; PVD, pulmonary vascular disease; PWP, 
pulmonary wedge preSSllre; PVR, pulmonary vascular resistance; Qp:Qs, pulmonary-
to-systemic blood flow ratio; Age and weight are expressed as median and range; 
hemodynamic data are expressed as mean ± standard deviation. 
Vascular pulsatility did not differ significantly (p = .29) between patients with mild to 
moderate PVD (geometric mean; 95% confidence interval: 23%; 20-26 ), patients 
with advanced PVD (18%; 14-24) and controls (21 %; 16-27) (fig la). In contrast, 
arterial wall distensibility was decreased (p < .001) in patients with mild-to-moderate 
PVD compared to controls (1.22, 1.04-1.42 vs 2.15, 1.67-2.77). Wall distensibility in 
patients with advanced PVD (0.55, 0.42-0.71) was decreased compared to patients 
with mild to moderate PVD and to controls (both p < 0.001) (fig.lb). 
Univariate correlations between age, hemoglobin concentration and hemodynamic 
data and the measurements ofpulsatility respectively distensibility are shown in table 2. 
Results of the multivariate regression analyses are showll in table 3. 
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Figure 1 Vascu/ar pu/safility (a) alld arteria/lVall disteJIsibility (b) of the pu/mollary 
arteries at base/ille alld at 100% oxygen illha/atioll ill the three patiellf 
groups. Data are e.lpressed as geomelric mealls al/(/95% cOllfidellce illler-
va/s. * p < 0.001 compared 10 cOlltm/s, ** p < 0.001 compared 10 moderate 
PVD. 
At baseline conditions and adjusted for patient group, the hemodynamic parameters 
pulmonary pulse pressure and pulmonary-to-systemic vascular resistance ratio (PYRI 
SYR) and, in addition, hemoglobin concentration were independently associated with 
vascular pulsatility. Adjusted for these variables, no difference in pulsatility between 
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Table 2a Univariate correlations between the various variables and vascular pulsatility. Data were analyzed separately 
for controls (n = 12) and patients (n = 43) 
Pulsatility at 30% Pulsatility at 100% 
controls p patients p controls p patients p 
age (years) -.010 ± .009 .27 .004 ± .005 .37 -.005 ± .009 .57 .001 ± .004 .SS 
Hb (mmol/I) -.04 ± .06 .50 -.06 ± .02 .006 -.03 ± .06 .65 -.05 ± .02 .03 
meanPAP .02 ± .02 .27 -.002± .002 .36 .016 ± .011 .15 -.000 ± .002 .99 
diastPAP .006 ± .014 .66 -.005 ± .002 .03 .005 ± .011 .67 -.002 ± .002 .22 
systPAP .009 ± .013 .50 -.000 ± .001 .S3 .01 ± .01 .29 .001 ± .001 .40 
pulm PP .01 ± .02 .67 .004 ± .002 .OS .03 ± .02 .19 .005 ± .002 .002 
shunt size .51 ± 1.30 .69 .04± .02 .OS -.41 ± 1.5S .80 .016 ± .015 .30 
PVR .15 ± .OS .07 -.011 ± .007 .12 -.IS±.19 .35 -.005 ± .006 .42 
PVRlSVR 3.19 ± 1.80 .08 -.18±.11 .10 .10 ± 1.21 .94 -.05 ± .OS .50 
PAP/SAP 1.53 ± 1.23 .21 -.06 ± .11 .55 .58 ± .73 .43 .05 ± .08 .56 
EDA .002 ± .003 .64 .001 ±.OOI .48 .004 ± .003 .21 .002 ± .001 .05 
Data given are regression coefficients ± standard error, with p-values. Pulsatility data are 10glO transformed. 
EDA indicates end-diastolic area (mm2): Hb, hemoglobin concentration (mmol/I): mPAP, mean pulmonary artery 
pressure (mmHg); diast. diastolic: syst, systolic: pulm. PP. pulmonary pulse pressure (mmHg): PAP/SAP, pulmonary-
to-systemic arterial pressure ratio: PVR, pulmonary vascular resistance (Woods' units.m2); PVRlSVR, pulmonary-to-
systemic vascular resistance ratio; shunt size, pulmonary-to-systemic blood flow ratio. 
Table 2b Univariate correlations between the various variables and arterial wall distensibility. Data were analyzed 
separately for controls (n=12) and patients (11=43) 
Distensibility at 30% Distensibility at 100% 
controls p patients p controls p patients p 
age (years) -.019 ± .008 .02 .012 ± .006 .05 -.001 ± .009 .96 .007 ± .005 .22 
Hb (mmol/I) -.12 ± .06 .06 -.050 ± .001 .08 .02± .06 .70 -.02 ± .03 .41 
mPAP .01 ± .02 .43 -.013 ± .001 <.001 .02 ± .01 .10 -.010 ± .001 <.001 
shunt size -.67 ± 1.44 .65 .05 ± .03 .06 -.26 ± 1.54 .87 .01 ± .02 :48 
PVR .07 ± .10 .48 -.042 ± .006 <.001 -.24 ±.I8 .18 -.030 ± .006 <.001 
PVR/SVR 2.00 ± 2.10 .33 -.72± .10 <.001 -.47 ± 1.15 .69 -.38 ± .08 <.001 
PAP/SAP 1.98 ± 1.32 .14 -.74 ± .08 <.001 .24 ± .71 .74 -.53 ± .06 <.001 
EDA .001 ± .003 .75 .001 ± .001 .44 .004 ± .003 .25 .003 ± .001 .02 
Data are given as regression coefficients ± standard error, with p-values. Distensibility data are 10g]O transformed. 
EDA indicates end-diastolic area (mm2); Hb, hemoglobin concentration (mmol/I); mPAP, mean pulmonary artery 
pressure (mmHg); PAP/SAP. pulmonary-to-systemic arterial pressure ratio; PVR, pulmonary vascular resistance (Woods' 
units.m2); PVR/SVR, pulmonary-to-systemic vascular resistance ratio; shunt size, pulmonary-to-systemic blood flow 
ratio. 
CHAPTER 7 
Table 3a Mliitivariate analysis (!f pliisatility at baseline and at 100% oxygen 
inhalation. Data given (ire regression ('{}~{/iciel/ts with JOlog pliisatility as 
dependellf variable. 
Pulsatility at baseline Pulsatility at 100% oxygen 
change p change p 
Pulse pressure .010 ± .003 +2% <.001 .009 ± .002 +2% <.001 
PVR/SVR -.05 ± .02 -II % .001 -.01 ± .01 -2% .20 
Hb -.05 ± .02 -II % .01 -.02 ± .02 -4% .41 
EDA .001 ±.OOI +.2% .30 .003 ± .001 +.7% .01 
EDA indicates end-diastolic area (mm2); Hb, hemoglobin concentration (mlHol/I); 
PVR/SVR, pulmonary-to-systemic vascular resistance ratio. Change indicates the 
percentage change in pulsatility per mmHg change in pulse pressure, per 0.1 unit 
change in PVR/SVR, per mmol/I change in Hb and per mm2 change in EDA. 
Data given are adjusted for patient group. Adjusted for the described variables, no 
differences between patient groups could be demonstrated for pulsatility (at baseline: 
p = .58; at oxygen inhalation: p = .23). 
patient groups was demonstrated (p = .58). Distensibility was independently associated 
with the pulmonary-to-systemic mean arterial pressure ratio (PAP/SAP), PVRlSVR 
and Hb. At baseline conditions, differences between patient groups, adjusted for the 
described variables, just failed to reach statistical significance (p = .06). At 100% 
oxygen inhalation, pulsatility was independently con'elated with pulse pressure and 
the end-diastolic area of the vessel, without significant differences between groups. 
At 100% oxygen inhalation, PAP/SAP and the end-diastolic area of the vessel were 
identified as variables independently correlated with distensibility. 
Adjusted for these variables, distensibility at 100% oxygen inhalation diffcred be-
tween the patient groups (p = .03). Pulmonary arterial wail distensibility in a vessel 
with a given end-diastolic area, at a given PAP/SAP was decreased with 26% in patients 
with mild-to-moderate PVD compared to controls (p = .012). In patients with advanced 
PVD, adjusted wall distensibility was decreased with 39% compared to controls 
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Table 3b Multivariate analysis of distensibility at baseline and at 100% oxygen 
inhalation. Data given are regression coefJicients with JOlog distensibility 
(IS dependellt variable. 
Distensibility at baseline Distensibility at 100% oxygen 
change p change p 
PAP/SAP -.06± .01 -13% <.001 -.05 ± .01 -II % <.001 
PVR/SVR -.04 ± .02 -9% .03 .004 ± .011 -1% .71 
Hb -.05 ± .02 -11% .008 -.007 ± .018 -2% .70 
EDA .001 ± .001 +.2% .22 .003 ± .001 +.7% .02 
EDA indicates end-diastolic area (mm2); Hb, hemoglobin concentration (mmol/I); 
PAP/SAP, ratio of pulmonary-to-systemic pressure; PVR/SVR, pulmonary-to-systemic 
vascular resistance ratio. Change indicates the percentage change in distensibility 
per 0.1 unit change in PAP/SAP and PVR/SVR, per ml1l0lll change in Hb and per 
mm2 change in EDA. 
Differences between patient groups for distensibility, adjusted for the described 
variables, just failed to reach statistical significance at baseline (p = .06). Distensibility 
at oxygen inhalation, adjusted for the described variables, differed between patient 
groups (p = .03): see text. 
(p = .024). The difference in adjusted distensibility between groups 2 and 3 (13%) 
was not statistically significant (p = .27) (fIg. 2). 
After 100% oxygen inhalation, as pulmonary vasodilator, the mean increase in end-
diastolic vessel area for the combined group of all patients was 2.7% (0.9-4.5, 95%-CI; 
P = .003). No significant correlations could be demonstrated between the increase in 
vessel area and vessel size, patient group, PVRISVR or the vasodilator response, 
defined as percentage change in PVR. 
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Figure 2 Relation between arterial wall distensibility at 100% oxygen inhalation, 
adjusted/or ([n end-diastolic vessel area (if 151111112, and the pullllonary-to-
systemic arterial pressure ratio. lIw solid regression line represents the 
relation in controls (open circles), the dotted regression line represents the 
relation ill patients with mild-to-moderate pulmonary vascular disease 
(closed circles) and the dashed regression line represents the relation in 
patients with advanced pulmon(//)' vascular disease (triangles) 
Discussion 
Our data demonstrate that pulmonary arterial wall distensibility is progressively 
decreased in patients with mild-to-moderate PYD and advanced PYD compared to 
controls. This in contrast to artelial pulsatility, which did not differ between the patient 
groups. Arterial wall distensibility correlated with distending pressure, represented 
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by PAP/SAP, but also, independently, with PVR/SVR and hemoglobin concentration 
at baseline conditions, and with vessel area at 100% oxygen inhalation. Also taking 
account of these variables, arterial wall distensibility appeared substantially decreased 
in patients with PVD compared to controls. This difference was accentuated by 
inhalation of 100% oxygen. These findings suggest a stiffening of the pulmonary 
arterial wall in PVD that can be measured ill I'il'o with IVUS. 
In patients with congenital heart diseases, associated with pulmonary hypertension or 
increased pulmonary blood t1ow, the pulmonary vasculature is subject to structural 
and functional changes 1-4. Although the most prominent vascular changcs, from a 
morphological point of view, occur in the small muscular pulmonary arteries, not 
accessible for the ultrasound catheter, also in the larger, elastic pulmonary mteries 
structural and functional alterations have been demonstrated4• I I. Structural alterations 
consist of increascd medial thickness, intima librosis and extracellular matrix 
modulation, including an increased deposition of collagen '-1. 22, 23. Functionally, 
impaired endothelial-dependent vasorelaxation of both the small and Im'ge arteries 
has been demonstrated already early in PVDJ Both the structural and functional chan-
ges will lead to a loss of elastic properties of the arterial wall 12, 24. The stiffening of 
the pulmonary arteries is likely to be ret1ected in their dynamic behavior. 
VasclI/ar plI/satility 
Vascular dynamics can be described with the use of pulsatility, defined in this study 
as the relative increase in vessel area during the cardiac cycle. Vascular pulsatility, the 
net result of a complex interaction between mechanical forces, acting on the vessel 
wall, on the one hand, and intrinsic properties of the wall itself on the other, did not 
differ hetween patients with PVD and controls. Pulsatility was most strongly associated 
with pulmonary pulse pressure. Pulse pressure forms a direct radial mechanical force 
acting on the arterial wall and is expected to be a major determinant of vascular 
pulsatility. In addition to pulse pressure, PVR/SVR and Hb were independent predictors 
of pulsatility, at baseline conditions, however not at vasodilation. 
Arteria/wall distensibility 
The elastic properties of a vessel wall can be characterized ill vivo by arterial 
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distensibility, the inverse of the stressfstrain elastic modulus. Arterial distensibility 
reflects the relative increase in arterial area (strain) per mmHg increase in arterial 
blood pressure, i.e pulse pressure (stress), and represents a measure for arterial 
compliance 7,20,24. A decreased distensibility of systemic arteries has been demonstrated 
in essential hypertension, coronary artery disease, diabetes mellitus and aging7. 
However, the arterial walls exhibits a nonlinear, viscoelastic behavior and therefore, 
distensibility is directly affected by the distending pressure. An ongoing debate exists 
about whether, in these conditions, the decrease in distensibility is a consequence of 
elevated distending pressure and, tllUS, of tile artery operating on a steeper part of its 
pressure-volume relationship, or a result of changes in the vessel wall itself1. [n our 
selies, pulmonary artelial wall distensibility decreascd progressively with the severity 
of PYD. The decrease in distensibility correlated strongly with an increase in 
pulmonary artery pressure exprcssed as PAPfSAP, retlecting an elevated distending 
pressure. However, independent from this distcnding pressure, distensibility at baseline 
conditions, similar to pulsatility, correlated with PYR/SYR and Hb. 
These findings suggest that changes in the pulmonary vascular bed at tile level of the 
resistance vessels, reflected by PYRfSYR, do correlate with pulsatility and 
distensibility of the larger pulmonary arteries, independent from a possible lise in 
pulmonary artery pressure. Hemoglobin concentration, regarded a measure for blood 
viscosity, wi11 affect inertia, pulse wave propagation and the shear stress on the arterial 
wall and, consequently, may influence directly vascular dynamics"' 10. 
During 100% oxygen inhalation, the independent correlation of both pulsatility and 
distensibility with PYR/SYR and hemoglobin concentration was lost, whereas the 
difference in distensibility between patient groups, after allowance for the impact of 
other variables, became more prominent. How can the effects of oxygen inhalation 
on these relations be explained? Inhaled oxygen is a powerful pulmonary vasodilator. 
In PYD, the effect of pulmonary vasodilation, if any, will be most prominent in the 
small muscular arteries and Illllscularized arterioles and is reflected in a decrease in 
PYR and PYR/SYR5 Apparently, oxygen did not affect the distensibility of the studied 
larger pulmonary arteries, suggesting that muscular tone is not an important 
contributing factorin the distensibility of these elastic arteries. This is in concordance 
with experimental data in the rat lung, suggesting that decreased distensibility in 
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monocrotaline-induced pulmonary hypertension is due rather to structural changes in 
the vascular wall than to increased muscular tonus25• 26. The discrepancy in vasodilator 
respons between muscular and elastic arteries may have led to the loss of the 
independent correlation between pulsatility and PVRISVR after pulmonary 
vasodilation. The effect of viscosity on vascular dynamics depends on the area of the 
vessel: the larger the vessel, the lesser the effect of viscosityJO. After 100% oxygen 
inhalation, the end- diastolic areas of the studied vessels increased. One could speculate 
that this vasodilation diminished, or eliminated, the measurable elTect of Hb on vascular 
wall dynamics. 
Vascular pulsatility, determined by IVUS, has been reported to correlate with vessel 
diameter l4. In the present study we demonstrated end-diastolic vessel area to be 
correlated with pulsatility and distensibility only during oxygen inhalation. However, 
the effect of end-diastolic area on both pulsatility and distensibility was limited to 
approximately 0.7% decrease per n11n2 decrease in vessel area. Whether this relation 
is caused by differences in arterial wall properties in arteries of different sizes or by 
the effect of the ultrasound catheter obstructing the arterial lumen relatively more in 
smaller vessels, can not be deduced from our data. 
An important tinding of our study is that, when taking account of all the described 
vmiablcs, pulmonary artelial wall distensibility still appeared to be decreased in patients 
with PVD compared to controls. An adjusted, mean decrease of approximately 40% 
was found in patients with advanced PVD. In our opinion, this decrease indicates a 
stiffening of the pulmonary arterial wall caused by intrinsic properties of the arterial 
wall itself, that could not be assessed with the studied hemodynamic variables. Arterial 
wall stiff'ness is believed to be important in both the pathogenesis and the clinical 
course of pulmonary vascular disease7• s, This means that pulmonary arterial wall 
distensibility is a new teature in the assessment of the pnlmonary vasculature, that 
may provide additional information on pulmonary vascular disease and its eftect on 
the right ventricular load. 
Oxygen is a powerful vasodilator of the pulmonary vascular bed and was associated 
in our series with a modest vasodilation of the arteries studied by IVUS. In contrast to 
our previous tlndings, the increase in vessel diameter could not be not associated with 
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vessel size14• Neither was it associated with PVRISVR, the vasodilator response as 
determined by percentage change in PVR or with patient group. This means that 
determination of pulmonary artery dilatation with IVUS is not interchangeable with 
the assessment of vasodilator response by currently used techniques, such as res-
ponse of PVR27. 28. 
In conclusion, we demonstrated that pulmonary arterial wall distensibility is 
progressively decreased in PVD. Our data snggest that this decrease is, in part, related 
to an increased distending pressure as a result of pulmonary hypertension and, in 
part, to a stiffening of the arterial wall in the disease process. These changes in arterial 
wall properties appear independent from hemodynamic datn, obtnined nt cardinc 
catbeterization, but can be assessed with IVUS of the pulmonnry arteries, on line, in 
the same procedure. Pulmonary artetial wnll distensibility Illay be n new variable in 
the ill vivo evaluation of the pulmonary vasculnture. This varinble tnkes into nccount 
the pulsatile nnture of the pulmonary circulation and thereby provides additionnl 
information on the progression of PVD and its consequences for the integrated 
pulmonary circulation and right ventricular load. 
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Introduction 
Children with congenital heart disease associated with pulmonary hypertension and/ 
or increased pulmonary blood flow, develop functional and structural alterations of 
the pulmonary vasculature I-4• These vascular changes are a major determinant in 
morbidity and mortality in these patients2• 5. 6. Pulmonary vascular disease may lead 
to elevated pulmonary vascular resistance, which may hamper surgical intervention 
or limit long-time survival. The functional state of the pulmonary vascular bed is 
currently assessed by hemodynamic evaluation, including respons to vasodilators, 
whereas structural alterations are evaluated by pulmonary wedge angiography and 
histological examination oflung biopsy. However, these current techniques are limited 
by practical and conceptual restrictions7-u Vascular changes iu pulmonary vascular 
disease have been demonstrated to affect pulmonary vascular impcdance and stiff-
uess9• [4. LI. These latter properties of the pulmonary vasculature cannot be assessed 
in the clinical setting, using the available techniques. Intravascular ultrasound (IVUS), 
using high-frequency imaging, enables examination ofpuhnonary vascular dynamics 
and biomechanical arterial wall properties iI/vivo in infants and children [6. Recently, 
children with congenital heart disease and associated pulmonary vascular disease 
were demonstrated to have a decreased wall distensibility of the elastic pulmonary 
arteries (see chapter 7). That study suggested that the decreased distensibility was 
due not only to elevated distending pressure in case of pulmonary hypertension, but 
also to altered intrinsic wall propertics in pulmonary vascular disease[7 rurthermore, 
changes of the arterial wall, observed with intravascular ultrasound, have been reported 
to be correlated with structural changes in the pulmonary vascular bed[s. [9. A part of 
the patient population described in this study, has been reported earlier with respect 
to qualitative IVUS parameters and the correlation between arterial wall distensibility 
and hemodynamic data 17· [9 
The purpose of the present study was to determine whether pulmonary arterial wall 
distensibility in children with pulmonary vascular disease, assessed with IVUS, is 
correlated with structural changes of the pulmonary vascular bed. We therefore 
compared pulmonary intravascular ultrasound findings with the results of pulmonary 
wedge angiography and histological examination of lung biopsy in children with 
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congenital heart disease associated with pulmonary vascular disease and in children 
with a normal pulmonary circulation. 
Methods 
Paliellfs. Patients who required cardiac catheterization and had increased pulmonary 
blood flow (pulmonary-to-systemic blood flow ratio> 1.2) andlor pulmonary 
hypertension (mean pulmonary artery pressure> 20mmHg), were prospectively 
enrolled in the study. Children with a normal pulmonary circulation, who underwent 
cardiac catheterization to exclude cardiac disease or with mild len-sided obstructive 
lesions and a normal left venU'icular end-diastolic pressure and pulmonary wedge 
pressures, served as controls. Patients with hemoglobinopaulies, interstitial pulmonary 
disease, liver or renal dysfunction or unstable condition were excluded. The study 
protocol was approved by the institutional Medical Ethical Committee and informed 
written consent was obtained from the parents of all patients before enrollment. 
C{/theterization {/nd II'US pmcedul'e 
All procedures were pelfonned under standardized general anesthesia2o• Hemodynamic 
evaluation and IVUS imaging of the pulmonary arteries were pelformed in the same 
procedure, according to a protocol previously reported lfi. Brieny, all paticnts underwent 
complete hemodynamic evaluation of the pulmonary and systemic vascular bcds, 
including vasodilator response to inhalation of 100% oxygen, is a powerful pulmonary 
vasodilator. Pulmonary blood now was determined using dye dilution technique, the 
shunt size was determined by oximetry. Before, during and after the procedure blood 
gas analyses were perfonned to maintain metabolic stability. An HP Sonos Intravascular 
Imaging System (Hewlett Packard, Andover, MA) was used. Sonicath 3.5 F or Spy 
3.0 F ultrasound catheters (Boston Scientitlc Corp., Watertown, MAl were used, both 
having a 30 MHz transducer at its tip. The ultrasound catheter was directed through a 
6 F long sheath along the pulmonary branch. At consecutive sites in the proximal 
artery, the segment arteries and the peripheral arteries, identified and det1ned by 
fluoroscopylO. 16, ultrasound images were obtained and recorded on S-VHS video-
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tape, simultaneously with the ECG. The images werc analyzed off-line independently 
by two observers, blinded for clinical and hemodynamic data (AC,RB). Pulmonary 
arterial luminal diameters and areas were mcasured at end-diastolic (minimal) and 
peak-systolic (maxima\) dimensions. The values of threc cardiac cycles were averaged 
for each observer and the mean of both avcrages was used for further analyses. Arterial 
wall distensibility, the inversc of the stress/strain elastic modulus and a measure of 
arterial wall compliance, was calculated by dividing the relative increase in 
planimetered vessel area during the cardiac cycle by pulmonary pulse pressure (100 x 
peak-systolic (ESA) minus end-diastolic area (EOA), divided by EOA x (systolic 
minus diastolic pulmonary artery pressure)21. 22. 
Wedge angiogmpily 
Pulmonary wedge angiography was performed in the same procedure and in the samc 
lung segments as IVUS, before the conventional angiographies. The balloon occlusion 
technique, described by Rabinovitch, was usedlO. Tapering rate was measured, after 
allowance for magnification, as the distance over which vessels tapered from 2.5 to 
1.5 !lUll luminal diameter. This was measured for as many vessels as possible and a 
mean tapering rate was then calculated lO, Pulmonary circulation time was defined as 
the time between detlation of the balloon and visualization of contrast in the pulmonary 
veins at the site of their entrance into the left atrium, and was determined by counting 
the number of cine ti'ames 10. Circulation time could not be accurately assessed in 9 
cases, because of incomplete balloon occlusion. The background haze, determined 
by the degree of filling of small periphcral arteIies was assessed as being moderately 
or markedly reduced by comparing the angiograms with standards, established by the 
control group 10. 
Hist%gic evaluation 
In patients who underwent subsequent cardiac surgery an open lung biopsy was taken 
during the surgical procedure. In one patient an open lung biopsy was taken as isolated 
procedurc for diagnostic purposes. Tissue was formalin fixed under vacuum and 
paraffin embedded. Five fun sections were cut at various levels and stained with 
hematoxylin-eosin (HE) and Elastic-van Gieson (EvG) and iron stain to allow for 
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proper identification of morphological structures. Vascular changes were described 
according to Wagenvoort l . 23 The medial thickness of the muscular arteries was 
calculated as a percentage of the total artery diameter, excluding the adventitial layer. 
The presencc or absence of the following vascular changes was recorded: intimal 
longitudinal smooth muscle, intimal proliferation, concentric laminar intimal fibrosis, 
angiomatoid dilatation lesions, fibrinoid nccrosis, plexiform lesions'3 The lattcr four 
vascular changes were regarded as advanced lesions. Further the presence or absence 
of eccentlic intimal fibrosis, recent thrombi and arterialisation of veins was recordedB 
Statistical aI/a lysis 
Arterial wall distensibility, taking account of differences between as well within 
patients, were evaluated by regression analysis for repeated measurements using the 
BMDP-statistical software package'·. Using backward elimination, the ffilgiographical 
and histological variables, most predictive for arterial wall distensibility were 
determined. In this analysis distensibility data were logarithmically transformed in 
order to obtain approximate normal distributions. In tirst instance, the angiographical 
and histological variables were analysed separately. In a following analysis, the 
resulting most important variables from each technique were evaluated simultrulcously. 
Finally, the pulmonary-to-systemic pressure ratio, reflecting arterial distending 
pressure, was included in the multivariate analysis. A univariate comparison of 
geometric mean distensibility between patients and controls was done using mixed 
model ANOYA. The limit of signiticance was set at p = 0.05 (two-sided). 
Results 
In total,S I patients with an increased pulmonary blood now andlor pulmonary 
hypertension were enrolled in the study. Additionally, 13 patients with a normal 
pulmonary circulation were studied (table I). All patients underwent hemodynamic 
evaluation, a pulmonary wedge angiogram and intravascular ultrasound study. In 32 
patients, including 4 controls, a lung biopsy was taken during subsequent cardiac 
surgery (n=3 I) or by means of a diagnostic open lung biopsy procedure (n= I). The 
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Table 1 Diaglloses of the study patiellls 
Diagnosis n 
L~ft-to-right shullt: 
VSD with or without ASD or PDA 
with pulmonary arterial banding 
ASD 
PDA 
cAVSD 
Truncus arteriosus 
No left-to-right shul/t: 
Persistent PH after corrected heart defect 
Unexplained PH 
Left sided obstructive lesions with PVC 
Controls 
Total 
23 
2 
6 
3 
2 
2 
3 
9 
13 
64 
ASD indicates atrial septal defect; cAVSD, complete atrioventricular septal defect; n, 
number; PDA, persistent arterial duct; PH, pulmonary hypertension; PVC, pulmonary 
venous congestion; VSD, ventricular septal defect. 
interval between catheterization procedure and biopsy ranged from 2 days to 12 months, 
median interval 2.1 months. Age, hemodynamic and angiographical characteristics 
of the patients are summarized in table 2. 
Examination of lung biopsies revealed essentially normal pulmonary arteries in the 
control group and the complete spectrum of morphologic vascular changes, ranging 
from muscular hypertrophy and intima hyperplasia to the characteristic lesions of 
advanced plexogenic arteriopathy in the patient group. Medial tllickness ranged from 
6 to 13% (mean 10%) in the control group and from 3 to 30% (mean 12%) in the 
patient group. Six patients had intimal hyperplasia as most severe vascular change, I 
had concentric laminar intimal fibrosis, without other advanced lesions and three 
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Table 2 Hemodynamic and angiographic characteristics of the study patielllS 
control patients 
n 13 51 
age (years) 4.8 (0.5 - 16.9) 2.8 (0.2 - 30.7) 
HemodYllamics 
mean PAP (nunHg) 13 (7 - 18) 26 (8 - 72) 
PAP/SAP 0.19 (0.13 - 0.25) 0.47 (0.12 - 1.02) 
shunt size (Qp/Qs) 1.0 (0.95 - 1.1) 2.1 (1.0-7.2) 
PYR (WU.m2) 1.3 (0.4 - 2.6) 2.4 (0.4 - 15.0) 
Wedge angiography 
tapering rate (mm) 14 (9.2 - 23.8) 13 (6.6 - 24.5) 
circulation time (sec) 0.89 (0.2 - 1.7) 0.74 (0.0 - 1.9) 
background haze (n) 
normal 13 28 
moderately reduced 0 16 
markedly reduced 0 6 
PAP indicates pulmonary artery pressure; PAP/SAP, pulmonary-to-systemic arterial 
pressure ratio; PVR, pulmonary vascular resistance; Qp/Qs, pulmonary-to-systemic 
blood tlow ratio; WU, Woods' units; n, number of patients. Data are presented as 
median value and range. 
patients showed combinations of concentric laminar intimal fibrosis, dilatation lesions 
and plexiform lesions. 
!lII/,{/l'ascular ultrasound data 
IYUS studies were pelionned in 2-7 consecutivc sites along the the pulmolHu')' arterial 
tree per patient. In total, 186 artery segments were studied. End-diastolic diameters 
of the studied vessels ranged from 2.0 mm to 10.4 mm. 
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Figure 1 Arterial wall distellsibility of the elastic pIIIII/OII(//)' arteries ill patiellts lVith 
II norlllal pulmollw:r circulation (controls) and patients with pulmollary 
\lascu/ar disease. Data (Ire expressed as geometric means ({nd 95% 
cOJ(fidellce illfervals. * p < .00] cOli/pared to COli trois. 
Arterial wall distensibility was decreased in patients with an abnormal pulmonary 
circulation compared to controls (geometric mean 1.0 %/mmHg; 95% confidence 
interval: 0.8-\.1 vs. 2.3 %/mmHg: 1.7-3.1; p < .00 I )(Jigure I). Univariate correlations 
in the patient group between arterial wall distensibility and the variables of 
angiographic respectively histological evaluation of the pulmonary vascular bed are 
shown in table 3. The results of the multiple regression analysis for the angiographic 
variables arc summarized in table 4a and for the histologic variables in table 4b. 
Subsequently, these angiographic and histologic variables were included simul-
taneously in a regression analysis, which identitled the tapering rate and a markedly 
decreased background haze on the wedge angiogram, the pulmonary arterial medial 
thickness and the linding of recent thrombi in the lung biopsy as independent predictors 
for arterial wall distensibility (table Sa). Moreover, adjusted for these variables, arterial 
wall distensibility was still decreased in patients with pulmonary hypertension and/or 
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Table 3 Univariate corre/ations between the studied variables and arterial wall 
distensibility. Data given are regression co~{ticiellls with IOlog distellsibility 
asdependellf variable. Data were llnalyzed for the patient group (angio-
graphy: II = 5 J .. biopsy: II = 28) 
PUllllo/WI)' wedge allgiography 
Tapeting rate (nun) 
Circulation time (sec) 
Background haze normal 
moderately reduced 
severely reduced 
End-diastolic area (nun2) 
Lung biopsy 
Medial thickness (%) 
Longitudinal smooth muscle 
Recent luminal thrombi 
Eccenttic intimal fibrosis 
Intimal thickening 
Dilatation lesions 
Advanced lesions 
Arterialisation of veins 
End-diastolic area (nun2) 
patients 
.018± .007 
-.074 ± .084 
0 
-.034 ± .060 
-.420 ± .087 
.001 ±.OOI 
-.019 ± .007 
-.024 ± .108 
-.395 ± .141 
-.046 ± .099 
-.196 ± .071 
.116 ± .122 
-.316± .122 
.072 ± .095 
.0003 ± .001 
p 
.016 
.38 
.58 
<.001 
.24 
.01 
.83 
.005 
.64 
.006 
.34 
.001 
.45 
.79 
The effects of the variables longitudinal smooUl muscle, recent luminal thrombi, 
eccentric intimal fibrosis, dilatation lesions, advanced lesions and arterialisation of 
veins were all described as present versus absent. Intimal thickening was tested for 
trend in the sequence of severity in pulmonary plexogenic arteriopathy: absent (0), 
intimal proliferation (I) or concentric laminar intimallibrosis (2). Advanced lesions 
are concentric laminar intimal fibrosis, dilatation lesions and pJexiformJesions. End-
diastolic area indicates the artedallumillal area measured by intravascular ultrasound. 
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Table 4 Multivariate analysis (!fthe angiogmphic variables (Il) allli the histologic 
variables (B). Data given are regression co~fJicients with IOlog distensibility 
as dependent I'{/riable. 
A 
angiographic variables 
background haze: moderately reduced 
markedly reduced 
tapering rate (mm) 
pulmonary vascular disease 
end-diastolic area (mm2) 
B 
histological variables 
medial thickness (%) 
recent luminal thrombi 
advanced lesions 
pulmonary vascular disease 
end-diastolic area (mm2) 
-.020 ± .057 
-.421 ± .083 
.014 ± .006 
-.303 ± .064 
.002 ± .001 
-.020 ± .007 
-.274 ± .117 
-.240 ± .095 
-.238 ± .095 
.002 ± .001 
change p 
-4% .73 
-62% <.001 
3% .02 
-50% <.001 
0.5% .\0 
change p 
-4% .005 
-47% .020 
-42% .01 
-42% .012 
0.5% .16 
Change indicates the percentage change in distensibility per: mm tapering rate, per % 
increase of medial wall thickness, per nlIn2 end-diastolic vessel area. It further indicates 
the change of distensibility in case of a markedly or moderately reduced compared to 
a normal background haze, in the presence compared to the absence of recent thrombi 
respectively advanced lesions, and in the presence compared to the absence of 
pulmonary vascular disease. 
increased pulmonary blood tlow compared to patients with a normal pulmonary 
circulation (p < 0.00 I; tlg. 2). 
To evaluate the effect of arterial distending pressure on these correlations, the analysis 
was repeated with the introduction of the pulmonary-to-systemic arterial pressure 
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Table 5. Multil'{{riate (///{/lysis of the angiogmphic and histologicall'ariables (A), 
and in eluding the pulmO//w)'-to-systemic arterial pressure mtio (B). Data 
gil'en are regression co~{ficients with IOlog distensibility as dependent 
I'ariable. 
A 
change p 
tapering rate (mm) .016± .006 4% .01 
background haze: markedly reduccd -.447 ± .116 -64% <.001 
medial thickness (%) -.017 ± .006 -4% .002 
recent luminal thrombi -.226 ± .099 -41% .02 
pulmonary vascular disease -.240± .072 -42% <.001 
end-diastolic area (n1l1l2) .002 ± .001 0.5% .IS 
B 
change p 
pulmonary-to-systemic arterial pressure ratio -.054 ± .ISO -12% .76 
tapcring rate (mm) .016 ± .007 4% .02 
background haze: markedly reduced -.434 ± .124 -63% <.001 
medial thickness (%) -.015 ± .008 -3% .07 
recent luminal thrombi -.2lO±.112 -3S% .06 
pulmonary vascular disease -.229 ± .OSI -41% .OOS 
end-diastolic area (mm2) .002± .001 0.5% .18 
Change indicates the percentage change of distensibility: per mm tapering rate, per % 
increase of medial wall thickness, per 0.1 unit change in the ratio of pulmonary-to-
systemic arterial pressure, per 111m2 end-diastolic vessel area, in case of a markedly 
reduced compared to a normal or moderately reduced background haze, in the presence 
compared to the absence of recent thrombi, and tinally, in the presence compared to 
the absence of pulmonary vascular disease. 
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ratio (PAP/SAP) as a variable into the model. The vru'iable PAP/SAP provided no 
additional value in predicting wall distensibility, while the correlations with the 
angiographical and histologicle variables appeared to be essentially unchanged (table 
Sb), 
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Figure 2 Relatiol/ between al1erialwall distel/sibilit)' eOlog)wlllllledial wall thickl/ess 
il/ the Ilil/g biopsy, Arterial wall distensihility is {Illjllsted.t()r a taperil/g 
rate {!f' 13 111111 al/d a I/orlllal hackgrollllli haze 011 plilmol/ary wedge 
wlgiography,for the ahsel/ce (!f'recel/t thrombi il/ the Ilil/g hiopsy al/d/or 
all end-diastolic vessel arell of J 51J1I111, The dashed regl'essioulil1e represents 
the relatiol/ il/ col/tmls (trial/gles), the solid regressiol/ lil/e represellls the 
relatiol/ il/ patiel/ts with pl/lmOlIllI)' vasclilar disease (circles), The solid 
circles represelll vailies ,!f'patiel/ts with adval/ced lesiol/s il/ their hmg 
biopsy, 
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Discussion 
OUf study demonstrates that, in children with pulmonary vascular disease associated 
with congenital heart disease, pulmonary arterial wall distensibility, assessed with 
IVUS, is decreased, This decrease was correlated with structural properties of the 
pulmonary vascular bed, as detelll1ined with pulmonary wedge angiography and lung 
biopsy, This correlation appears to be independent from pulmonary artery pressure, 
expressed as the ratio of pulmonruy-to-systemic arterial pressure, Moreover, after 
adjustment for the various angiographic and histologic variables, arterial wall 
distensibility still appeared to be decreased in patients with pulmonru'y vasculru' disease 
compared to that in controls, 
The IVUS technique has been recently proposed as a tool in the assessment of 
pulmonru'y vascular disease I6, 18,25,27, Accuracy and a high degree of interobserver 
agreement of ultrasound measurements of luminal area have been reported ear-
lierI6, 17, 28, Changes in the apperu'ance of elastic pulmonary arteries, assessed with 
IVUS both ill vitro and ill vivo, have been correlated with histologic assessment of 
pulmonary vascular disease18, 19. However, the in vivo investigation of functional 
arterial wall properties of proximal pulmonary arteries in children with pulmonary 
vascular disease have not been correlated before with structural changcs of the 
pulmonary vasculru' bed, 
Pulmonary ru'teriopathy in congenital heart disease involves the complete pulmonary 
vasculature I , Although the morphological changes are most impressive in the small 
muscular arteries, both functional and stl1lctural alterations of the proximal, elastic 
pulmonary arteries have been demonstrated in pulmonary vascular disease, These 
alterations include impaired endothelial-dependent relaxation and medial thickening 
by extensive extracellulru' matrix modulation3, 29,31, These vascular changes will lead 
to a decreased compliance of the pulmonru'y arteries9, 14, 15 In a previous study, 
described in chapter 7, we demonstrated that pulmonary arterial wall distensibility 
was decreased in the course of pulmonary vascular diseasc I7 This decrease in 
distensibility could be partly related to an elevated arterial distending pressure in 
pulmonary hypertension, and additionally to the presence of pulmonary vascular 
disease itself, suggesting altered intrinsic wall properties in that condition, The pre-
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sent study demonstrates the decrease in distensibility to be correlated with structural 
changes in the vascular bed, assessed with pulmonary wedge angiography and lung 
biopsy, 
Pulmonary wedge angiography enables tile visualisation of peripheral pulmonary 
arteries as small as 100-300 fun in diameter 32, A rapid tapering of tile pulmonary 
arteries have been reported to correlate with both hemodynamic parameters and 
structural vascular changes in lung biopsies, although the predictive value for a given 
taper length was low lO,32, 33, A reduced background haze, due to diminished or absent 
filling of the small, so-called supernumerary branches, thin-walled artelies that branche 
perpendicular from muscular and elastic arteries, has been shown to correlate with 
the number of occluded small vessels in lung biopsy and to predict advanced plexogenic 
arteriopathy32, 33, From the angiographic variables, both a rapid tapedng of peripheral 
pulmonary arteries and a markedly decreased background haze were independently 
predictive for a decreased distensibility, 
From the histologic variables, an increased medial thickness of muscular arteries, the 
presence of recent thrombi and the presence of advanced vascular lesions were 
independently predictive for a decreased arterial wall distensibility, Increased 
muscularity of the pulmonary arterial tree, judged by extension of muscle to peripheral, 
normally nOIl-ll1UScuJarised arteries and increased medial thickness of muscular 
artedes, is an early feature of pulmonary arteriopathyl, II, The proliferation of vascular 
smooth muscle cells is associated with an extensive modulation of the extracellular 
matrix, including increased connective tissue deposition3 I, 34, This results in a stifiening 
of the arterial wall 14,35-37, 
Both the rapid tapering rate and the increased muscularization of pulmonary arteries 
arc features of early stage of pulmonary vascular disease, whereas a markedly decreased 
background haze and the presence of advanced lesions are characterics of severe 
pulmonary arteriopathyl, 32, 33 The signiticance of the presence of recent thrombi in 
lung biopsy is not clear, and in plexogenic arteriopathy it is probably an accompanying 
phenomena, In our sedes recent thrombi were found in lung biopsy of only three 
patients, all of who had a severely elevated pulmonary artery pressure and pulmonary 
vascular resistance, 
When the information obtained by wedge angiography and lung biopsy was analysed 
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simultaneously, the tapering rate, markedly reduced background haze, medial thickncss 
and the presence of recent thrombi, all appeared to be independent predictors for wall 
distensibility. However, in combination with the information from the wedge 
angiogram, the presence of advanced lesions in the lung biopsy was not of signitlcant 
predictive value for distensibility anymore. This may be due to the fact that a markedly 
reduced background haze and the presence of advanced lesions in lung biopsy were 
highly related in our selies: 2 out of the 4 patients with histologically advanced lesions, 
and none out of the 28 patients without advanced lesions, had a markedly reduced 
background haze on the wedge angiography (p = 0.01). 
Because of the viscoelastic properties of the arterial wall, the stress-strain relationship 
is not linear22. Theretore, arterial distending pressure affects the tllllctional distensibility 
of the arterial wall in such a way that an elevated distending pressurc will decrease 
distensibility. We demonstrated earlier, that the arterial distending pressure, retlected 
by PAP/SAP, was con'elated inversely with arterial wall distensi-bilityl7 However, 
the introduction of the hemodynamic variable PAP/SAP in the analysis showed that 
the correlations between arterial wall distensibility and angiographic and histological 
parameters were independent of this arterial pressure variable. 
A second important IInding of the present study is that, after allowance has been 
made for the studied variables, arterial wall distensibility appeared to bc still 
significantly decreased in patients with pulmonary vascular disease. Apparently, in 
patients with an abnormal pulmonary circulation functional alterations of elastic 
pulmonary arteries occur already early in the course of vascular disease. These 
alterations constitute an increased functional arterial stiffening, and may be due to 
changes in the extracellular matrix in the elastic arteries that paralel the muscularisation 
and matrix modulation of the muscular arteries. These changes in functional properties 
cannot be assessed with the comlllonly used techniques, but undoubtly will have 
unfavourable effects on the pulmonary circulation and the work load of the right 
ventricle9• 15. 
Limitations of the stIU/)' 
. . 
The number of control patients in whom a lung biopsy was taken was small. Also tile 
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number of patients with advanced lesions in their lung biopsy was relatively small. 
Therefore, the tinding that some variables did not show independent correlations with 
arterial wall distensibility, could have been due to the numbers studied. The design of 
this in vivo study allowed no cOlTesponding histologic sections of the pulmonary 
arteries studied with IVUS. Therefore, the measured arterial wall distensibility could 
not be correlated directly with the histopathological and chemical composition of the 
vascular wall. 
Future applications 
The finding that arterial wall distensibility of the elastic puhnOlHu'y arteries is cOl1'elated 
with structural changes of botb early and advanced arteriopathy at the level of the 
vascular bed, independent from arterial distending pressure, may provide new 
opportunities in the clinical assessment of pulmonary vascular disease. The possibility 
to measure functional changes early in the course of the disease process may be of 
special interest in the preoperative evaluation of patients who will need univentricular 
heart repair. Furthermore, it will increase our insight into the functional consequences 
of the various aspects of pulmonary vascular remodeling. 
In conclusion, intravascular ultrasound of the pulmonary arteries allows in vivo 
measurement of pulmonary arterial wall distensibility. Pulmonary arterial wall 
distensibility was decreased in patients with pulmonary vascular disease and this 
decrease was correlated with structural changes of the pulmonary vascular bed assessed 
with pulmonary wedge angiography and histologic examination of lung biopsy. These 
cOl1'elations were independent from pulmonary-to-systemic arterial pressure ratio, as 
a measure for arterial distending pressure. Moreover, adjusted for the angiographic 
and histological parameters, arterial wall distensibility appeared to be still decreased 
in patients with pulmonary vascular disease. Pulmonary arterial wall distensibility 
may constitute a new parameter in the assessment of pulmonary vascular disease, that 
provides information on both functional and structural properties of the pulmonary 
vasculature. 
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Abstract 
Congenital heart disease (CHD) associated with increased puJmonm'y blood now leads to 
pulmonmy plexogcnic arteriopathy (PPA). The p(lthogcncsis of the characteristic lesions in 
PPA is not well understood. Active endothelial cell proliferation has been demonstrated in 
these lesions and therefore VEGF. a key mediator of angionesis. might playa role in their 
pathogenesis. 
The aims ufthe study were to assess the pulmonary vascular expression of vascularendothclial 
growth factor (VEGF) in patients with pulmonary plexogcnic arteriopathy, and to compme 
the findings to the expression in patients with pulmonary venous congestion and in controls. 
We further sought for con-elations between the imll1uIloiocalization ofVEGF and hemodynamic 
and histological data. 
Thirty-four patients, undergoing cW'diac catheteri7.ation and subsequent cardiac surgery were 
studied prospectively. Patients were grouped in moderale PPA (u = IS), advanccd PPA (n = 7), 
pulmonary congestive vasculopathy (pey) (n = 5) and controls (n = 4). Inll1UnoreactivcYEGF 
was detected in pulmonary arterial smooth muscle and endothelial cells in 13 out 34 cases. 
The staining was more frequent in patients with advanced PPA as compared to patients with 
moderate PPA (p = 0.006) and controls (p = 0.(8). No differences in the frequency of YEGF 
expression could be demonstrated between controls, patients with PVC and moderate PPA, 
Measured hemodynamic parameters did not differ signiticantly between VEGF-positive and 
VEGF-negative patients. Marked VEGF positivity was detected in the characteristic lesions 
of advanced PPA. 
Conclusion: The pulmonary arterial expression pattern suggests an role for YEGF in the 
pathogenesis of the proliferative lesions of advanced PPA. 
166 
CHAPTER 9 
Introduction 
Pulmonary hypertension in congenital heart disease (CHD) may be associated with 
different types of pulmonary arteriopathy. CHD with left-to-right shunts and increased 
pulmonary blood t10w leads to plexogenic artcriopathy (PPA)I. 2. The morphologic 
vascular changes of PPA have been documented extensively"'. Advanced lesions of 
PPA include concentric-laminar intimal tlbrosis (CLIF), tlbrinoid necrosis, dilatation 
lesions and plexiform lesions. These lesions of advanced PPA distinguish it li'Dlll 
other pulmonary vasculopathies, resulting li'Dlll, e.g., hypoxia or pulmolUu'y congestion. 
The latter, also termed pulmonary congestive vasculopathy (PVC) develops in cases 
of mitral stenosis or left ventriclular dysfunction. Thc recognition of the type of 
puhnonary arteriopathy is of paramollnt clinical importance2.4; pev is reversible if 
the cause of pulmonary venous congestion can be removecf'i, In contrast, untreated 
PPA advances to a certain "point of no return", hallmarked histologically by the 
emergence of the characteristic advanced lesions of PPA, mentioned above. When 
such lesions are found, the disease process has not only become irreversible, but also 
progresses even when the underlying hemt defect is corrected'. PPA may also occur 
in the absence ofCHD and even without a known etiological factor, where it constitutes 
one of the histological subtypes of so-callcd clinically nnexplained pulmonary 
hypertension". 
Interestingly, fibrinoid necrosis, CLIF and the plexiform lesion, three of thc main 
histological hallmarks of advanced PPA, occur at a vcry specific site ofthc pulmonary 
arterial tree, namely at the origin of so-called supernumerary arteries (SNA's)7.8. 
These are small arterial branches which arise perpendicularly ti'omlarger pm'ent mteries 
and run straight into the pulmonary alveolar parenchyma. Apparently, this site is 
uniquely vulnerable to injury in case of high flow/high pressure pulmonary 
hypertension. At present, the exact calise of the vascular injury, and the vascular 
proliferative remodelling process presumably resulting from it and Icading to intimal 
cellular proliferation and the formation of the plexiform lesion, have not yet been 
elucidated at the molecular level. 
Vascular endothelial growth factor (VEGF), a potent mitogen apparently acting 
exclusively on vasculm' endothelial cells, is known to playa role in angiogenesis in 
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widely divergent circumstances, such as embryonic development, wound healing, 
tumor growth, rheumatoid arthritis and ischemic retinopathy9. 10 YEGF has been 
demonstrated to induce and facilitate angiogenesis, to promote endothelial cell growth 
and migration and to int1uence capillary permeability 10. It has been shown that 
endothelial proliferation and angiogenesis occur in advanced plexogenic lesions11.ln 
this study we tested the hypothesis that YEGF plays a role in the remodeling process 
occuring at the origin of SNAs in PPA. Therefore, we examined the expression patterns 
of YEGF in pulmonary arteries in PPA and compared it to the expression in normal 
pulmonary arteries and in PCv. Furthermore, we correlated the pattern of VEGF 
expression with hemodynamic and morphologic characteristics. 
Methods 
Clillical parameters 
After approval of the Medical Ethical Committee of the University of Rotterdam and 
after parental informed consent, patients witll PPA, associated with congenital heart 
disease or idiopathic pulmonary hypertension, and patients with PCY, who underwent 
diagnostic cardiac catheterization, were prospectively enrolled in the study. Pulmonary 
venous congestion was detlned as a pulmonary capillary wedge pressure (PCW) >15 
mmHg in the absence of a left to right shunt. Children with a normal pulmonary 
circulation and mild left-sided obstructive lesions (PCW < 15 nunHg), who underwent 
diagnostic cardiac catheterization, served as controls. Complete hemodynamic 
evaluation was performed, including measurement of pulmonruy arterial pressure, 
calculation of shunt size, pulmonary and systemic vascular resistance. Shunt size was 
determined using oxymetry. Pulmonru'y blood now was determined using the dye 
dilution technique. 
Tissue specimens 
Lung biopsies were taken subsequently during cardiac surgery for CHD or as an open 
lung biopsy procedure for diagnostic purposes. Tissue was formalin fixed under vacuum 
and pmafiln embedded I. 
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Routine histochemical staining and immunohistochemical staining was performed 
on serial sections to allow for proper identification of morphological structures, and a 
precise correlation of morphology with patterns of immunoreactivity. 
Illlllllllloil is!ocilelll is!ry 
Sections (5 /lIn) of paraffin-embedded lung tissues were deparaffinized in xylene and 
graded ethanols and hydrated in 5% phosphate-buffered saline (PBS). Routine 
histology was performed by staining sections with hematoxylin-eosin and Elastic-
van Gieson, using standard protocols. For immunohistochemistry the sections were 
incubated with 10% normal goat sernm to block nonspecific binding. Thereafter, the 
sections were incubated with affinity purified rabbit polycJonal antibody against human 
VEGF (Santa Cruz Biotechnology, Santa Cruz, USA) in dilution I :200 for 30 minutes. 
This antibody reacts with the human 121, 165, and 189 amino acid splice variants of 
VEGF by immunohistochemistry on formalin-fixed, paraftln-embeddcd tissues l2 . After 
rinsing twice with PBS-tween 0.2%, the sections were incubated for 30 minutes with 
biotinylated antiimmunoglobulins (Multi link, Biogenex, San Ramon, CAl in a dilution 
of I :50, with 2% normal goat serUIll and 2% normal human serum in PBS. After 
Iinsing twice WitlI PBS, sections were incubated WitlI preformed avidin-biotin-enzyme 
complex (ABC, Biogenix, San Ramon, CAl I: 50 in PBS for another 30 minutes. 
After rinsing with PBS, and washing in tris-HCL at pH 8.0, chromogen was added 
for the enzyme detection with the alkaline-phosphatase method using li'eshly prepared 
solutions ofNaphtol AS-MX -phosphate, New Fuchsin, Sodium nitrite and Levamisole 
in tris-HCL at pH 8.0. The chromogene reaction was allowed to take place over 30 
minutes in the dark. Sections were rinsed with tris-HCL at pH 8.0, slightly 
counterstained with Meyer's hematoxylin and mounted in an aqueous-base mounting 
medium. Negative controls consisted of replacement of the primary antibody by I: I 0 
diluted normal rabbit sel1lm (Dako, Glostrup, Denmark). Placental blood vessels where 
used as positive controls for VEGF immunostaining. The presence and the micro-
anatomical pattern of expression of VEGF in the lung biopsies was investigated in 
detail. VEGF expression was defined as negative or positive staining. The entire se-
ries of sectios was processed and evaluated twice, in order to document consistency 
of immunostaining patterns. 
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Vascular lesions, present in the lung biopsies were classified histologically as described 
by Wagenvoort and MooiJ, IJ, Patients with PPA were regarded as having mild to 
moderate PPA if concentric laminar intimal fibrosis, angiomatoid dilatation lesions, 
fibrinoid necrosis and plexiform lesions were absent li'om the biopsy, The presence 
of one or more of the above mentioned lesions in the lung biopsy was considered to 
indicate advanced PPAJ, 
StlltistiClli (I//(/iysis 
Values are given in means ± standard deviation, if not indicated otherwise, For 
comparison of continous variables between groups analysis of variance (ANOVA) or 
Kruskal-Wallis tests were used, where apropriate. For comparison of categorical 
variables between groups the chi square test and subsequently the Fisher exact test 
was used, P-values < 0,05 were considered significant. 
Results 
Thirty-nine patients were included in the study, [n 5 patients, interpretation ofVEGF 
immunostaining was not possible because of insufticient sample size or suboptimal 
tissue quality, leaving 34 evaluable eases, There were 18 patients with mild to moderate 
PPA and 7 patients with advanced PPA, The group with pev consisted of 5 patients 
and the control group included 4 children (tables I and 2). Staining for VEGF was 
found in 13 out of the 34 lung biopsies, In these cases VEGF was localized in pulmonary 
arteries, as described in detail below, In addition a faint to moderate positivity was 
seen, especially in bronchial and bronchiolar epithelium and smooth muscle. 
[n 13 cases, VEGF positivity was detected in vascular smooth muscle cells (VSMC's) 
of the media (Iigure I, page 177), In addition, arterial endothelial cells, including 
those ofnon-muscularized branches, were positive. VEGr imnwllostaining was often 
more prominent in supernumerary arteries then in the adjacent much larger parent 
artery (figure I), [n the characteristic lesions of advanced PPA we detected increased 
VEGF positivity, [nlesions of concentric laminar intimal tibrosis VEGF was expressed 
in the intimal cells forming the characteIistic onion skin-like layer (tigure I), 
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Table 1 Anatomical and histological diagnosis 
Diagnosis number of patients 
controls pve moderate PPA advanced PPA 
Left-sided obstructive lesions 4 5 
VSD 
- isolated ± ASD II II 
- with left -sided obstr. lesion 2 
ASD 3 
cAVSD 2 2 
PDA 
ToF with left pulmonary 
artery from aorta 
Idiopathic PPA 
Total 4 5 18 7 
ASD indicates atrial septal defect; cAVSD complete atlioventricular septal defect; 
PDA, persistent ductus arteriosus; PPA, pulmonary plexogenic arteriopathy; ToF, 
Tetralogie of Fallot, VSD, ventricular septal defect. 
Table 2 Baseline characteristics 
controls pev moderate PPA advanced PPA 
(n = 4) (n = 5) (n = 18) (n =7)* 
Age (yr) 3.3 ± 1.3 3.9 ± 3.9 4.8 ±7.6 9.9±12.3 
mean PAP (mmHg) 13 ± 2 31 ± 12 24 ± 12 51 ± 16 
Qp/Qs 1.0 ± 0.0 1.0 ± 0.0 2.9 ± 1.6 2.3 ± 1.6 
PVR (WU.m2) 0.9 ± 0.3 S.0±4.0 2.3 ± 1.6 8.2 ± 4.2 
* n = 6 for hemodynamic data. PAP = pulmonary artery pressure; pev = pulmonary 
congestive vasculopathy; PPA = pulmonary plexogenic arteriopathy; Qp/Qs = 
pulmonruy-to-sytemic blood flow ratio; PVR = indexed pulmonary vascular resistance. 
Data given are mean ± SD. 
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In plexiform lesions, pronounced staining ofYEGF was seen in the cells forming the 
plexus as well as in the cells lining dilated, angiomatoid vessels (tigure I). 
The number of patients who showed detectable expression ofYEGF in YSMC's and 
endothelial cells of the muscularized and nOIl-lllllscularized pulmonary arteries varied 
between the patient groups (p = 0.03). No differences in the frequency of YEGF 
expression could be demonstrated between controls, patients with PCY and mild-to-
moderate PPA. However, YEGF expression occurrcd more frequently in patients with 
advanced PPA (table 3). When compared to patients with reversible arteriopathy 
(moderate PPA and PCY), YEGF positivity in YSMCs was signiticantly more frc-
quent in patients with advanced PPA (p = 0.007). The age of the patients with YEGF 
expression was higher than that of those negative for YEGF (median 6.0 vs 1.1 years, 
p = 0.006). However, when stratitkd for patient group, age was not independently 
related to YEGF expression. The hemodynamic parameters mean, systolic and diastolic 
pulmonary artery pressure did not differ between YEGF positive and YEGF negative 
patients (32 mmHg ± 20 vs 27 mmHg ± 14; 49 mmHg ± 28 vs 39 nUllHg ± 20, and 20 
mmHg ± 15 vs 16 mmHg ± 9, respectively), neither did pulmonary arterial pulse 
pressure (28 ± 16 vs 24 ± 13). The pulmonary-to-systemic blood tlow ratio (2.7 ± 2.1 
vs 2.0 ± 1.3) and the pulmonary vascular resistance (4.6 WUm' ± 4.4 vs 3.2 WUm' 
± 3.2) did not differ between the groups (for all p > 0.05). 
Discussion 
To our knowledge, this is the first study documenting YEGF positivity in the arterial 
lesions characteristic of advanced PPA. On the basis of its knowu biological activities, 
it is quite possible that YEGr is involved in the pathogenesis of the advanced lesions 
of PPA. YEGF is a direct angiogenic factor, that promotes endothelial cell 
proliferation9 , an important histological feature of advanced PPA. A potential role for 
YEGF in the process of structural vascular changes in pulmonary hypertension was 
tlrstly suggested by TudeI' et aI., who brietly reported on increased levels of mRNAs 
encoding YEGr in the lung of a patient with unexplained pulmonary hypertension 14 
In an ex vivo rat lung model of acute and chronic hypoxia, the same investigators 
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Table 3 VECF expressioll ill pullllollary artery SlIlooth lIluscle cells 
VEGF+ VEGF- Signiticance (p-value) 
(n) (n) compared to: 
Controls I 3 controls mod.PPA 
PCV 2 3 0.6 0.4 
Moderate PPA 4 14 0.7 
Advanced PPA 6 0.08 0.006 
PCV indicates pulmonary congestive vasculopathy; PPA, pulmonary plexogenic 
arteriopathy. 
found increased VEGF gene transcripts, VEGF protein content and also increased 
levels of mRNA for its receptors Flk-I and Fit-I. They localized the increased VEGF 
mRNA expression in alveolar cells and, to a lesser degree, in alveolar macrophages 
and vascular smooth muscle cells l5• 16. In this respect, however, it should be noticed 
that PPA differs essentially from hypoxia-induced pulmonary hypertension, which 
does not associate with the characteristic lesions of advanced PPA, even when it is 
pronounced and has been present for a long pcriod of time i7 We inul1unolocalized 
VEGF protein predominantly in vascular structures and found a positive correlation 
between the staining for VEGF in the smooth muscle cells of the pulmonary arterial 
wall and the presence of histological lesions indicative for advanced PPA. 
Responsiveness ofVEGF expression to hypoxia has been related to its gene promoter 
and 3'-untranslated region, which contain sequence motifs that share high homology 
with hypoxia-responsive enhancer elements of the human erythropoietin gene l ". In 
PPA, mechanisms other than those operating in hypoxic pulmonary hypertension may 
be responsible for the vascular VEGF expression. If exposed to increased pulsatile 
t1ow, vascular endothelial cells are altered in their surface characteristics and, together 
with smooth muscle cells, in their functional state by nuid mechanical forces l9 A 
shear stress responsive element (SSRE) has recently been identilied in the promoter 
region of genes, encoding for various vascular modulators2o, including the VEGF 
receptors Flk-land FIt-1 16. VEGF-inducing growth factors, like ·I~GF-Il, PDGF-BB 
and bFGF, which show restricted sequence homology with VEGI\ are now known to 
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be directly upregulated at the transcriptional levcl by mechanically transduced 
mechanisms2o. VEGF expression may be upregulated by similar mechanisms. In our 
study we were unable to demonstrate a correlation between pulmonary hemodynamic 
features and the expression of VEGF protein. However, the subtle, local tluid 
mechanical forces, regulating vascular tone and homeostasis at the cellular level are 
not necessarily retlected directly by hemodynamic data. As indicated earlier, plexiform 
lesions occur immediately distal to ramification sites and especially at the origin of 
SNA's7. 8. At these sites, complex hemodynamic tlow protiles with areas of recirculation 
may result in steep gradients of shear stress, that parallel those in systemic arterial 
branching points2I. 22, which have recently been demonstrated to have a great impact 
on endothelial adaptive functions2J Whether VEGF expression is upregulated directly 
by altcred tluid mechanical forces or indirectly by induction through other factors 
remains to be elucidated. 
The occurence ofVEGF in cells ofUle ehmacterisistic lesions of advanced PPA suggests 
a role of VEGF in the development of the irreversible pulmonary vascular changes. 
Wether this role is causal to the development of these lesions cannot be deduecd from 
our data. Unfortunately, no well-functioning animal model exists, to study, in an 
expetimental setting, the effects of pulmonary overt1ow on the pulmonary vasculature 
leading to PPA, which would allow to evaluatc the effects ofVEGF-blocking thcrapy. 
Such anti- VEGF therapy is expected to have therapeutic potential for a variety of 
neoplastic and angiogenic disorders 10. 
Recently, a soluble VEGF-receptor has been identilied, which blocks the mitogenic 
effects ofVEGF in vitro and in vivo lO. 
In conlusion, we demonstrated that VEGF protein is more frequently expressed in 
smooth muscle cells and endothelial cells of pulmonary arteries of patients with 
advanced PPA compared to patients with moderate PPA, pev and controls. We further 
demonstrated that immunoreactive VEGF is localized in the characteristic lesions of 
advanced PPA. The localization of VEGF in the wall of small pulmonary arteries and 
at the sites where the characteristic lesions originate is in accordance with our hypo-
thesis, that local, mechano-transducive mechanisms are responsible for the expression 
of VEGF during progression of the disease. 
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Figure 1 
a. Positive VECF e.\jJression in vascular slIIooth lI1uscle and endothelial cells of a 
slllall pullllon(/l)' artel), in a patient with lIIultiple VSD's (lIIoderate PPA), biopsy 
taken at the tillle ofpuIIllOi/(/I)' artel)' banding; lIIagnificatiOiI 20x. 
b. Pronounced positive staining for VEC F in endothelial cells of a supel'llulllerary 
artel)' in a patient with isolated vClltricular septal defect, who !wd 1II0derate 
PPA; lIIagnification 20x. 
c. No detectableVEGF~posifi\'ify ill the medial layer ofpulmOllW)' arteries and 
SllperlllllllermT arteries ill ({ COli/IV! patient; l1lagll{{icatioll 20x. 
d. Norlllal arteriole of cOlllparable size to that shown in 1 e in a collfrol patient; 
lI1agnification 40x. 
e. Positive staining/or VECF in a lesion 0/ concentric lall/inar intillla1.fibrosis in a 
patient with ventricular and atrial septal d4ect, who had advanced PPA; 
lIIagnification 40x. 
f Distinct positivity.for VECF in the cell convolute o/a plexiforllliesion, illlmediately 
distal to the origin l!fa supel'l/ulllel'llry (/I·tel)' in a patient with advanced idiopathic 
PPA. Note also positivity/or VECF in sOllie l!fthe surrounding pnel/ll/ocytes and 
aiveolllr IIIl1crop!/{/ges; lIIagnification 20x. 
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a. normal muscular 
pulmonm)' artery witil a 
thin media, bounded by 
intel7lal and external 
lamina elastica, 
accompanying a broll-
cilllS (Elastica-van 
Gieson stain, x 40). 
b. medial iI)1Jertropily of a 
muscular pulmOlwl)' 
artel)' in the presence of 
pulmon{/])' hypertension 
(Elastica-van Gieson 
stain, x 40). 
c. plexiform lesion at tile 
origin of a supemumer-
m)' artel)\ branching 
from a muscular pulmo-
n{/])' artel),. The distal 
part of the supemumer-
(/])' artel), is vel)' dilated 
and tilin-walled. 
Intimal fibrosis is present 
in the parent artery 
(Elastica- van Gieson, 
x 100). 
Figure 2 (chapter 4) Histologic evaluation of lung biopsy 
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Abstract 
The vascular lesions in advanced pulmonary plcxogcnic arteriopathy (PPA) are characterized 
by local abnormal vasodilatation, arterial wall injury and endothelial cell proliferation. The 
pathogenesis of these typical lesions is poorly understood. 
The aim of the study was to investigate whethercndothclial and inducible nitric oxide synthase 
lllay be involved in the development of these specific arleriopathy. 
\Ve investigated the expression of endothelial and inducible nitric oxide synthase by 
immunohistochemical analysis in lung biopsies of 29 patients with early and advanced 
plcxogenic arteriopalhy, 6 <..:hildren with congestive vascuiopathy and 4 patients wilh a normal 
pulmonary circulation. Both endothelial and inducible nitric oxide were weakly expressed in 
the endothelium of muscular pulmonary arteries in control patients. The level or expression of 
endothelial nitric oxide synthase did not differ signit1cantly between the patient groups and 
was not correlated with histological vascular changes. In contrast, the inullunoreacivily to 
inducible nilric oxide was increased in patients with pulmonary hypertension associated with 
increased pulmonary blood !low, compared to controls (p = .OI2) and to patients with increased 
pulmonary blood flow and normal pulmonary artery pressure (p = .013). The level of 
immunoreactivity to both isororms of nitric oxide synthase was positively con-elated with 
pulmonary pulse pressure and pulmonary blood flow. Marked immunoreactivity to both 
endothelial and inducible nitric oxide was observed in various cells forming the plexus in 
plexiform iesi()lls. 
Conclusions: The expression of inducible nitric oxide synthase ilppears to be increased in 
patients at risk for pulmonary plexogenic arteriopalhy. Both endothelial and inducible nitric 
oxide synthase are markedly expressed in advanced lesions of PPA. These findings suggest 
that hoth isofonns of nitric oxide synthase are involved in the pathogenesis of pulmonary 
plexiform artcriopathy. 
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Introduction 
Pulmonary hypertension leads to structural and functional changes of thc pulmonary 
arteries, which, in turn, sustain or even aggrevate the pulmonary hypertension 1-3 
Structural changes include medial hypertrophy of the arteIial wall and narrowing of 
the vascular lumen by intimal ulickening, leading to an increase in pulmonary vascular 
resistance4 , Pulmonary plexogenic arteriopathy (PPA) is a specific form of pulmonary 
vascular disease, in which histologically charactedstic vascular alterations, such as 
dilatation lesions and plexiform lesions, may emerge4,5, PPA may develop in patients 
with congenital heart disease, where an increased pulmonary blood flow appears to 
be an obligatory factor and elevated pulmonary artery pressure seems to accelerate 
disease progression6, The mechanism through which these characteristic lesions 
develop is unknown, It has become clem' that the endothelium plays an important role 
in the pulmonary vascular remodeling process6, The vascular endothelium, pre-
eminently suited to detect changes in mechanical forces, such as cyclic strain and 
shear stress, produccs substances with both vasodilator or vasoconsllictor properties 7, S, 
Endothelial alterations early in pulmonary vascular disease, may calise an imbalance 
between vasodilatory and vasoconstrictive activity, resulting in pulmonary 
vasoconstIiction and vascular cell proliferation6, 9-13 Whether or not it plays a causative 
role in vascular remodeling, Ule endoUlelial dysfunction in itsel f may promote disease 
progression 14, An important role in the maintenance of basal pulmonary vascular 
tone and in pulmonary hypertension is attributed to the endothelial-derived relaxing 
factor nillic oxide (NO), synthesized by the enzyme nitric oxide synthase (NOS) 
converting L-arginine to L-citrulline6, 15-18, Experimental and clinical evidence exist 
that endothelium-dependent relaxation is impaired in pulmonary vascular diseasc, 
although data on the involvement of NOS appear to be controversiaJl9, 20, Giaid et al. 
showed that expression of the endothelial isoform of NOS (ecNOS) was decreased in 
patients with pulmonary hypertension and that it was absent in plexiformlesions u , 
whereas other experimental studies showed the expression of ecNOS to be enhanced 
in pulmonary hypertension21 , 22, To date, three isofonns of NOS have been identitled, 
The oliginal classification in the endothelial and nemonal "constitutive" forms (ecNOS 
and nNOS) and an "inducible" form (iNOS) is misleading, because it has become 
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clear that gene expression of both ecNOS and nNOS is upregulated under different 
conditions (e,g, shear stress, nerve injury) and that, conversely, iNOS functions as a 
constitutive enzyme under physiologic conditions in a variety of cells, including 
vascular endothelial cells23, All three isoforms of NOS have been demonstrated in 
cndothelial cells of the normal human pulmonary vasculature lJ, 24, 25, 
Advanced vascular lesions in plexogenic arteriopathy, such as dilatation lesions and 
plexiform lesions, are characteIized by local abnollnal vasodilatation and endothelial 
cell proliferation26, The effects of NO on blood vessels include vasodilation and 
stimulation of angiogenesis by migration and proliferation of endothelial cells ls, n 
Therefore, we considered that NO might be involved in the abnormal local vasodilation 
and angiogenesis in advanced plexogenic ru'tel'iopathy, Int1ammatory and immunologic 
stimuli, such as cytokines, are suggested to be involved in the pathogenesis ofplexifonn 
lesions, Since the same stimuli have been demonstrated to induce iNOS expression, 
leading to a more prolonged and higher output of NO than the other two isoforms, the 
inducible isoform of NOS is of special interest in this respect l4, 23,26,28, Therefore, 
we investigated immunohistochemically the presence of iNOS and ecNOS protein in 
the pulmonary arteries of patients with congenital heart disease associated with 
pulmonary plexogenic ru'teriopathy and congestive vasculopathy and compared the 
findings with those in controls, 
Patients and Methods 
Patiellts 
Thirty five patients with congenital heart disease, who underwent cardiac catheteri-
zation and had increased pulmonru'y blood t10w (pulmonary-to-sytemic blood t10w 
ratio> 1,2) and/or pulmonary hypertension (mean pulmonary artery pressure 
> 20 mmHg) and in whom subsequently a lung tissue specimen was obtained, were 
enrolled in the study, after written informed parental consent. Four patients with a 
normal pulmonary circulation, who underwent cardiac catheterization and cardiac 
surgery because of mild left sided obstructive lesions (peW < 15 mmHg) served as 
controls, In all patients a complete hemodynamic evaluation was performed, including 
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measurements of pulmonary artery pressure, determination of shunt size by oximetry 
and calculation of pulmonary and systemic vascular resistancc. Blood flow was 
detennined using the dye dilution techniquc. In addition to the control subjects 
(group I), 10 patients had a congenital heart defect associated with increased pulmonary 
blood flow and normal pulmonary artery pressure (group 2), 6 patients without 
illtracardiac shunts had pulmonary hypertension due to pulmonary venous congestion 
(group 3). Eighteen patients had heart defects associated with both increased pulmonary 
blood flow and pulmonary hypertension (group 4). One patient with clinically 
unexplained pulmonary hypertension, showed histologically advanced PPA. We have 
chosen to assign this patient to group 4, because those were the patients at risk for 
advanced PPA. 
Tissue specimells 
Lung tissue was obtained as a biopsy during cardiac surgery (n = 36), as an open lung 
biopsy procedure for diagnostic purpose (n = 2) or at autopsy (n = I). Tissue was 
formalin fixed under vacuum and paraffin embedded. Fivc ~un sections were cut at 
various levels and stained with hcmatoxylin-eosin (HE) and Elastic-van Gieson (EvG) 
to allow for proper identilication of morphological structures and precise correlation 
of morphology with patterns of immunoreactivity. Vascular changes were described 
according to Wagenvoort2• 29. 
IllllllllJlOhistochemistry 
The peroxidase-antiperoxidase (PAP) techniquc was used for staining ecNOS and the 
avidin-biotin complex (ABC) method was used for staining iNOS. Sections (5 ~n) of 
paraffin-embedded lung tissues were deparaffinized in xylene, degraded in ethanol 
and rinsed in water. For the PAP method, sections were put in methanol! hydrogen 
peroxide 3% for 20 minutes to quench of endogenous peroxidase. For antigen-retrieval 
sections were cooked in citric acid buffer at 100°C for 10 minutes. Slides were allowed 
to return to room temperature over several hours to minimize tissue destruction. 
Subsequently, sections were rinsed in 5% phosphate-buffered saline (PBS) and 
incubated with 10% normal rabbit serum (PAP) or normal goat serum (ABC) for 15 
minutes to block nonspecific binding. The sections were then incubated overnight 
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with mouse monoclonal antibody either against ecNOS in dilution I :40 or against 
iNOS in dilution I :50. The antibody reacting with the endothelial NOS was raised 
against a 140 kDa immunogen, corresponding to amino acids 1030-1209 of the carboxy 
terminal reductase domain of human ecNOS and has specifity for human, rat and 
mouse ecNOS. The antibody reacting with the inducible NOS was raised against a 
130 kDa immunogen of mouse iNOS, corresponding to amino acids 961-1144 of the 
carboxy terminal half, that has a speciflty for human, dog, rat and mOllse iNOS 
(Transduction Laboratories, Lexington, KY, USA). Both antibodies are monospecific 
for each their NOS isoform and showed no cross reactivity using Western blotting 
techniques. Specifity on paraftlne material was tested by using aortic endothelium for 
ecNOS and activated macrophages in rheumathoid arthritis for iNOS as positive 
controls (data not shown). After rinsing once with PBS-tween 0.2%, and once with 
PBS 5% the sections were incubated for 30 minutes with rabbit-anti-mouse serum in 
a dilution of 1:25 (DAKO, Glostrup, Denmark), rinsed with PBS 5%, incubated with 
mouse PAP-complex I :300 (Sigma Chemical CO, St. Louis, MO, USA) for another 
30 minutes. Chromogen consisted of 3,3' diaminobenzidine tetrahydrochlodde (DAB)I 
hydrogenperoxide in PBS 5%. The chromogen reaction was allowed to take place 
over 7 minutes in the dark. Sections were .insed with water, slightly counterstained 
with Mayer's hematoxylin and regraded to xylene by increasing alcohol concentrations. 
For iNOS detection sections were incubated with biotinylated anti-immunoglobulins 
(Multilink, Biogenex, San Ramon, CA, USA) in dilution I :50 with 2% normal goat 
serum and 2% normal human serum for 30 minutes, followed by incubation with 
preformed avidin-biotin-alkaline phospatase complex (ABC, Biogencx, San Ramon, 
CA, USA) I :50 for another 30 minutes. Chromogen consisted of Naphtol AS-MX-
phosphate, New Fuchsin, Sodium Nitrite and Levamisole in tris-HCL at pH 8.0, which 
was added for 30 minutes. Sections were slightly counterstained with Mayer's 
hematoxiylin and mounted in an aqueous-base mounting medium. Negative controls 
consisted of replacement of the primary antibody by non-immunogen serum (Dako, 
Glostrup, Denmark). 
11l1111111101t is tocltelll ica/ ana lysis 
Large and small muscular arteries, identified on the basis of accompanying airways, 
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were studied. The intensity of the immunostaining was graded semiquantitatively 
from I to 3. with I corresponding to the weak staining in controls and 3 representing 
strong staining. The grading was performed by two of the investigators, who were 
unaware of the clinical or hemodynamic data. 
Statistical (//wlysi.l' 
For compatison of continuous variables between groups analysis of variance (ANOYA) 
or Kruskal-Wallis tests were used, where appropriate. For comparison of categorical 
variables between groups, chi square tests were used. Correlation coefficients were 
calculated using linear regression technique. A p-value < .05 was considered signiti-
cant. Yalues are given as means ± standard deviation, unless indicated otherwise. 
Results 
In total, 39 patients were enrolled in the study: Anatomical diagnoses of the congenital 
heart disease and the clinical and hemodynamic characteristics of the patients are 
shown in table I and 2. Lung tissue specimens, stained with HE and EvG revealed 
essentially normal pulmonat'Y at'teries in the control group and the complete spec-
trum of morphologic vascular changes, ranging from musculat' hypertrophy and intima 
hyperplasia to the characteristic lesions of advanced plexogenic arteriopathy in the 
other patient groups. Histological characteristics of the patients are shown in table 2. 
Endothelia/nitric oxide synthase 
Immunohistochemical analysis revealed weak staining for ecNOS in the pulmonary 
vascular endothelium in the control group. No differences in staining pattern were 
observed between muscular arteries of different sizes. Also in the patients, a positive 
staining of vascular endothelium was present in muscular arteries, both with or with-
out morphologic changes. In the advanced lesions of plexogenic arteriopathy positive 
immunoreactivity was observed. In concentric laminar intimal fibrosis, positivity was 
seen in endothelial cells but not in the subintimal cells (tig I). In plexiform lesions, 
distinct immunostaining for ecNOS was present in several cells forming the plexus 
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Table 1 Clinical diagnoses of the study patiellfs 
Diagnosis 
VSD 
cAVSD 
PDA 
isolated 
+PDA 
+ASD 
Left pulmonary artery from aorta 
ASD 
(sub)valv. AoS ± CoAo ± MS 
Unexplained PH 
Controls 
Total 
group 1 
(n) 
4 
4 
group 2 
(n) 
7 
3 
10 
group 3 
(n) 
6 
6 
group 4 
(n) 
7 
2 
3 
4 
19 
ASD indicates atrial septal defect; cAVSD, complete atrioventricular septal defect; 
CoAo, coarctation of the aorta; MS, mitral stenosis; PDA, persistent ductus artellosus; 
PH, pulmonary hypertension; VSD, ventricular sepal defect. 
Group 1: controls; group 2: patients with increased pulmonary blood now and nor-
mal pulmonary artery pressure; group 3: patients with pulmonary hypertension not 
associated with increased pulmonary blood now; group 4: patients with pulmonary 
hypertension associated with increased pulmonary blood tlow, including one patient 
with unexplained plexogenic arteriopathy. 
(fig I). Immunoreactivity was not found in the cells lining the dilated angiomatoid 
vessels. The intensity of the immunoreaction in vascular endothelium, as graded 
semiquantitatively, was comparable to the control subjects in 26 patients. In 9 patients 
the level of immunostaining of the vascular endothelium of muscular arteries of all 
sizes, was increased. Semiquantitative grading of the illlIllunoreaction did not correlate 
with the severity of the morphologic changes (fig 2). Seven of the 9 patients with 
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Table 2 Characteristics of the stlldy patiellts 
controls group 2 group 3 group 4 
normal Qp increased Qp normal Qp increased Qp 
normal PAP normal PAP increased PAP increased PAP 
n 4 10 6 19 
median age (years) 3.3 6.6 2.4 0.7 
(range) (1.8-4.8) (0.6-32.1) (1.1-10.9) (0.3-30.7) 
HemodYllwllics 
meanPAP (mmHg) 13 ± 2 13 ± 4 31 ± 12 41 ± 14 
PCW (nlluHg) 9±2 7±2 16±4 IO± 2 
shunt size (Qp/Qs) 1.0 ± 0.0 2.3 ± 1.8 1.0 ± 0.0 3.1 ± 1.5 
PVR (WU.m2) 0.9 ± 0.4 1.4 ± 0.8 5.0±4.0 5.1 ± 3.8 
Histology 
medial thickness (%) 9±3 7±3 12 ±4 16 ± 5 
patients with as most advanced lesions: 
intima proliferation 0 2 3 
CLIF 0 0 0 I 
advanced lesions 0 0 0 7 
Immlllloh istochem i stl)' 
endothelial NOS 1.0 ± 0.0 1.1 ± 0.3 1.2 ± 0.3 1.4 ± 0.5 
inducible NOS 1.2 ± 0.5 1.6 ± 0.7 1.8 ± 1.0 2.4 ± 0.7 
Advanced lesions indicate dilatation lesions and/or plexiform lesions; CLIP, concentric 
laminar intimal fibrosis; n, number of patients; NOS, nitric oxide synthase; PAP, 
pulmonary artery pressure; PCW, pulmonary capillary wedge pressure; PVR, 
pulmonary vascular resistance; Qp, pulmonary blood now; Qs, systemic blood now; 
WU, Woods' units. Increased Qp is defined as Qp/Qs > 1.2; increased PAP is detlned 
as meanPAP > 20nlluHg. Age is given as median and range. 
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increased intensity of staining were from group 4. Difference in staining intensity 
between the groups did not reach statistical significance (p = 0.16) (fig 3). Patients 
with all' increased level of immunoreactivity had a larger plilmonary-to-systcluic blood 
flow ratio (3.2 ± 1.3 vs. 2.0 ± 1.6; P = 0.018) and a larger pulmonary pulse pressure 
(40 ± 13 mmHg vs. 25 ± 14mmHg; p = 0.008) compared to that in the other patients. 
No differences in mean pulmonary artery pressure or pulmonary vascular resistance 
could be demonstrated between patients with different staining level. 
Illducible lIitric oxide syl/thase 
Immunohistochemical analysis revealed weak staining for iNOS in the pulmonary 
vascular endothelial cells in controls (tig I). No differcnces in staining pattern were 
observed between muscular arteries of different sizes. Positive staining for iNOS was 
present in all patients. However, the intensity of the immunoreaction differed 
remarkably between patients (tig 1). Intense immunostaining was present in the 
endothelium of arteries affected by concentric laminar intimal tibrosis, as long as the 
vessel was not completely occluded (tig I). Also in the cellular plexus of plexiform 
lesions a marked immunoreaction for iNOS was present (tig I I). In addition, endothelial 
cells lining dilated, angiomatoid vessels showed iNOS positivity. Semiquantitative 
analysis of the immunohistochemical data revealed no signitlcant correlation with 
the scverity of morphologic vascular changes (p = 0.25) (tig 2). The immunoreactivity 
to iNOS differed significantly between the patient groups (p = 0.012) (fig 3). The 
level of immunostaining in patients with both increased pulmonary blood now and 
pulmonary hypertension was higher than in controls (p = 0.012) and in patients with 
increased pulmollmy blood now and normal pulmonary artery pressure (p = 0.013). 
The level of immullostaining did not differ significantly between patients with 
pulmonary hypertension Witll or without increased pulmonary blood tlow (p = 0.19). 
The level of immunostaining was higher in patients with pulmonary hypertension 
than in those with normal pulmonmy artery pressure (2.2 ± 0.8 vs. 1.5 ± 0.7, P = 0.006). 
The level of immunoreactivity showed a positive correlation with the size of the left-
to-right shunt (I' = 0.39; P = 0.019) and the pulse pressure (I' = 0.35; P = 0.034), but not 
with mean pulmonary artery pressure or pulmonary vascular resistance. 
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Figure 2 Re/atioll betweell the semiqllolltative gradillg or illllllllllOrmctivity to the 
elldothe/ill/ respectively illdllcible isotrJl"JII or lIitric oxide sYllthose ill 
Illuscular arteries {/Ild the 111011J/IO/ogic vascular changes. No signffic(lllt 
d(Oerellces ill immunoreactivity between the various v{{.\'cu/ar cli1l11Res were 
demonstrated. Data are expressed as meall ± standard deviatioll. 
Discussion 
We found that both the endothelial and inducible isoforms of nitric oxide synthase 
protein are expressed in the pulmonary vascular endothelium in children with a nor-
mal pulmonary circulation, as well as in patients with congenital heart disease 
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associated with increased pulmonary blood flow andlor pulmonary hypertension. In 
plexogenic arteriopathy, marked immunoreactivity for ecNOS and iNOS was identified 
in advanced vascular lesions, in,eluding concentric laminar intimal fibrosis, dilatation 
lesions and plexifol'lnlesions. Semiquantitative analyses of the immunohistochemical 
data revealed that a higher intensity of the immunostaining for both isofol'lns was 
associated with an increased pulmonary arterial pulse pressure and an increased 
pulmonary blood flow. No correlation, however, was fonnd with the severity of the 
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Figure 1 1IIIIIlllllostail/il/gfor ecNOS (immlll/opel'Oxidase; browlI) and iNOS 
(alkaline phosphatase; red) il/illng biopsy sections (4patients with 
different mOlphologicalvasclllar changes. 
a. weak immllnostaining for iNOS in el/dothelial cells (!( a muscular artery in a 
control patient (x 40); 
h. pronollnced il1llll11llostaillingfoJ' iNOS in the endothelillm (~lall artery with 
medial hypertrophy ill a palient with pulmonary hypertensiolllllld increased 
plllmonGlT blood jlow (x 40); 
c. immllnostaining fi,r ecNOS in endothelial cells of a plllmon(/l}' artery (/{(ected 
by severe cOl/centric laminar intima/.fibrosis (x 100); 
d. distinct inllllllllostainingfor ecNOS in cells with ill a plexifiJl'llllesiol/ (x 40); 
e. imlllunostainil/g for iNOS in endothelial cells ()f a pulmonary artel)' a{fected by 
severe concentric laminar intilllaifibrosis (x 40); 
.t: distinct imlllllnostail/ingfor iNOS in cells within (/ plexiform lesion (x 40). 
histological vascular changes. The level of immunoreactivity for iNOS was signi-
ficantly increased in patients with pulmonary hypertension compared to those with-
out pulmonary hypertension and was most prominent in patients in which pulmonary 
hypertension was associated with increased pulmonary blood flow. 
The finding of increased NOS protein in pulmonary endothelium in patients with 
pulmonary hypertension, seems in contlict with the impaired endothelium-depen-
dent vasorelaxation that has been demonstrated in both clinical and experimental 
conditions of pulmonary hypertension 19• 20. However, several mechanisms other than 
decreased NOS expression, including decreased respons to NO or dominant 
vasoconstrictive activity, have been suggested to be involved in this impairment 17 • .1o . .1J 
To date, it remains unclear whether impaired endothelium-dependent vasorelaxation 
in flow-related pulmonary hypertension is associated with decreased NO activity and, 
if so, at which level of the NO pathway this occurs. Studies on the expression of NOS 
in pulmonary arteriopathy have yielded contlicting results. In various experiments, 
for example, hypoxia has been shown to up regulate cNOS, whereas other experiments 
suggest down regulation of cNOS in similar conditions21 • 22 • .14. In contrast to the 
findings ofGiaid et aI., our data showed that the expression of ecNOS protein was not 
decreased in pulmonary vascular endotllelium of children with congenital heart disease 
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Figure 3. The immunoreactivity to endothelial and inducible nitric oxide 'TllIhase, 
as graded semiquantitatively, in the dijlerelll patient groups. Patients with 
pulmollary hypertension, associated with increased pulmonary bloodf/mv 
(group 4), had significantly higher immunoreactivity than controls and than 
pll/ients with increased PUilIlOlWI)' bloodpow, but J/ormal pulmoJ/wy artel), 
pressure (group 2). * indicates p = .012 compared to controls; **, p = .013 
compared to group 2. Data are expressed as meaJ/ ± standard deviatioll. 
and did not correlate with the severity of morphological vascular lesions. The 
expression of iNOS in pulmonary endothelial cells, to our knowledge not previously 
studied in patients with pulmonary hypertension, was increased in pulmonary 
hypertension. The observation that staining for both ecNOS and iNOS was present in 
pulmonary artelies with severe concentric laminar intimal fibrosis, until complete 
occlusion of the vessel, suggests prolonged NO production until late in plexogenic 
arteriopathy. Semiquantitative analysis suggested the expression of both isoforms of 
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NOS to be associated with pulmonary flow and pulse pressure. Although this is 
obviously no evidence for a causal relation, it is in concordance with experimental 
data showing pulmonary endothelial ecNOS expression to be upregulated by shear 
stress and cyclic strain ls. 35. This is further supported by the presence of a "shear 
stress-responsive element", in both Ule human ecNOS and iNOS gene, similar to that 
found in the promotor of several shear stress inducible endothelial genes36. 
An important finding in our study is that iNOS expression was most prominent in 
patients in whom pulmonary hypertension was associated with increased pulmonary 
blood flow, which is exactly the subset of patients at risk for developing advanced 
PPA. Plexiform lesions and dilatation lesion are pathognomic for this type of pulmonary 
arteriopathy. The predilection place for these lesions is close to the origin of 
supernumerary arteries. These are small, additional arterial branches, which arise 
perpendicular or obliquely li'om elastic as well as from muscular arteries. 
Morphologically, dilatation lesions develop as a circumscript dilatation of the muscular 
part of a supernumerary artery, close to its orifice of the parent artery, leading to 
extreme thinning of the wall. Proximal to this dilated segment there is destruction of 
the arterial wall, referred to as librinoidnecrosis, with thinning of the media. In the 
plexiform lesion, a plexus of narrow slit-like vascular channels develops within the 
dilated lumen. The distal portion of the artery is very dilated and thin-walled 2 The 
local wall injury has been assumed to be associated with increased exposition to 
mechanical stress at the origin of supernumerary arteries2, whereas the morphological 
changes are regarded as the result of abnormal dilation and angiogenesis. 
The known biological effects of NO, include vasodilation, inhibition of smooth muscle 
cell proliferation and stimulation of angiogenesis by migration and proliferation of 
endothelial cells ls. 27. The constitutive forms of NOS synthesize small amounts of 
NO on demand. Stimuli, including shear stress and cyclic strain, lead to an increase 
in cytosolic calcium, which activates the NOS to give of a short burst of NOl8 In 
contrast, iNOS is functionally calcium independent and releases large amounts of 
NO continuouslyls. The large amounts of NO, that are characteristically produced by 
iNOS, may lead to oxidative inj ury l8.25. Although this may be of bene lit in infection-
control reactions, in ule vascular' system increased iNOS expression has been associated 
with the development of vasculitis37• 38. 
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Our tindings of increased iNOS expression in patients at risk for the development of 
fibrinoid necrosis, dilatation lesions and plexiform lesions, as well as our tindings of 
marked expression of ecNOS and iNOS in these specific lesions, are suggestive for 
the involvement of iNOS in the development of arterial wall injury OCCUlTing in PPA 
and for the involvement of both ecNOS and iNOS in the pathogenesis of dilatation 
lesions and plexiform lesions. 
The expression of iN OS is known to be induced by inflammatory and immulogic 
stimuli. In this respect, the findings of TudeI' et ai, who demonstrated perivascular T-
and B-cells and macrophages in plexogenic arteriopathy, intiltrating plexiform lesions, 
and those of Humbert et aI., who found elevated serum levels of cytokines in patients 
with PPH, are of special interest26• 28. }9. 
Limitations (!fthe stlldy 
The use of immunohistochemistry rather allows conclusions on the presence of the 
protein under study than on its activity or the actual protein production. An advantage 
of the immunohistochemistry technique, important to this study, is that it demonstrates 
directly the microanatomical localization of the protein under study. Our data does 
not allow conclusions on a causal or accompanying nature of the associations found 
in our study. Semiquantitative analysis of immunohistochemical data cannot be more 
than an estimation of relative differences in staining intensity, and may be hampered 
by numerous confounding factors. However, the influence of these factors was 
minimized by standardized processing of biopsy material, staining the entire series of 
sections simultaneously and relate staining intensity to a standard staining. 
In conclusion, the present study demonstrates characteristic patterns of the expression 
of ecNOS and iNOS in the pulmonary vascular remodeling process in human 
pulmonary hypertension. The increased presence of iNOS in the pulmonary vascular 
endothelium of patients at risk for PPA and the positive correlation of this increased 
presence with pulmonary blood flow and pulse pressure, suggests that iNOS is involved 
in the pulmonary vasculm'remodeling process in this charactelistic disease. By showing 
the presence of both ecNOS and iNOS in dilatation lesions and plexiform lesions the 
present study emphasizes the potential importance of these enzymes in the development 
of the advanced vascular lesions of plexogenic arteriopathy. 
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General discussion 
In the desclibed studies we investigated biomechanical and molecular aspects of 
pulmonary vascular remodeling in children with congenital heart disease, in order to 
increase insight in the pathophysiology of this still unraveled process. Pulmonary 
vascular disease forms an ongoing threat for children with congenital heart disease 
and pulmonary hypertension or increased pulmonary blood !low. The pulmonary 
vascular remodeling process in plexogenic arteriopathy may progress to irreversibility 
and thereby precludes curative therapy of both heart and vascular disease'. On the 
other hand, early stages of pulmonary arteriopathy, associated with increased 
contractile vascular responses, thickening and stiffening of the pulmonary arteries, 
may seliously complicate clinical cOlJl'se and corrective surgery2. J. A new challenge 
in the current era is formed by the surgical procedures in the management of 
univentricular hearts, stich as Norwood- and Fantail procedures, that are performed 
in a rapidly increasing li'equcncy and require higher demands on the evaluation and 
understanding of the pulmonary vasculature. In these procedures, in which no 
ventricular force faces the pulmonary vasculature, already early stages of pulmonary 
vascular disease may jeopardize surgical outcome and prognosis. 
In the past 40 year's, the clinical assessment ofpulmonar'y vascular disease in children 
with congenital heart disease has been relIned by hemodynamic critcria, lung biopsy, 
including morphomctry, and wedge angiography·. Pathological studies have revealed 
insights in the sequence of morphologic changes of the pulmonary vasculature in 
development and disease"'). However, it became clear that comprehension of the 
pathophysiology of pulmonary vascular disease, would require fundamental studies 
of the processes of cellular and molecular' dysregulation. 
In the recent years, basic research in vascular biology has rapidly expanded our 
knowledge on an impressive list of cells, modulators, mediators, growth factors, 
molecules and mechanisms that may be involved in vascular remodeling (for reviews 
seeS. "). 
Pulmonary vascular rcmodeling in pulmonary hypertension includes a series of 
switches in vascular smooth muscle cell phenotype. Differentiation li'om precursor 
cells to VSMC's causes muscularisation of normally non-muscular peripheral arteries. 
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Hypertrophy and hyperplasia of vascular smooth muscle cells and extracellular ma-
trix modulation lead to thickening of the arterial media, already early in pulmonary 
vascular disease4, 10, whereas migration ofVSMC's into the subendothelial space is 
the basis of intimal proliferation. The modulation of Ule extracellular matrix includes 
increased deposition of glycoproteins and connective tissue, such as collagen. These 
changes in the arterial wall, combined with an increased vasoconstrictive respons, 
will lead to a stiffening of the wall and, thus, loss of arterial compliance lO, 12, 13, 
Although predominantly in the small muscular arteries, these changes also occur in 
elastic arteries 14, 1.1. One of the major characteristics of the pulmonary vasculature is 
its low arterial compliance, crucial for the unique property of the pulmonary circulation 
to be a low resistance, low pressure and high tlow circulation. Since the normal 
postnatal pulmonary remodeling is disturbed in congenital heart defects and since the 
proliferative and matrix-producing potential of the neonatal pulmonary circulation in 
respons to stress is high compared to adults, arterial wall compliance may progressively 
decrease already early in the course of vascular disease lO, 16. The physiologic and 
clinical consequences of these pathologic vascular changes for the integrated 
puhnonary circulation and ventricular-vascular coupling are not well understood. Our 
studies have shown that intravascular ultrasound of the pulmonary arteries provides a 
new and direct measure for arterial wall distensibility, that is correlated with altered 
functional wall properties ear'ly in pulmonary vascular disease and with structural 
properties of tbe vascular bed, bOUl independent from hemodynamic parameters. 
Although the predictive value of this new variable in the individual patient, with res-
pect to progression and consequences of the disease, remains to be determined, the 
opportunity to measure directly intrinsic arterial wall properties in vivo, creates vUIiolis 
possibilities. In an experimental setting, it allows the investigation of the functional 
consequences of different aspects of vascular remodeling and the effccts of intervention. 
In the clinical setting it may allow a more functional assessment of the pulmonary 
vasculature early in PVD, which is of special interest in the context of univentricular' 
heart repairs, Finally, direct assessment of pulmonary vascular dynamics and functional 
wall properties will increase our insight in the vascular' arId physiological consequences 
of the so-called ForHan circulation, in which the pulsatile pulmonary flow has been 
converted to a nearly continuous tlow. 
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Endothelial dysfunction has been recognized to playa vital role in pulmonary 
hypertension, The pulmonary vascular endothelium is a metabolically active and 
dynamic organ with many functions, including biosynthesis and metabolism of 
circulating hormones and vasoactive substances, modulation in vascular tone, 
regulation of hemostasis and thrombosis, and participation in inflammation and local 
vessel wall function 17, The vascular endothelial cells, lining the inner pulmonary artedal 
wall, are pre-eminently suited to signal a variety of stimuli, including changes in 
mechanical forces such as shear stress and cyclic strain, and to respond by producing 
vasoactive substances, cytokines and growth factors, This has been suggested to initiate 
a cascade of cellular and humoral interactions and responses, leading to vasocon-
stdction and cellular proliferation and migration, These processes are being studied 
intensively in a variety of models, both animal or isolated cell systems, of pulmonary 
vascular disease, which represent predominantly hypoxia or monocrotaline induced 
pulmonary hypertension, Pulmonary plexogenic arteriopathy, however, cannot be 
studied in these models, Although the early stages of PPA may show striking similmities 
with the mentioned arteriopathies, and even may share a common pathway, the 
characteristic advanced lesions do not occur in any of the experimental models that 
m'e currently in use, Due to this restriction, knowledge on the pathogenesis of this 
specific entity is scarce, What factors, mechanical, chemical or humoral, are involved 
in the development of the pathognomic lesions of PPA and at what point in the time 
course of the disease, does PPA distinghuish itselffrom other pulmonary m'tedopathies? 
To date, these questions cannot be answered, 
The purpose of our immunohistochemical studies was to lInd clues on what humoral 
factors might be involved in tile development of the characteIistic lesions of PPA, 
Because of their known biological activities, both VEGF and NO were, in our opinion, 
canditates in this respect. Advanced vascular lesions in plexogenic arteriopathy, such 
as dilatation lesions and plexifonll lesions, are characterized by local abnormal 
vasodilatation and angiogenesis, Endothelial cell proliferation has been demonstrated 
to be an important feature of plexiform lesions lg, 19, VEGF is known to be a direct 
angiogenic factor, that promotes endothelial cell proliferation 20, Further, it has been 
demonstrated to playa role in the cmbryonicdeveiopment of the pulmonm'y vasculature 
and different types of pathological angiogenesis2o, 21, Our llnding that a pronounced 
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immunoreactivity to VEGF protein was present in the characteristic lesions and the 
finding that VEGF was expressed more frequently in pulmonary VSMC's and 
endothelial cells of patients with advanced PPA compared to patients with reversible 
arteriopathies, strongly support a role for VEGF in the development of advanced 
PPA. 
In addition to vasodilation and inhibition of smooth muscle cell proliferation, the 
properties of NO include stimulation of angiogenesis by Illigration and proliferation 
of endothelial cells22 , 23, Our hypothesis holded that increased NO release Illay induce 
dilatation lesions and plexiform lesions. Indeed, we found a marked immunoreaction 
to both ecNOS and iNOS localized in cells forming the plexus in these lesion. Further, 
semiquantitative analysis suggested that iNOS expression was increased predominantly 
in patients with both increased pulmonary blood flow and pulmonmy hypertension, 
which is exactly the subset of patients at risk for advanced PPA. Oxidative injury may 
playa role in the mechanism of tibrinoid necrosis, a typical form of arterial wall 
injury that occurs at the origin of supernumerary arteries, the predilection place for 
the plexiform lesion. 
Obviously, the presence of protein, as demonstrated with immunohistochemistry, is 
not synonymous with biological activity of the protein. Neither do these tindings 
allow conclusions on a causal or accompanying relationship between the presencc of 
these proteins and the development of vascular lesions. As described earlier, the process 
of vascular remodeling involves a myriad of factors and interactions and it would be 
ingenuous to suggest that one or two factors were responsible for the characteristic 
morphological and clinical patterns of PPA. On the other hand, the presence and the 
specific micro-anatomical localisation of the protein undcr study can be reliable 
demonstrated with immunohistochemical techniques. And, as history has proven many 
times, the key to resolve apparently inconceivable phenomena rests in starting with 
close observation of the event. Our observations direct, as I'm' as we know for the tirst 
time, at tlVO humoral factors that may be involved specifically in the development of 
advanced PPA. These should form the starting point for further research on the exact 
functional role of VEGF and both isoforms of NOS in this context. This, however, 
will require longitudinal and interventional studies, which for obvious reasons arc 
not possible in human plexogenic arteriopathy and will also not be possible in the 
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commonly used experimental models of pulmonary hypertension. To unravel the 
pathogenetic mechanisms of pulmonary plexogenic arteriopathy, an experimental 
model of this characteristic entity is mandatory. In our opinion, a major effort has to 
be made to develop a model of tlow- and pressure related pulmonary plexogenic 
aneriopathy, leading to the characteristic lesions of this mysterious disease. Such a 
model would allow functional studies, time-related studies and interventional stu-
dies. 
The comprehension of the specific activities ofYEGF and iNOS as well as those of 
many other factors, would help to understand the pathophysiology of pulmonary 
vascular remodeling and would provide opportunities for novel therapeutic strategies, 
directed at patients with secondary, as well as unexplained pulmonary hyper-
tension ll• 24. 
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Summary 
Children with congenital heart disease and increased pulmonary blood flow, with or 
without pulmonary hypertension are subject to pulmonary vascular disease, called 
plexogenic arteriopathy. This disease constitutes a pulmonary vascular remodeling 
process, in which functional and structural changes of the pulmonary vasculature will 
lead to an increase in pulmonary vasculm' resistance and, thus, in workload of the 
right ventricle. In pulmonary plexogenic arteriopathy, if untrcatcd, the vascular 
remodeling proces may become irreversible, especially when a combination of high 
pulmonary blood flow and high pressure is present. Pulmonary vasculm' disease CPVD) 
is an important cause of morbidity and mortality in children with congenital heart 
disease. The assessment of the progression and the functional consequences of PVD 
is rough and hampered by the lack of knowledge on thc pathogenesis and patho-
physiology of the process. 
In the described studies, biomechanical and molecular aspects of pulmonary vascular 
remodeling in children with congenital heart disease were investigated in order to 
increase insight in the pathophysiology of this process and its consequences for the 
pulmonary circulation. 
To understand the mechanisms used by the pulmonary vasculature to adapt to 
pathological conditions, it is of eminent importance to have insight into the normal 
pulmonary developmental changes in utero, at birth and during the postnatal period. 
The pulmonary vasculature has a unique position in the human circulation and is 
capable of enOlTIlOUS structural and functional adaptations, for instance during 
intrauterine life and iu the transition period. In chapter 2, a concise state of the art is 
given on pulmonary vascular anatomy, physiologic events and humoral and cellular 
mechanisms in the vasculature during these characteristic time periods. Subsequently, 
the same aspects are discussed in relation to PYD. One should acknowledge that the 
pathophysiology of plexogenic arteriopathy is practically unknown. 
This lack of knowledge, hampers the clinical assessment of the progression and 
functional consequences of the disease process. The study in chapter 3 compm'es the 
results of hemodynamic and histologic evaluation of the pulmonary vasculature in a 
selected group of patients with complex congenital heart disease, and studied the 
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relationship with clinical outcome. Discrepancies in the results of both techniques 
occurred especially in patients with unfavourable hemodynamic characteIistics, who 
frequently showed morphological vascular changes in their lung biopsy indicating 
only early stages of PVD. Preoperative hemodynamic data did not allow prediction 
of peri operative pulmonary hypertensive crises. In the 15 surviving patients both 
techniques did not accurately predict persisting pulmonary hypertension after surgical 
correction of the heart defect at a mean follow up of 6 years. This study illustrates the 
li1nitations of hemodynamic and histological evaluation of the pulmonary vascular 
bed and indicates the urge to develop additional diagnostic tools. In chajJlel' 4, the 
currently available diagnostic techniques are discussed. All techniques have their 
indisputable value, but they also have their practical and conceptual limitations. The 
functional consequences of pulmonary vascular disease for the integrated pulmonary 
circulation and, thus, for the work load of the heart can be evaluated only partly. 
Aspects of the integrated pulmonary circulation include the pulmonary vascular bed 
with its specitic functional and structural properties, and also the vascular capacitance 
function, the reflection of pulse waves and the resistance to inertia. Pullnonary vascular 
disease aftects all these aspects. 
The study in ch"jJlel' 5 demonstrates the feasibility of pulmonary intravascular ultra-
sound imaging in infants and children and the unique potential of the technique to 
study simultaneously the appearance of the pulmonary arterial wall and its dynamics 
ill vivo. The specitic potential advantages of intravascular ultrasound in assessing 
pulmonary vascular disease are discussed. 
Chaplel' 6 describes the study that investigated the ill vivo appearance of the pulmonary 
arterial waH, as assessed by pulmonary intravascular ultrasound, in 47 children with 
congenital heart disease and difterent stages of pulmonary vasculopathy and in 14 
children with a normal pulmonary circulation. The tindings were compared with 
hemodynamic and histological evaluation. A normal ultrasound aspect of pulmonary 
arteries was defined. IVUS was able to detect differences in arterial wall appearance 
between controls, patients with mild-to-moderate PVD and advanced PVD. The nor-
mal aspect was found less ti'equently in patients with PVD, whereas an inner layer of 
soft echo reflections was found more frequently in patients with moderate PVD. The 
thickness of this specitic layer correlated with pulmonary blood flow and pulmonary 
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artery pressure and, interestingly, with the medial thickness of muscular arteries in 
the lung biopsy. When adjacent structures allowed the outer border of the arterial wall 
to be detined, wall thickness could be measured and correlated with pulmonary artery 
pressure and pulmonary vascular resistance. The eehographic changes of the arterial 
wall did not correlate with the presence of advanced lesions in lung biopsy. 
In nearly the same patient groups, the effects of pulmonary vascular remodeling on 
vascular wall dynamics, assessed ill I'il'o with IVUS, were studied. In the chapters 7 
alld 8 the dynamic variable pulmonary arterial wall distensibility is introduced. 
Associations between this new pulmonary variable and functional aspects of the 
pulmonary vasculature, as determined by hemodynamic evaluation are studied and 
described in chapter 7. Pulmonary arterial wall distensibility was progressively 
decreased in pulmonary vascular disease, and multivariate analysis suggests that this 
decrease is, in part, related to an increased distending pressure as a result of pulmonary 
hypertension and, in part, to a stiffening of the arterial wall in the disease process. 
On the other hand, associations between arterial wall distensibility and structural 
aspects of the pulmonary vasculature, as determined by pulmonm)' wedge angiography 
and lung biopsy are described in chapter 8. The decreasc in arterial wall distensibility. 
found in patients with pulmonary vascular disease, was correlated with structural 
changes at the level of the pulmonary vascular bed. These correlations were 
independent ti'om pulmonary-to-systemic arterial pressure ratio, as a measure for 
m'lerial distending pressure. Moreover, taking account of the distending pressure and 
the angiographic and histological parameters, arterial wall distensibility appeared to 
be still decreased in patients with pulmonary vascular disease. 
Chapters 9 alld 10 describe two of the studies in our search for specitic cellular events 
and biologic modulators that are involved in the emergence of the advanced lesions 
ofplexogenic arteriopathy, and that thus must be characteristic for this typical disease. 
Because of its specific biological properties, we thought vascular endothelial growth 
factor (VEGF) a candidate to be involved in the development of plexiform lesions. 
In chapter 9 we report on the pulmonary arterial expression ofVEGF protein, assessed 
with immunohistochemistry, in lung biopsy tissue of patients with different types of 
PVD and controls. Vascular immunoreactivity to VEGF was detected in 13 out of 34 
cases and was localized in pulmonary arterial smooth muscle and endothelial cells. 
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Immunoreactivity was present more frequently in patients with advanced pulmonary 
plexogenic arteriopathy (PPA) compared to controls and patients with reversible 
pulmonary vascular disease. Moreover. marked immunoreactivity for YEGF was 
detected in the charactelistic lesions of PPA. Although the presence of YEGF does 
not allow conclusions on causal relationships, tllese data suggest an active role for 
YEGF in the pathogenesis of tlle charactelistic lesions of PPA. 
In chapter 10, data are presented on the endothelial expression of the endotllelial 
constitutive and the inducible isoforms of nitric oxide syntllase (ecNOS and iNOS 
resp.) in lung biopsy tissue of patients with different types of PYD and controls. 
Because of the various biological activities of NO, local overproduction of this mole-
cule could explain specific features of the characteristic dilatation lesions, tibrinoid 
necrosis and plexiform lesions. We found the iImnunoreactivity to ecNOS, compared 
to controls, unchanged in children with congenital heart disease and pulmonary 
hypertension, independent of the type of arteriopathy and independent of tlle severity 
of morphological vascular lesions. Semiquantitative analysis of the immuno-
histochemical data suggested tlle amount of ecNOS to be associated with pulmonary 
t10w and pulse pressure. The level of immunoreactivity to iNOS was increased in 
patients with compared to tllOse without pulmonary hypertension, and con'elated with 
pulmonary blood flow and pulmonary pulse pressure. Moreover, expression appeared 
to be highest in patients with the combination of increased pulmonary blood flow and 
pulmonary hypertension. Marked immunoreactivity to both ecNOS and iNOS protein 
was present in tlle endothelium in dilatation lesions and in a subset of endothelial 
cells in plexifollll lesions. These data suggest a pulmonary arterial upregulation of 
iNOS in children with congenital heart disease and pulmonary hypertension and a 
local role for NO in the pathogenesis of advanced lesions of PPA. 
The studies in chapters 6, 7 and 8 demonstrate tllat the pulmonary vascular remodeling 
process in children with congenital heart disease not only affects the pulmonary 
vascular bed, but also the larger elastic arteries. It further demonstrate that this 
remodeling is associated with changes in arterial wall properties of the elastic arteries 
and does lead to functional consequences, such as an increase in the pulsatile load of 
the right heart. These vascular changes can be assessed in vivo with pulmonary 
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intravascular ultrasound during a cardiac catheterization procedure. Qualitative aspects 
of the pulmonary arterial wall and arterial wall distensibility both provide additional 
information on the pulmonary vasculature and allow the investigation of the functional 
consequences of dilt'erent aspects of vascular remodeling and the effects of intervention. 
Long-term outcome analyses will be needed to determine if these variables arc of 
value in the clinical evaluation of pulmonary vascular disease. 
The studies in chapters 9 and 10 identify three proteins, with potentially very strong 
biological activities, that show characteristic expression patterns in the course of 
pulmonary plexogenic arteriopathy, suggestive for a role in the pathogcnesis of the 
advanced lesions in this arteriopathy. Further research will be needed to tind out if 
these proteins really represent increased activity and have a causal effect in patllO-
genesis. 
In order to answer these and many more questions, in our opinion, a strong effort has 
to be made to develop an adequate animal model of Ilow- and pressure-related 
pulmonary plexogenic arteriopathy. Basic studies of mechanisms to altered vessel 
growth and remodeling will lead to further therapeutic strategies for pulmonary vascular 
disease. 
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Samenvatting 
Kinderen met een aangeboren hartafwijking, welke gepaard gaat met een toegeno-
men longdoorstroming, al dan niet met een verhoogde druk in de longvaten, ontwik-
kelen een pulmonale vaatziekte. Deze vaatziekte wordt pulmonale pi ex ogene 
arteriopathie (PPA) genoemd en bestaat uit een proces van vaatwund remodellering. 
Functionele en structurele vaatafwijkingen leiden hierbij uiteindelijk tot een verho-
ging van de longvaatweersland en dus tot een toegenomen belasting van het hart. 
Indicn geen behandeling plaatsvindt, kan dil ziekteproces op een bepaald moment 
onomkeerbaar worden. Oit gebeurt met name wanneer de toegenomen long-
doorstroming gepaard gaat met een verhoogde druk in de longvaten. Pulmonale vaat-
ziekte vonnt een belangrijke oorzaak van morbiditeit en mortaliteit bij kinderen met 
aangeboren hartafwijkingen. 
De progressie van deze vaatziekte kan slechts grofweg vastgesteld worden met de 
huidige diagnostische technieken. Dit wordt mcde veroorzaakt door een gebrek aan 
inzieht in de pathogenese en palhofysiologie van het ziekteproces. 
De studies, besehreven in dit proefsehrift, bestuderen biomeehanisehe en molecu-
laire aspeclen van pulmonale vaatwand remodellering bij kinderen met aangeboren 
hartafwijkingen, met als doel het inzicht Ie vergroten in de pathofysiologie van dit 
proces en de consequenties voor de pulmonale circulatie. 
Om de mechanismen te begtijpen, die een rol spelen bij de aanpassing van de pulmonale 
vasculatuuf aan pathoiogische omstandigheden, is het van groat beiang am illzicht te 
hebben in de veranderingen die oplreden in de longvaten lijdens de normale ontwik-
keling in utero, lijdens de geboorte en tijdens de poshlatale peri ode. De pulmonale 
vaseulatuur bezet een unieke plaats in de menselijke circulatie en is in staat tot in-
drukwekkende strueturele en functionele aanpassingen, bijvoorbeeld tijdens de 
intrauterine ontwikkeling en tijdens de transitie peri ode. In i1{}(!fds/lik 2 wordt de 
huidige stand van zaken samengeval betreffende de kennis over de analomische en 
fysiologische gebeurtenissen en de humorale en cellulaire regulatie van de pulmonale 
vasculatuur tijdens deze kenmerkende perioden. Vervolgens worden diezelfde aspee-
ten besehreven in relatie tot pulmonale vaatziekte. Men dient zieh Ie realiseren dat de 
pathofysiologie van PPA vrijwel onopgehelderd is. 
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Dit gebrek aan inzicht bemoeilijkt in de kliniek het vaststellen van zowe! de progres-
sie als de functionele gevolgen van het ziekteproces. In h()(!f'dstuk 3 worden de resul-
taten vergeleken van hClllodynamische en histologische evaluutie van het longvaat-
bed in een geselecteerde groep patienten met complexe hartafwijkingen. Tevens wordt 
de relatie van deze resultaten met het klinisch beloop bestudccrd. Er bleek sprake van 
discrepanties tussen de resultaten van beide technieken, met name bij patienten met 
ongunstige hemodynamische kenmerken, bij wie de histologic frequent vaat-
afwijkingen liet zien passend bij nog vroege stadia van de vaatziekte. Pre-operatieve 
hemodynamische data bleken geen voorspelling toe te laten over het optreden van 
postoperatief optredende, zogenaamde pulmonale hypertensieve crisen. Bij de 15 
overlevende patienten in dit onderzoek, bleken beide diagnostische technieken, bij 
een gemiddelde follow-up duur van 6 jaar, niet in staat het persisteren van pulmonale 
hypertensie, na chirurgische cOl1'ectie van de hartafwijking, accuraat te voorspellen. 
Deze studie illustreert de beperkingen van hemodynamische en histologische evalua-
tic van het longvaatbed en benadrukt de behoefte aan uunvullende diagnostische mo-
gelijkheden. 
In IIOU.t{/stuk 4 worden de diagnostische technieken besproken, welke tegenwoordig 
in gebruik zijn om de pulmonale vasculatuur te beoordelen. Al dezc technieken heb-
ben onbetwist hun waarde, echter allen hebben zij ook hun praktische en conceptuele 
beperkingen. De functionele gevolgen van pulmonale vaatziekte 1'001' de ge'integrecrde 
pulmonale circulatie, en dus 1'001' de werkbelasting van het hart, kunnen slechts ge-
deeltelijk geevalueerd worden De ge'integreerde pulmonale circulatie bevat namelijk 
niet aileen het longvaatvaatbed met zijn specitleke functionele en stl1lcturele eigen-
schappen, maar ook de vaatwand compliantie, de retlectie van polsgolven en de weer-
stand tegen inertie. Pulmonale vaatziekte be'invloedt al deze aspecten. 
De stu die in hoojdstuk 5 toont de uitvoerbaarheid aan van intravasculaire echogratlc 
in de longvaten van kinderen en zuigelingen en, bovcndien, de unieke mogelijkhcid 
van deze techniek om tegelijkertijd zowel het aspect als de dynamiek van de pulmonale 
vaatwand ill vivo te bestuderen. De specitleke, potentiele voordelen van intravasculaire 
echografie in de beoordeling van pulmonale vaatziekte worden besproken. 
Hoojdstllk 6 beschrijft het aspect van de pulmonalc vaatwand ill vivo, beoordeeld mct 
intravasculaire echogratle, bij 47 kinderen met eell aangeboren hartafwijking en ver-
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schillende stadia van pulmonale vaatziekte, en in 14 kinderen met cen normale 
pulmonale circulatie. De bevindingen werden vergeleken met hemodynamische en 
histologische evaluatie. Het normale echogratlsche aspect van een longslagader werd 
gedetlnieerd. Met behulp van intravasculaire echografie was het mogelijk om ver-
schiIIen in het aspect van de vaatwand te detecteren tussen controle kinderen, kinde-
ren met miide tot matige pulmonale vaatziekte en kinderen met ernstige vaatziekte. 
Het nonnale patroon kwam mindel' vaak 1'001' bij de kinderen met pulmonale vaat-
ziekte, terwijl bij de kinderen met milde tot matige pulmonale vaatziekte aan lumen 
zijde, cen band van zachte echoreflecties werd waargenomen. De di kte van deze band 
correleerde met de bloedstroolll door de longen, de druk in de longvaten en met de 
mediadikte van musculaire artericn in de long biopsie. Wanneer de bllitengrens van 
de vaatwand goed herkend kon worden, als gevolg van aangrenzende strllcturen, kon 
de totale vaatwand-dikte gemeten worden. Deze correleerde evencens met de druk in 
de longvaten, maar ook lllet de longvaatweerstand. De veranderingen in het echo-
gratlsch aspect van de vaatwand correleerden niet met de aanwezigheid van gevor-
derde vaatafwijkingen in de long biopsie. 
In de, voor een belangrijk deel, zelfde paticnten groep, wercl het effect van het 
remodeIIerings proces op de dynamiek van de vaatwand bestucleerd met behulp van 
intravasclllaire echografie. In de hoofdstukkell 7 ell 8 wordt de nieuwe variabele 
"clistensibiliteit van de longslagader" ge·introduceerd. 
De associatie tussen deze nieuwe villiabele en de functionele aspecten van de pulmonale 
vasculatuuf, bepaald door middel van hemodynamische evaluatie, wordt beschreven 
in I/{}{!fds/llk 7. De mtericle distensibiliteit was progressief verJaagd bij pulmonale 
vaatziekte. De resuitaten van mllitvariate analyse suggereren clat dit deels samen-
hangt met een toegenomen rek van de vaatwand door verhoogcle clrllk in de long-
vaten, en deels met het stugger worden van de vaatwand zelf tijdens het ziekte proces. 
In IlOofds/llk 8 worden de associaties bestlldeerd tussen artericle distensibiliteit en 
structurele aspecten van de pulmonale vasclllatuur, vastgesteld door middel van 
pulmonale wedge angiografie en long biopsie. De venllindcrde artericle distensibiliteit 
in patienten met pulmonale vaatziekte blcek gecorreleerd met strllcturele vaat-
afwijkingen op het niveau van het vaatbed. Dezc correia ties waren onat11ankelijk van 
de dl1lk in de longvaten. Bovendien bleek dat wanneer behalve met de drllk in de 
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longvaten, ook rekening werd gehouden met de angiogratische en histologische va-
riabelen, de mteriele distensibiliteit nog steeds vedaagd was in kinderen met pulmonale 
vaatziekte. 
De /lOoJdsfllkkel/ 9 el/ 10 beschrijven twee van de studies in onze zoektocht naar 
specifieke cellulaire gebeurtenissen en biologisch actieve stoffen, die betrokken zijn 
bij de ontwikkeling van de karakteristieke vaatafwijkingen van PPA en die dus ken-
merkend moe ten zijn voor deze typische ziekte. 
Op grond van zijn specitieke biologische eigenschappen, was ons inziens "vascular 
endothelial growth factor"(VEGF) een potentiele kandidaat om betrokken te zijn bij 
het ontstaan van een zogenaamde plexiforme laesie. In /lOoJdsfllk 9 wordt de arteriele 
expressie beschreven van het VEGF eiwit, bepaald met immunohistochemische tech-
nieken, in long biopsieen van patienten met verschillcnde typen pulmonale vaatziekte 
en van controle patienten. Immunoreactiviteit gericht tegen VEGF werd gevonden in 
13 van de 34 patienten en was gelokaliseerd in de arteriele gladde spiercellen en in de 
endotheelcellen. Im1l1unoreactiviteit wcrd vaker gevonden bij patienten met gevor-
derde, onomkeerbm'e PPA dan in patientcn met cen normale pulmonale circulatie en 
patienten met weI OInkeerbare vormen van pulmonale vaatziekte. Bovendien werd 
een duidelijke immunoreactiviteit tegen VEGF aangetoond in de karakteristieke vaat-
afwijkingen van PPA. Hoewel de aanwezigheid van VEGF geen conclusies toelaat 
over een oorzakelijke relatie, suggereren deze bevindingen een actieve rol voor VEGF 
in de pathogenese van de karakteristieke vaatafwijkingen van PPA. 
In ho'!fdsfllk 10 wordt de arteriele expressic van de "endothelial constitutive" en de 
"inducible" vonn van nitric oxide synthase (ecNOS en iNOS) beschreven in long 
biopsie materiaal van nagenoeg dezelfde studie populatie. Op grond van de diverse 
bekende biologische eigenschappen van stikstofmonoxidc, zou een locale overpro-
duktie van dit molecuul enkele specifieke aspecten kunnen verklaren van de km'akte-
ristieke dilatatie laesies, fibrinolde necrose en plexiforme lesies in PPA. De immuno-
reactiviteit tegen ecNOS was vergelijkbaar in paticnten met een normale pulmonale 
circulatie en die met pulmonale vaatziekte, ongeacht het type vaatziekte of de ernst 
van de histologische vaatafwijkingen. Semiquantitatieve analyse van de 
illllllunohistochemische gegevens Iiet een correlatie zien tussen de intensiteit van de 
immunorcactie, tegen zowel ecNOS als iNOS, en de bloed doorstroming van de long 
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en de polsdruk in de longvaten. De intensiteit van de immunoreactie tegen iNOS was 
toegenomen in patienten met een verhoogde druk in de longvaten, vergeleken met 
diegenen met een normale druk, en was het hoogst wanneer de verhoogde dl'llk was 
gecombineerd met een toegenomen longdoorstroming. Duidelijke immunoreactiviteit 
tegen ecNOS en iNOS werd aangetoond in endotheelcellen in dilatatielaesies en in 
diverse endotheelcellen in plexifonne laesies. Deze bevindingen suggereren een toe-
genomen productie van iNOS in de longvaten van kinderen met een aangeboren hart-
afwijking en verhoogde druk in de longvaten, en een locale rol 1'001' NO in the 
pathogenese van de geavanceerde laesies van PPA. 
De studies in de hoofdstukkell 6.7 ell 8 tonen aan dat het proces van pulmonale vaat-
wand remodellering in kinderen met een aangebOl'en hartafwijking zich niet beperkt 
tot het longvaatbed, maUl' dat oak de grotere elastische longslagaders zijn betrokken 
in het ziekteproces. Zij tonen verder aan dat deze remodellering is geassocieerd met 
veranderingcn in de dynamischc eigenschappen van de vaatwand van elastische 
arterien, welke functionele gevolgen hebben, zoals een toename van de pulsatiele 
werkbelasting van het hart. Deze vasculaire verandcringen kunnen ill \Ilvo beoor-
deeld worden met pulmonale intravasculaire echogratle tijdens een hartcatheterisatie 
procedure. Kwalitatieve aspecten van de pulmonale vaatwand en arteriele distensi-
biliteit leveren nieuwe informatie betreffende de pulnionale vasculatuur en maken 
het mogelijk de funetionele consequenties van de verschillende aspecten van vaat-
wand remodellering te onderzoeken, evenals het effect van interventies. 
Lange tennijn analyse zal moeten uitwijzen of deze nicuwc variabelen van waarde 
zijn in de klinische evaluatie van pulmonale vaatziekte. 
De studies in de hoofdstukken 9 en 10 identificeren drie eiwitten, met krachtige bio-
logische aetiviteit, met karakteristieke expressie patronen in het beloop van PPA, 
welke een 1'01 suggereren in de pathogenese van de karakteristieke laesies in deze 
vaatziekte. Verder onderzoek zal nodig zijn om het oorzakelijke effect van deze drie 
protei'nen vast te stellen. 
Om deze en nog vele andere vragen te kunnen beantwoOl'den, dienl een krachtige 
inspanning ondernomen te worden om een adequaat diermodel te ontwikkelen 1'001' 
deze bloedstroom- en druk gerelateerde pulmonale pi ex ogene arteriopathie. Basale 
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studies naar mcchanismen betrokken bij afwijkende vasculaire groei en remodellering, 
wilen lIiteindelijk leidcn tot niellwe preventieve en therapeutische mogelijkheden 
voor patienten met pulmonale vaatziekte. 
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List of abbreviations 
ABC avidin-biotin-enzyme complex 
cAMP cyclic adenosine Illonophospate 
cGMP cyclic guanosine monophosphate 
CHO congenital heart disease 
CUF concentric laminar intimal fibrosis 
EM electron microscopy 
ECG electrocardiography 
EOA end-diastolic area 
ESA end-systolic area 
ET-l endothelin-l 
EVE endogenous vascular elastase 
EvG elastic-van Gieson 
FGF fibroblast growth factor 
Hb hemoglobin concentration 
HE hematox ylin-eosi n 
IGF insulin-like growth t1ctor 
IVUS intravascular ultrasound 
LAP left atrial pressure 
L-NA NG-ni tro-L-arginine 
NO nitric oxide 
ecNOS endothelial constitutive nitric oxide synthase 
iNOS inducible nitric oxide synthase 
p02 oxygen tension 
pC02 carbon dioxide tension 
PAP pulmonary artery pressure 
PBS phosphate-buffered saline 
PCV pulmonary congestive vasculopathy 
POE5 phosphodiesterase type V 
POGF platelet derived growth factor 
PGE2 prostaglandin E2 
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PGI2 
PPA 
PPHN 
PYD 
PVR 
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Qp 
Qs 
RA 
RV 
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TGF" 
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prostacyclin 
pulmonary plexogen ic arteriopathy 
persistent pulmonary hypertension of the newborn 
pulmonary vascular disease 
pulmonary vascular resistance 
pulmonary wedge pressure 
pulmonary blood now 
systemic blood tlow 
right atrium 
right ventricle 
systemic arterial pressure 
supernumerary artery 
shear stress responsive element 
systemic vascular resistance 
transposition of the great arteries 
transforming growth factor" 
ventricular septal defect 
vascular smooth muscle cell 
vascular endothelial growth factor 
Woods' units 
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Wolter Mooi, ik wil jou bijzonder bedanken voor de manicr waarop jij, na het onge-
lukkige overlijden van Prof. dr C.A. Wagenvoort, welhaast geruisloos ons onderzock 
binnengleed, om vcrvolgens zcer nadrllkkclijk en met veel elan je stempel op het 
werk te drllkken. 
Ralf Geiger, was gibt es in Insbrllck, das wir nicht haben in Rotterdam? Bedankt voor 
de anderhalf jaa!" dat je onze ploeg versterkt hebt en voor alles wat je in die tijd 
gebracht hebt. 
Met name bedank ik de mensen die vele uren noeste arbeid gestoken hebbcn in di-
verse onderdelen van de studies: 
Add Cromme-Dijkhuis, voor het tot bloedens toe analyseren van al die intravasclllaire 
echoballen. 
Wim Hop, voor de uitp"ttende, complexe maar uiteindelijk verheldercnde statistische 
analyses. 
Marco K!"lIit en Arno van Vliet, respectievelijk mister Dye and mister Wedge, voor al 
jllllie hulp. 
Daphne van Zuuren, Mohammed Ollhlolls en Jaap van Ocveren, voor jullic zeer bij-
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